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ABSTRACT 
Melatonin, a hormone of the pineal gland , was evaluated in 
a variety of animal models of depression. 
Measurements of the frog righting reflex and rat locomotor 
activity showed that low doses of melatonin have a serotonin-
like potentiating effect following monoamine oxidase inhibition. 
High doses of melatonin caused a reduction in the duration of 
rat immobility in the Porsolt model of depression and exerted 
a chlorpromazine-like effect on conditioned avoidance 
behaviour . 
In view of the indoleamine hypothesis of depr essive disorders, 
the poss i bility of melatonin being a potential antidepressive 
is discussed and it is concluded that melatonin might be use-
ful in the treatment of "agitated " depress i ons . 
C HAP T E R 1 
LITERATURE REVIEW 
1.1 DEPRESSION: 
1.1.1 Introduction : 
Depression is the most common psychiatric disorder. 
According to Kline (1964) more human suffering has 
resulted from it than from any other single disease 
affecting mankind. 
The term depression has been used to denote a variety of 
conditions including (i) a normal lowering of mood in 
response to adversity; (ii) a symptom similar to sadness; 
(iii) a syndrome representing an abnormality of mood; and 
(iv) an illness with a recognized aetiology and prognosis. 
This lack of definition has led to controversy regarding 
its classification. 
Whether depression is primarily a biological, genetic or 
cognitive disorder has been the subject of even more 
controversy since influences at all levels have been 
found to cause changes in each other. The various 
theories regarding the definition, classification and 
aetiology of depressive disorders are discussed. 
1.1.2 Signs and Symptoms: 
Although no consensus can be reached regarding the 
classification and aetiology of depressive illnesses, 
many of the s y mptoms are cornmon to the entire group of 
..... - 2 -/ 
- 2 -
affective disorders. The signs and symptoms of depression 
are outlined in Table lAo 
The primary change is in mood. The depressive suffers 
from feelings of sadness, hopelessness, guilt, apathy and 
lowered self-esteem. Other disturbances in sleeping, 
appetite, libido and so forth are common but not essential 
accompan iments. 
Th is uniformity of symptoms suggests that all depressions, 
regardless of the cause, are expressed in a similar neuro-
physiological way. 
. . . .. - 3 - / 
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TABLE 1: 
SIGNS AND SYMPTOMS OF DEPRESSION 
Manifestations 
Emotional 
Dysphoric m::JOd 
~~g!!giY~ 
Negative self-
ccncept 
Poor concentration 
and slow thinking 
Behavioural 
Loss of interest 
and motivation 
Neglect of 
personal 
appearance 
Psychorrotor 
retardation 
Agitation 
!'b:l!'!!~~! 
Sleep disturbance 
Loss of libido 
Appetite 
disturbances 
Constipation 
Menstrual 
disturbances 
Other general 
ccmplaints 
Description 
Crying 
Sad, unhappy, blue 
Lowered self-esteem 
Self-reproach and 
self-criticism 
Pessimism 
Restless, fearful, 
worried, irritable 
Early morning 
wakening 
Insomnia or hyper-
somnia 
Impotence, frigidity 
Anorexia or increase 
in appetite 
Headache 
Hot flushes 
Dryness of mouth 
Blurred vision 
Dizziness 
Dyspnoea 
Patient's expressions 
"1 can't help crying." 
"The pleasure has gone out 
of life." 
"1 am inferior. " 
"It's all my fault." 
"Things will never get any 
better." 
"1 have no desire to do 
anything." 
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1.1.3 Concepts of Depression: 
Beginning with Freud's paper on "r-burning and Melancholia" 
in 1917 (Freud, 1950), numerous concepts of depression 
have been formulated. These can be grouped into 4 
general categories: psychoanalytic, cognitive, behavioural 
and biolog ical. 
1.1.3.1 ~~l~~2~~~~l!~~~~_~2~~~E!~: 
1.1.3.1.1 "Aggression-turned Inward": 
This concept, originally proposed by Abraham in 1911 
(Abraham, 1948) and later elaborated by Freud (1950) 
attempted to explain depression in terms of psychoanalytic 
theory. Depression was seen as hostility directed inward 
upon the loss of a loved object. 
Abraham suggested that the essential difference between 
grief and depression is that a mourner is consciously 
concerned with the lost person, whereas a depressed 
individual is overcome with feelings of loss, anger, guilt 
and low self-esteem. Freud expanded these ideas, suggesting 
that in mourning the loss is conscious, whereas in depression 
the true loss is unconscious. Depression was therefore seen 
as a failure of the normal mourning process. 
Although this is the most widely quoted psychological theory 
of depression, there is little systematic evidence to 
support it (Weissman et al., 1971). 
• . • .. - 5 - / 
- 5 -
1.1.3.1.2 "Object Loss": 
Depression was conceptualized as a reaction to the real or 
fantasized loss of a loved person, either by death or 
separation, loss of a material possession , l oss of status 
and so forth (Spitz, 1946). 
Bibring (1 965) extended this by suggesting that loss of 
self-esteem was the essential element in depression. 
Bibring's hypothesis differs from the id-psychological 
approach of Freud and Abraham by placing more emphasis on 
the ego. He viewed depression as the emotional expression 
of a state of helplessness and powe r lessness of the ego. 
In other words , depression appeared when one could not live 
up to one's ego ideals. 
These theories suggest that depression is primarily a 
disturbance in mood. 
1.1 . 3 . 2 ~99~!~!Y~_~Y~9~e~~!§: 
This concept of depression postulated by Beck (1967) suggests 
that the primary disturbance is in thinking which, in turn, 
causes the disturbed mood state. 
This alteration in cognition is characterized by negative 
expectations. The depressed person has a negative view of 
himself, his experiences and of the future. 
. . • • . - 6 -/ 
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1.1.3.3 ~~b~~i9~E~1_~Q~9~E~~: 
Behaviourists conceptualize depression as a set of mal-
ad a p ti ve behavioural responses elicited either by uncontroll-
able aversive stimuli or by loss of reinforcement . 
1.1.3.3.1 "Helplessness" : 
The animal model of "learned helplessness" developed by 
Seligman (1975) has many similarities with human depression 
(see Section 1. 4.3). He has concluded from these studies 
that an individual, who is unable to exercise control over 
his reinforcers, develops feelings of helplessness, power-
lessness and passivity which constitute the depressed state. 
1.1.3.3 . 2 Loss of Reinforcement: 
Le winsohn and his co-workers suggested that a low rate of 
response-contingent positive reinforcement acts as an 
eliciting stimulus for depression (Lewinsohn, 1974). 
Depression would ensue either if the environment failed 
to provide reinforcement or if the individual failed to 
emit the appropriate response to potential reinforcers . 
Some depressive patients exploit the "sick role" to 
substitute for the loss of reinforcement, a characteristic 
which has been labelled "hysteroid dysphoria" by Klein and 
Davis (1969) . 
1.1.3.4 ~iQ1Qgi9~1_~YEQ~b~~~§: 
(See Section 1.2 for a detailed discussion.) 
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1.1 . 3.4.1 Biogenic Amine Hypothesis: 
This postulates that the primary cause of depression is a 
defect in biogenic amine metabolism. Depression is 
associated with a relative deficiency of catecholamines 
(Bunney and Davis, 1965; SChildkraut, 1965) or indole-
amines (Glassman, 1969; Lapin and Oxenkrug, 1969) at 
functionally important receptor sites . 
1.1.3.4.2 Choline r g ic Hypo t hes i s: 
Janowsky et al. (197~) propose that depression is a 
disease of central cholinergic predominance. 
There are numerous other biological concepts of depression 
including , a disturbance in adrenocortical hormone metabolism, 
a disturbance in electrolyte metabolism and so forth. 
The question is whether these biological changes seen in 
depression are the cause or a consequence of the depressed 
state. 
To conceive depression as the behavioural expression of a 
single input is probably a gross oversimplification. A 
comprehensive theory of depression requires input from all 
all 4 levels of analysis, rather than narrow adherence to 
anyone approach. Akiskal and McKinney (1973; 1975) have 
attempted to integrate the various conceptual models of 
depression into a unified hypothesis. According to them, 
depression is seen as a "psychob iological final common 
pathway" of various interlocking processes at chemical, 
experiential and behavioural levels . 
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1.1.4 Classification of Depression: 
Defining and classifying depressive disorders are crucial 
for research. Classification is of considerable importance , 
both in the development of new concepts of depressive ill-
nesses and when the appropriate course of treatment is under 
consideration. 
Confusion in the classification of affective disorders has 
arisen because of the multiple use of the term "depression" . 
It has been used to describe a physiological mood state, a 
symptom, a syndrome and a disease entity. Depressive 
disorders can be classified according to aetiology, 
symptomatology or biochemistry. 
until recently, two schools of thought predominated. 
The gradualists (Lewis, 1938; Hoch , 1953 ; Menninger, 1963) 
proposed that depression is a single clinical disorder that 
can express itself in a variety of forms. They maintained 
that the difference between neurotic and psychotic 
depressions is one of degree and should not be classified 
separately. 
The separatists (Kiloh and Garside, 1963; Carney, Roth 
and Garside, 1965; Kl erman, 1971) divide depressive 
disorders into two distinct groups. Those which are 
" endogenous· and those which are "reactive". Endogenous 
depressions have no apparent cause, whereas reactive 
depressions are exagge rated reactions to adversity . 
• . • . • - 9 - / 
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The term psychotic and neurotic depressive react ions 
refer to the clinical picture and a distinction is also 
made between them. Psychotic depressive disorders are 
more severe, contact with reality is lost and delusions 
are present. Neurotic depressive disorders are milder 
with no delusions . The link between these two dichotomies 
is that endogenous depressions often tend to be psychotic 
in clinical picture, while reactive depressions tend to be 
neurotic. In practice, this simplistic classification 
does little justice to the range of disorders seen and 
an appreciable number of cases fall within the ill-defined 
areas separating the two groups. The American Psychiatric 
Association (APA) adopted the separatist view and classified 
depressive disorders into two broad categories based on 
aetiology (APA, 1968). The classification is shown in 
Table 2. 
The "major affective disorders " consist of "manic-depressive 
illnesses" and "involutional melancholias". The onset of 
these disorders "does not seem to be related directly to a 
precipitating life experience" (APA, 1968). This infers 
a biological origin. On the other hand, the neurotic and 
psychotic depressive reactions are "reactive" to life events 
and are therefore psychogenic. The important disadvantage 
of this classification system is that the affecti ve 
disorders are divided on an aetiological basis even though 
the aetiology of depressive illnesses is still unclear. 
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TABLE 2: 
AMERICAN PSYCHIATRIC ASSOCIATION'S CLASSIFICATION OF THE 
AFFECTIVE DISORDERS 
NOMENCLATURE DESCRIPTION 
I MAJOR AE'I"ECI'IVE DISORDERS Illness not r:elated to a 
precipitating life event . 
A. MANIC-DEPRESSIVE ILlNESSES 
l. MANIC-DEPRESSIVE ILLNESSES, Manic episodes only -
MANIC TYPE excessive elation, irritability, 
talkativeness, flight of ideas, 
and lOCltor: acti vi ty • 
2. MANIC-DEPRESSIVE ILlNESSES, Depr:essive episodes only. 
DEPRESSED TYPE Depressed mood, mental and 
motor r:etar:dation. 
3. MANIC-DEPRESSIVE ILLNESSES, Depressive and manic episodes. 
CIOCUlAR TYPE 
4. OTHER MAJOR AFFECTIVE 
DISORDERS 
Includes "mixed" manic- Manic and depressive symptoms 
depressive illnesses appear almost simultaneously. 
B. INVOLUTIONAL MELANCHOLIAS Occur:s in the involutional 
per:iod - wony, anxiety, 
agitation and insomnia. 
Delusions may also occur:. 
I! PSYCHOTIC DEPRESSIVE REACTIONS Depressed mood due to sane 
experience. Delusions are 
present. 
I II DEPRFSSIVE NEURC6ES Includes reactive depressions. 
Depr:ession due to internal 
conflict or loss of a loved 
object • 
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The difficulties of classification have led to alternative 
ways of describing depressed patients. Pollitt (1965) 
classified depressive patients according to the presence 
or absence of the "depressive functional shift". The 
term describes the somatic features of depression such as 
loss of appetite, loss of mass and early morning wakening. 
He proposed that the absence of the depressive functional 
shift (justified or J type) was a result of psychological 
stress, whereas its presence (somatic or S type) represented 
a physiological disorder. Although the usefulness of this 
proposal has still to be determined, it seems unrealistic 
to classify the numerous forms of depressive disorders 
according to the presence or absence of somatic features 
(Mendels, 1970). 
Van Praag (1962; 1976) divided depressions into "vital 
depression" and "personal depression". "Vital depression" 
describes "endogenous depression" but the term refers 
exclusively to a syndrome not an aetiology . Likewise 
"personal depression" is a descriptive concept describing 
"reacti ve depression". Mixed forms are also common. 
The major problem with the previous systems of classification 
is that they assume depressive disorders to be either 
inherently psychological or inherently biological. This 
is seen in the mind/body, endogenous/reactive and neurotic/ 
psychotic dichotomies. Any emotional state, including 
depression, however, is the behavioural expression of 
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psychological, somatic and psychomotor inputs and 
consequently depressive disorders should be classified 
comprehensively taking all 3 level s o f influence into 
consideration. 
A major advance in this area is the Robins-Guze (1 970) classific-
ation of depressive disorders into "primary" and "secondary 
depression". '\Secondary depression" refers to feelings of 
sadness and hopelessness that occur in the presence of 
another illness. This illness may be either a nonaffective 
psychiatric disorder such as anxiety, neurosis, hysteria or 
it may be a medical illness such as rheumatoid arthritis, 
viral infections and chronic heart conditions. A primary 
disorder of mood with no other pre- e xisting p s y c h iatric 
syndrome is termed "primary depression". This is further 
subdivided into unipolar and bipolar affective illness. 
Unipolar depression refers to · one or more episodes of 
dBpression, whereas bipolar depression is characterized b y 
manic attacks either in the patient or in his biological 
relatives. This subdivision has been supported by numerous 
workers, who from genetic, biochemical and pharmacological 
studies, have concluded that there is a quantitative 
difference between bipolar and unipolar depressive diseases. 
These differences are summarized in Table 3. The value of 
this classification is that depressive disorders are defined 
independe ntly of aetiology and therefore it eliminates the 
endogenous/reactive controversy . It is also the most 
comprehensive to date as it incorporates gene tics, bio-
chemistry, neurophysiology and response to pharmacotherapy 
(Table 3). 
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'fAULt:: 3: 
D1FFERENTIAL CH ARACTERISTICS OF BIPOLAR, UNIPOLAR AND SECONDAHY Dl::prU;SSIONS 
(ModiCied from 1\kiskal and MCKinney, 1975) 
VAAIABLE BIPOLAR OEPRESSICN UNI POLAR DEPRESSl OO SECCM:Y\RY DEPftESSION HEFl-:H1N.',"S 
Clinical Features Retarded in psychaootor Agitated in psycharotor Depressive features Biegel ana Murphy, 1971 
activity . activity. super inposed on non-
affective psychiatric 
symptomatology e.g. 
hysteria ~ 
Postpar tLnTI episodes. Reich and Winokur , 1970 
Manifested in affective Clinically heter~ Winokur et al., 1970;71 
episcx:les only. geneous - manifested in 
fot1TlS other than 
depression e .g. 
alcoholisn. 
Median age at onset 30 Median age at onset 45 Perris, 1966 
years . years. 
Clinical COUrse Episcrle lasts 3-6 Episode las ts 6-9 No clear-cut Perris, 196B 
rronths. rronths . episodes. either winokur, 1970 
transient or chronic. 
Greater than 3 episodes 1-2 episodes per l ife-
per lifetirre. time. 
Genetics High genetic loading loW genetic loading for Perris , 1966 
for affective illness depression . Winokur et al. , 1969 
suggesting dominant Mode of inher itance Cadoret et al . , 1970 
transmission. uncertai n. 
Ei ther X-linked Reich et a1. , 1969 
dc:xninant, Winokur-e~al., 1969 
Mendlewicz ct ill. , 
or 1972 
autosomal dominant. Green et al., 1973 
Polygenic inheritarK:e Gerr.hon et al., 1971 
suggested. Bake r et al-:-; 1972 
Higher suicide rate in Murphy et al., 1971 
their families . 
Neurophysiology "Augmenter" on evoked "Reducer" on evoked Borge e t al., 1971 
potentials. potentials. Bochsbaum et al., 1971 
Biochemistry low platelet MA0 1 ~rma 1 platel et MAO Murphy and Weiss , 1972 
activity. activi t y. Jacobsen et a1., 1973 
Lower M.HPG2 excretion. Maas et al . , 1973 
Schiidkraut et a1., 
1973a; 1973b -
Beckman et al . I 1975 
More marked decrease MenCIels et a1. , 1972a 
in lurrber CSF 5-HlM~. Ashcroft et a1., 19na 
Subnormal steroid Pbove normal steroid Dunner et al., 1972 
excret ion. excretion. 
Lower 17-hydroxycortico- Jacobsen et al ., 1973 
steroi d concentration 
in ur ine. 
Pharmacology Lithium carbonate Less likely to respond Goodwin et a1.. 1972 
responsive. to 1i thium car bonate . Noyes e t al-:-; 1974 
May swi tch to hypanania Tricyclic responsive. Bunney ~ U., 1970 
with t ricyclics. r-turphy et aI., 1971 -
"Hysteroid dysphorias" Rcbinson et a1., 1973 
ard " atypical d~ 
pressions" may respond 
to MAO inhibitor. 
IMAO = monoamine ox ida se 
2MHPG = 3-methox y-4-hydroxyphenylglycol 
lCSF 5HlAA : cerebrospinal fluid 5-hydroxyindol eacetic acid 
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1.1.4.1 Biochemical Classification : 
----------------- - ----- - --
In r ecent year s there has bee n an attempt to classify 
depr e ssive disorders on a biochemical rather than a 
clinical basis. various biochemical classifications 
based on urinary MHPG levels, CSF 5-HlAA concentratio ns 
and platelet MAO activity have been proposed. 
Schildkraut et al. (1973a; 1973b; 1977) have shown that 
bipolar manic-depressive patients excrete a significantly 
smaller amount of MHPG (the predominant metabolite of brain 
noradrenaline) than do unipolar and non-specific depressive 
patients. This has been supported by numerous investigators 
who have found low urinary MHPG levels in a substantial 
number of depressive patients (Maas et al . , 1968; 1973; 
Beckmann and Goodwin, 1975; Goodwin and Post, 1975; 
Casper et al., 1977). These findings have led to the 
suggestion that there may be two biological groups of 
depressive disorders: one with a relatively low MHPG 
excretion such as bipolar manic-depressive depressions and 
the other with a relatively high MHPG excretion such as 
unipolar depressions. Pati e nts excreting less than normal 
quantities of MHPG showed a tempo rary brightening of mood 
following ~-amphetamine a dmini s trati o n, whe r e as patie nts 
who excreted normal amounts of MHPG tended to have either 
no e l evation of mood o r d ep ression with ~-amphetamine 
(Fa wcett and Siomopoulous, 1971; Fawcett et al., 1972). 
Consequently it has been suggested that g-amphetamine be 
used to identify various depressive subgroups (Garver and 
Davis, 1979). 
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Fu rther studies have demonstrated that low urinary levels 
of MHPG are correlated with successful desipramine and 
imipramine treatment (Fawcett et al., 1972; Maas et al., 
1972a; Beckmann and Goodwin, 1975) and high or normal levels 
of MHPG with successful amitriptyline treatment (Schildkraut, 
1973; Beckmann and Goodwin, 1975). De s ipramine has been 
shown to selectively inhibit the reuptake of noradrenaline 
(Eckhardt and Maxwell, 1973), whereas amitriptyline 
selectively inhibits the reuptake of serotonin (Carlsson 
et al., 1969; Maas, 1975). In clinical trials, imip ramine 
seems to be similar to desipramine with respect to correla-
tion between therapeutic efficacy and low MHPG levels 
(Fawcett et al., 197 2; Beckmann and Goodwin, 1975), how-
ever in the laboratory, imipramine has almost equal effects 
on serotonin and noradrenaline reuptake (Maas, 1975; 
Randrup and Braestrup, 1977). The reason fo r this 
discrepancy is not ye t known. 
It has been postulated from these results that at least two 
biochemical sUbtypes of depression exist. "Noradrenaline 
depression" characterized by (1) low urinary MHPG levels, 
(2) a favourable response to treatment with imipramine or 
desipramine and (3) an elevation in mood following ~-amphet-
amine treatment. "Serotonin depression" characterized by 
(1) normal or elevated urinary MHPG levels (Maas, 1975), 
(2) low CSF 5-HIAA levels (){sberg et al., 1976), (3) a 
favourable response to amitriptyline treatment and (4) a 
lack of mood change during ~- amphetamine treatment. 
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Additional evidence for a "serotonin depression" has been 
presented (van Praag and Korf, 1971q; ~sberg et a1., 1973; 
1976; Bertilsson and Sjoqvist, 1973). 
~sberg et a1. (1973; 1976) measured the CSF concentration 
of 5-HlAA (a metabolite of serotonin) of a group of dept-essed 
patients. Twenty-nine % of these patients had sub-normal 
5-HlAA concentrations. Within this subgroup, there was a 
significant negative correlation between the 5-HIAA 
concentration in the CSF and the severity of depression. 
A group of depressed patients with a subnormal 5-HIAA 
concentration in the CSF has also been reported by Mendels 
et a1. (1972a) and by van Praag et a1. (1970; 1973a). 
The rate of accumulation of 5-HIAA in the CSF after 
probenecid administration is presumed to reflect the rate 
of synthesis of brain serotonin (van Praag et al., 1970; 
Korf et a1., 1970). Van Praag and Korf (1971a) have shown 
that some depressive patients exhibit a normal rise in 
5-HIAA after probenecid pretreatment whilst others show a 
subnormal response. These patients exhibiting a subnormal 
response have been reported to respond favourably to 
5-hydroxytryptophan (5-HTP) administration (van Praag and 
Korf, 1974). Several investigators have confirmed these 
results (Goodwin et al., 1973; Sjostrom, 1973; Bowers, 1974). 
This suggests that within the group of vital depressive 
patients, there is a subgroup with disturbances in serotonin 
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metabolism, although they are indistinguishab le in 
psychopathological terms. 
Platelet MAO activity may be useful to classify depressive 
disorders further . Murphy and Weiss (1972) reported low 
platelet MAO activity in bipolar manic-depressive depressions. 
These results , in conjunction with the find ings of Schild-
krant et al. (1973a, 1973b, 1977), suggested that a subgroup 
characterized by low MHPG excretion and low MAO activity 
exists. Recent evidence shows there to be a subgroup of 
depressive patients with l ow MHPG excretion along with 
relatively high platelet MAO activity. These individuals 
have histories of asocial, eccentric or bizarre behaviour 
and show psychotic disorganization when treated with tri-
cyclic antidepress.ive d rugs (TADs) (Schildk raut, 1977). 
Growth hormone (GH) is released into the peripheral circulation 
following insulin-induced hypoglycaemia and it has been post-
ulated that this is regulated in part by the central nor-
adrenergic system (Martin, 1976). This GH response to 
insulin-induced hypoglycaemia has been found to be deficient 
in many depressed patients (Mueller et al., 1969; Sachar 
et al., 1971b ). A subgroup of t h ese depressives also 
exhibi ted diminished urinary MHPG levels which suggests 
that a defective GH response may be a characteristic of 
"noradrenaline depression" (Garver et al. , 1975). 
Evidence for a biochemical classification is summarized 
in Table 4 . These findings suggest that various measures 
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TABLE 4: 
PROPOSED BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE 
NORADRENALINE 
DEPRESSION 
LDw MHPG excretion in 
association with high 
or low platelet MAO 
activity. 
Normal CSF 5-HIAA 
levels. 
Normal rise in CSF 
5-HIAA after pro-
benecid administration. 
lDw GH response to 
insulin-induced 
hypoglycaemia. 
Responsive to 
imipramine or 
desipramine. 
Includes bipolar manic-
depressive depression 
and schizoaffective 
depression. 
Brief antidepressive 
response wi th ~­
arrphetamine. 
DISORDERS 
SEROTONIN 
DEPRESSION 
Normal or high MHPG 
excretion. 
Normal platelet MAO 
activity. 
LDw CSF 5-HIAA levels. 
Subnormal rise in 
CSF 5-HIAA after pro-
benecid administration. 
Normal GH response to 
insulin administration. 
Responsive to 
ami tripty line. 
Includes unipolar 
chronic depressions 
and non-specific 
depression. 
No antidepressive 
response with d-
arrphetamine. 
REFERENCES 
Schildkraut et al., 1973a, 
1973b, 1977-
Maas, 1975 
Murphy and Weiss, 1972 
van Praag et al., 1970, 
1973a --
Mendels et al., 1972a 
~sberg et al., 1973, 1976 
van Praag and Korf, 1971a 
Goodwin et al., 1973 
Sjostrom-;-1973 
Bowers, 1973 
Garver et al., 1975 
Fawcett et al., 1972 
Maas et al.-,-1972 
Schildkraut, 1973a 
Beckmann and Goodwin, 
1975 
Schildkraut et al., 1977 
Fawcett and Siomopoulous, 
1971 
Fawcett et al., 1972 
CSF, cerebrospinal fluid, 5-HIAA, 5-hydrOKyindoleacetic acid, 
GH, growth hormone, MAO, monoamine oxidase, MHPG, 3-methoxy-4-hydroxy-
pheny Ig 1 ycol. 
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related to catecholamine and indoleamine metabolism may 
be clinically useful in classifying depressive disorders. 
1.1.5 Aetiology of Depressive Illnesses: 
There is no consensus regarding the aetiology of depressive 
disorders. Some investigators suggest that depression is 
the result of a neuropharmacological dysfunction, whereas 
others believe it to be due to a basic fault in character 
development. This is discussed more fully in Section 1.1.3. 
There is no single cause of depression. The specific form 
that a syndrome will take in a given individual results from 
an interaction between a number of predisposing and 
precipitating factors. These are summarized in Table 5. 
1.1.5.1 ~E~9i~E9~i~9_~~~!2E~: 
In response to the same degree of loss, some people are 
more liable to depression than others. What constitutes 
the Achilles' heel of these people? A number of pre-
disposing factors have been postulated. 
1.1.5.1.1 Genetic Vulnerability: 
Most workers accept that some, if not all, depressive 
disorders are inherited. Heredity has been shown to be 
an important factor in manic-depressive illnesses and 
involutional melancholia (Winokur and Clayton, 1967; 
Mendlewicz et al . , 1975). 
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TABLE 5: 
FACTORS INVOLVED IN THE AETIOLOGY 
OF DEPRESSION 
PREDISPOSING FACTORS DESCRIPTION 
Genetic vulnerability 
Biological and neuropharma- Disturbance in catecholamine 
cological abnormalities metabolism, indoleamine 
metabolism, sodium metabolism 
Personality traits Presence of a "depressed 
personality" - strong oral needs, 
obsessive - compuls ive 
Developmental events Childhood loss - real or symbolic 
e.g. parental deprivation 
PRECIPITATING FACTORS 
Environmental events Loss of reinforcement 
Interpersonal events 
Physiological stressors Iatrogenic stressors e.g. 
reserpine 
Endocrine disturbances 
Somatic disorders 
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For example, it has been shown that if one of a set of 
monozygotic twins had an involutional psychiatric illness, 
there would be a 60% chance that the second one would also 
develop such an illness (Stenstedt, 1959). The percentage 
was much lower in dizygotic twins which suggested a hereditary 
factor . Combinin~ all the twin studies, there is a con-
cordance rate of approximately 75 % for identical twins and 
20% for nonidentical twins which again indicates a genetic 
factor (Adams and Victor, 1977). 
Winokur (1969) conducted a series of family studies and found 
that affective illness occurred much more frequently in the 
first-degree relatives of a group of patients with depressive 
disorders than in a control group. He also found an 
increased incidence of alcoholism in the relatives of 
patients with affective disorders which suggested that 
alcoholism may be a manifestation of a depressive element. 
A group of patients who had a history of depressive illnesses 
in two generations was compared with a group of patients who 
had no other family members with psychiatric illness (Winokur, 
1969). It was demonstrated that the two-generation group 
contained almost all the manic patients, whereas the family-
history-negative group contained very few manic patients. 
From these results he proposed that two different types of 
depressive disorders existed: manic depressive illness and 
depressive illness. This classification based on genetic 
background has been supported by Angst (1966), Perris (1966) 
and Leonard (1968). 
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Bipolar affective illness is thought to be a dominant trait 
which can be transmitted as either X-linked dominant (Winokur 
et al., 1969; Reich et al., 1969; Mendlewicz et al . , 1972) 
or autosomal dominant (Green et al., 1973). The mode of 
transmission of unipolar illness is less clear, though some 
studies favour polygenic inheritance (Gershon et al., 1971; 
Baker et al., 1972) (Table 3). 
The levels of catecholamines in the brain and in the adrenal 
medulla are genetically determined and hence a genetic 
abnormality may affect the amount of functional neurotrans-
mitter at the synaptic cleft. There are a number of possible 
sites of genetic dysfunction. An alteration in a protein 
molecule could cause enzymatic changes, resulting in altered 
synthesis, storage, release, reuptake or metabolism of the 
neurotransmitter. Other loci of dysfunction have been 
proposed, 4 of which deserve special mention. 
(1) An alteration in the gene(s) that controls the avail-
ability of rate-limiting enzymes involved in biogenic amine 
synthesis. 
(2) An increase in the functional capacity or the level of 
catechol-O-me thylt ran sfer a s e (COMT) or MAO wh i c h wo uld 
decr e ase t h e b i o genic amines in the synaptic cleft. 
(3) A dysfunction in either the vesicular, presynaptic or 
postsynaptic membrane which would interfere with the release 
and reuptake of electrolytes and/or biogenic amines (Mendels 
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and Frazer, 1973). This may involve a deficiency in 
either the membrane sodium ion/potassium ion dependent 
adenosine triphosphatase (Singh, 1970; Bunney et al., 1972b) 
or the carrier protein. 
(4) An alteration in receptor site sensitivity due to a 
structural gene mutation that codes for an aberrant lipo-
protein-receptor complex on the postsynaptic membrane. 
This is supported by the work of Prange et al. (1969) who 
postulated that the enhancement of tricyclic antidepressive 
action by thyroid hormone may be due to a hormone-m ediated 
increase in receptor site sensitivity. 
These 4 plausible sites of dysfunction are schematized 
in Fig. l Ao 
Thus theoretically a defective gene could result in the 
deficiency of catecholamines which has been proposed as 
the cause of the depressive syndrome (Schildkraut, 1965; 
Bunney and Davis, 1965) . 
Although it seems likely that a genetic factor plays a 
part in the development of depression, it is not known 
whether this is necessary or whether it is a sufficient 
cause in itself. 
1.1.5.1.2 Biological and Neuropharmacological Abnormalities: 
Di s turbances in catecholamine metabolism (Schildkraut, 1965; 
Bunney and Davis, 1965), indoleamine metabolism (Coppen, 
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(1 ) Mutation in control genes 
that monitor functional 
levels of rate-limiting 
(4) Structural gene mutation 
that codes for defective 
lipoprotein-receptor complex 
enzymes h (3) Membrane I ~~ i.=====vt==~ .~YSfunct~n* 
Vesicular Synthesis ~------------- ~ 
membrane of Biogeni 
Amines 
Mitochondria 
Extr.a,neuronal 
~COMT 
(2) Increased COMT 
or MAO activity 
/ 
/ 
Postsynaptic f membrane 
*involving Adenosine Triphosphatase or Carrier Protein 
COMT, catechol-O-methyltransferase; MAO , monoamine oxidase 
Fig. l Ao Schematic Presentation of 4 Possible Sites of Genetic Dysfunction in 
Depressive Illness. (Modified from Akiskal and McKinney, 1975). 
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1967; Lapin and Oxenkrug, 1969) and sodium metabolism 
(Coppen, 1965) have been implicated in the aetiology of 
depression. These and other biochemical abnormalities 
seen in depressed patients will be discussed in detail 
in Section 1. 2 
1.1.5.1.3 Personality Traits: 
Personality traits will determine or modify ones reactivity 
to stress and adversity. Some studies have suggested the 
presence of a "depressed personality". In 1911, Abraham 
(1960) studied manic-depressive patients and stressed their 
tendency to have obsessive-compulsive personalities with 
unusually strong oral needs. 
Laughlin (1956) described the characteristics of a person 
whom he believed was likely to develop a depressive disorder. 
These characteristics include several groups of traits: 
(1) overserious, overconscientious, gloomy and subdued; 
(2) have an unconscious need for love and a desire to be 
dependent, which makes them particularly vulnerable to 
rejection and disappointment; (3) compliance, overpoliteness 
and subservience, which suggests that the person denies all 
feelings of anger and hostility; (4) meticulousness, 
rigidity and perfectionism which are features of the 
obsessive-compulsive personality seen particularly in 
involutional melancholias. Although these characteristics 
are often seen in depressed patients, the specific relation-
ship between them and depression in unknown . 
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1.1.5.1.4 Developmental Events: 
Childhood loss or stress occurring at crucial periods of 
development are thought to sensitize the individual to 
depression in later life. According to Abraham (1960), 
the withdrawal of love from the infant during its oral 
phase of development results in a sense of unfulfilme nt 
and feelings of anger and despair in the child. The 
emotional development of the child is fixated at this oral 
stage and in adult life, these individuals depend on people 
and events to supply emotional gratification. According 
to this theory, repetition of the infantile loss (symbolic) 
later in life causes feelings of anger and despair to recur 
and predisposes the individual to depression. 
Research studies have suggested that adolescents and adults 
who have experienced a parental deprivation in childhood 
become particularly sensitized to loss and prone to 
depression in the face of it (Gregory, 1966a; 1966b; 
Granville-Grossman, 1968; Bowlby, 1973) . 
There is evidence from animal studies to support this. 
Rhesus infants separated from their mothers or peers show 
a similar reaction to human infants experiencing anaclitic 
depression (Seay et al., 1962; McKinney et al., 1971b; 1972) . 
Young et al. (1973) separated 3 to 4 year old monkeys who had 
experienced a traumatic separation during infancy, from 
their peers and observed a "despair-like" reaction . 
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Although this relationship between loss in childhood and 
depression in later life makes clinical sense, it has not 
yet been firmly established . 
1 .1 .5 . 2 ~E~~!E!~~~!09_~~~~2E§: 
A precipitating factor alone may be sufficient to invoke a 
depressive illness. However, it may also trigger off a 
depressive syndrome in a predisposed individual . 
1.1.5.2.1 Environmental Events: 
The most frequent precipitating factor is loss - the real 
o r fantasized loss of anything the patient hol ds dear . 
The concept of loss incorporates anyth i ng which leads to 
a loss of reinforcement, for example, loss of a personal 
relationship (death of a spouse, loss of children through 
marriage), loss of mate rial possessions (financial troubles), 
loss of physical and mental capacities (debilitating, chronic 
illnesses), loss of self-esteem (failure to achieve a desired 
goal) or loss of control over ones destiny (helplessness to 
alter the future). The stresses of life in a wider sense, 
such as war, poverty , injustice, corruption , lack of 
communication between people and nations, and the rapid 
pace of our accelerating world also result in a decrease in 
positive reinforcement and loss of control over ones destiny. 
HoweveG the relative contribution of these factors to the 
incidence of depression is still unclear. 
The events that take place betwee n the depressive patient 
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and his interpersonal env ironment also act as an important 
p recipitant in depression (Feldman, 1976). 
He postulated that the processes of reciprocal stimulation 
and reinforcement that exist between two people, for example, 
in marriage , are important not only in the initiation but 
particularly in the maintenance of the depressive illness . 
Interpersonal conflicts result in a decrease in positive 
reinforcement which precipitates depression. If the 
conflict is maintained in a family system, this serves to 
prolong the depressive disorder. The effect of inter-
personal events on a depressive patient may be genetically 
determined. It has been reported that genetic pre-
disposition renders 10 to 15 % of the population 
extremely vulnerable to interpersonal stresses (Perris, 
1966; Cadoret et al., 1970; Gershon et al., 1971). 
Although the onset of reactive depression is usually 
associated with one of the above-mentioned stresses, it is 
not necessarily true that the stress directly caused the 
illness (Mendels, 1970). Often the patient has experienced 
similar stresses at other times of his or her life without 
becoming depressed. In addition, there are many other 
people who do not become depressed on exposure to similar 
experiences. 
1.1.5 .2.2 Physiological Stressors: 
Iatrogenic stresses can induce direct physiochemical changes. 
Goodwin and Bunney (1971) have shown that reserpine which 
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depletes or displaces the biogenic amines in the CNS, 
precipitates depression in 15 to 20 % of hypertensive 
patients when given in doses of more than 0,5 mg per day. 
Similar depressive states have been found following a-
me thyldopa (Bunney and Davis, 1965). It was thus post-
ulated that these drugs act as chemical triggers and upset 
a vulnerable biochemical-neurophysiological system in 
genetically predisposed individuals. 
High doses of corticotrophin or cortisol (Clark et al., 
1952) have also induced a depressive reaction in some 
patients . Other drugs , for example barbiturates, analgesics 
and phenothiazines (Simonson, 1964) may also be associated 
with the development of depression. 
A number of endocrine disturbances have been implicated in 
the aetiology of depression. Depressive disorders have 
been observed in patients with Addison's disease (Engel and 
Margolin, 1942; Mi chael and Gibbons, 1963) , Cushing's 
syndrome (Carpenter et al., 1972), hyperparathyroidism 
(Karpati and Frame , ;L964 ) (l,nd hypothyroidism (Whybrow and 
Hurwitz , 1976). The exact nature of the relationship 
between these endocrine diseases and depressive illness 
is unclear. 
Castelnuovo-Tedesco (1961) proposed that diseases that 
specifically interfere with the normal functioning of the 
nervous system may produce depression. These include 
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cerebral arteriosclerosis, senile dementia, neurosyphilis, 
multiple sclerosis and various vitamin deficiency syndromes. 
According to Castelnuovo Tedisco, other somatic disorders 
that are likely to be complicated by depression are: 
(1) certain infectious diseases, especially infectious 
hepatitis, influenza, infectious mononucleosis, atypical 
pneumonia, rheumatic fever and tuberculosis; (2) psycho-
somatic disorders such as ulcerative colitis, asthma, 
neurodermatitis and rheumatoid arthritis; (3) anaemias and 
(4) malignancies. The experience of somatic and psychomotor 
debilitation which frequently accompanies such disorders may 
in itself be depressionogenic. 
Akiskal and McKinney (1975) have attempted to integrate 
these diverse predisposing and precipitating factors into 
a unified model of depression . (Fig. IB). They proposed 
that genetic, physiological, environmental and developmental 
factors lead to biochemical alterations in the patient which, 
in turn, lead to a reversible functional derangement in the 
diencephalic mechanisms of reinforcement. The major virtue 
of this hypothesis is that it provides a conceptual bridge 
between the behavioural and biological models of depression. 
1.1.6 Treatment of Depression: 
There is considerable controversy regarding the treatment 
of depression with two schools of thought predominating. 
The authors who accept depression as being primarily a 
psychological disorder believe that psychotherapy is 
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Fig. lB. unified Model of the Aetiology of D.epressille Disorders. 
(Modified from Akiskal and McKinney, 1973.) 
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essentia l in its treatment. They question th e use of 
medication to solve what they consider to be essentially 
a psychological or social problem. They argue that drug 
treatment may dilute the patient's anxiety so much that he 
is diverted from improving his underlying personality 
problem and, as a result, further episodes of depression 
could occur. On the other hand, those who conceive 
depression to be fundamentally a biochemical or genetic 
abnormality, suggest treatment should be aimed at correcting 
the disturbed state of the nervous system with anti-
depressive drugs. Psychodynamics and psychotherapy are 
regarded as relatively unimportant except in supportive use. 
However, there is evidence suggesting that depressive dis-
orders which are biological in origin ("endogenous depress ion") 
are more responsive to psyc hotherapy. Greenblatt et al. 
(1964) demonstrated that the response rates of various 
depressions differed markedly when hospitalized depressives 
were treated with placebo. They proposed that the 
comparatively low placebo response rate in "manic-de-
pressive ,,(l) or "involutional psychotic,,(l) depressions 
demonstrated the need for antidepressive medication. In 
contrast, "neurotic" or "character disorder" depressions 
could be tr e ated adequately by interpersonal techniques 
(I)The diagnostic criteria used in this study are specified 
e lsewhere (Greenblatt et al., 1964) • 
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without the use of medication. This suggests that no 
matter what interpersonal events elicit depressive disorders, 
once they assume severe proportions, they become biologically 
autonomous and are relatively refractory to psychotherapy 
(Akiskal and McKinney, 1973). 
These studies emphasize the need for distinguishing between 
the types of depressions when deciding on appropriate 
treatment. Therapy should be individualized according 
to the patient and the phase of his illness, and may 
involve medication, psychotherapy and/or direct guidance. 
1.1.6.1 ~~Y~~2!~~E~EY; 
Psychotherapy provides emotional support and reassurance 
to counteract the depressive patient ' s low self-esteem and 
feelings of hope l essness. Maladaptive patterns and pre-
disposing events are investigated and restructured in order 
to help the patient cope with, and understand, his depression 
so that any future episodes can be dealt with using the 
individual's own resources. As recovery develops, psycho-
therapy is also of use when the patient is intolerant of 
the side effects or refractory to a given antidepressive. 
There is a wide range of psychological treatments including 
individual and group t herapy, family and marital therapy, 
behavioural therapies and psychoanalysis. Lazarus (1968) 
has discussed 3 methods of treatment effective in 
depress ion, all of which seem to involve the patient's 
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realization that he can control important reinforcers by 
his own actions. (1) Assertive training (Wolpe and 
Lazarus, 1969) where the patient learns to assert himself 
and to exercise control over his interpersonal events. 
(2) Affect ive expression in which the individual merely 
expresses anger. (3) Morita therapy (Kora, 1965; Burgess, 
1968) which reinforces active behaviour in depressed 
patients. Taulbee and Wright (1971) developed the 
"Tuscaloosa Plan" whereby mistreatment of the depressive 
patient acts as a power ful reinforcer. 
The effectiveness of these therapies suggests that depression 
may be antagonized when the patient comes to realize that 
his own responses are effective in alleviating his condition 
and producing gratifications. This approach has been 
supported experimentally by Seligman's helplessness model 
(S eligman , 1975). He demonstrated that learned helpless-
ness can be broken down by forcing the passive dog to see 
that its responses produce reinforcement. Melges and 
Bowlby (1969) also see mitigation of helplessness as the 
central theme in the treatment of depression. 
Some authors stress the importance of explaining to the 
depressed patient that depression is self-limiting 
(Campbell, 1953; Kraines, 1957; Ayd , 1 961 ). They suggest 
that the patient be told his illness has a physical basis 
and that he will be cured. It is believed that this 
"formulation of the patient" greatly assists in alleviating 
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the depressive disorder. 
Beck (1970) has developed a cognitive therapy for depression, 
the aim of which is to change the negative cognitive set of 
the depressive patien t to a more optimistic one. Thi s is 
done by reconstructing the stages in the development of 
the patient's depression, teaching him to recogn ize his 
cognitions and to neutralize inaccurate negative thoughts. 
In short, antidepressive drugs have not replaced psycho-
therapy. Even in manic-depressive illness where the 
effec tiveness of medication has been proved beyond doubt , 
psychotherapy is considered essential to shorten the ill-
ness and to alleviate t he patient's suffering 
1957) . 
1.1.6.2 ~~§E~~~!~~~~~~~: 
(Kraines, 
Hospitalization is indicated in more severe cases of 
depression as it provides care and protection against 
suicidal risks . 
In some cases a hostile, ambivalent or dependent relation-
ship ex i sting between the depressed patient and his or her 
family may contribute to the perpetuation of the illness 
and removal from these environmental pressures is often 
beneficial. Hospitalization, although being a more extreme 
form of environmental change, offers a temporary respite 
from this domestic stress . In addition, the controlled, 
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protective surroundings of the hospital may itself help 
in resolving the illness since it is well-known that many 
patients improve simply on being admitted to a hospital. 
In addition, a hospital can also provide a therapeutic 
regimen that is not available at home, for example ECT. 
1.1.6.3 §1~~~E9~9~~~1§!~~_!~~E~EY: 
Cerletti and Bini introduced electroconvulsive therapy (ECT) 
in 1938 and up until the mid-sixties, it was the most common 
method of treatment for hospitalized depressive patients. 
Despite the efficacy of antidepressive drugs, there is ample 
evidence that ECT does resolve a depressive episode in a 
significant number of patients. The evaluation of the 
efficacy of ECT, however, has been complicated by the fact 
that (i) some depressed patients seem to respond better to 
ECT than others, and (ii) the depressive disorder is of t en 
self-limiting. For example, a number of workers have found 
patients suffering from "endogenous depression" to be more 
responsive to ECT (Carney ~ ~., 1 965; Mendels, 1965'; 
Ilaria and Prange, 1975) . 
1967 ; 
Riddle (1963) and Davis (1965) reviewed the effectiveness 
of ECT and th e two studies taken together show ECT to be 
superior to placebo or no treatment ~n 2 studies; more 
effective than antidepressive drugs in 4 studies; and 
equivalent to drug therapy in 3 studies. From the 
available ev id ence , a number of investigators have suggested 
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that ECT is the same as, or superior to, any drug treatmen t 
for psychotic depressives (Cole, 1964; Wechsler et al . , 
1965). The physiological, biochemical and psychological 
effects of ECT have been summarized by Holmberg (1963) and 
are outlined in Table 6. 
ECT rapidly alleviates the depressive disorder and, as a 
result, is of particular use in cases where there is a risk 
of suicide. It is also recommended for depressed patients 
who are refractory or hypersensitive to antidepressive 
the r apy or who refuse to take their medication. 
However, the administration of ECT entails certain dis-
advantages. These include memory loss (both anterograde 
and retrograde), difficulty in concentration , confusion , 
fractures and dislocations, risk of anaesthetic, and 
cardiovascular complications. There is also a high relapse 
rate but this can be prevented by administering maintenance 
doses of antidepressive drugs for 6 months after ECT. 
Unilateral ECT (where both electrodes are placed on the 
nondominant cerebral hemisphere), however, has been reported 
to reduce the inc i dence and severity of these side effects 
to some extent. 
1.1. 6. 3.1 l1echanism of Action: 
There is a mass of widely diverse and often contradictory 
theories regarding the mechanism of action of ECT. Fear, 
hormones, muscular exertion, anoxia, amnesia and biochemical 
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TABLE 6: 
EFFECTS OF ELECTROCONVULSIVE THERAPY 
Physiological Effects 
Biochemical Effects 
Psychological Effects 
(Holmberg, 1963) 
An initial jerk produced by direct 
cortical stimulation 
Followed by tonic and clonic convulsions 
During the convulsion - spasm of glottis 
and respiratory 
muscles 
- elevation of 
blood CO, tension 
- reduction of 0, 
tension 
- i ncrease in 
cerebral 
circulation 
- increase in brain 
metabolism 
Heart rate frequen t ly rapi d and irregula r 
possible fluctuations in blood pressure 
Excitation of autoncmic regulatory 
centres - psychomotor 
Cholinergic effects 
Hyperglycaemia 
restlessness 
- salivary and 
bronchial 
secretions 
- transient 
arrhythmias 
- Elevated nitrogen canpounds, potassium, 
calcium, phosphorus and steroids in blood 
- Elevation of catecholamines and serotonin 
in blood 
- Increased brain serotonin (especially in 
brain stem) 
Memory impairment - amnesia (may be both 
anterograde and retrograde) 
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changes in the CNS have been implicated in its mechanism, 
but proof is lacking to substantiate these claims. 
Holmberg (1963) suggested that the effectiveness of ECT is 
dependant upon the production of seizure activity in the 
brain. He reported that increas ing the convulsive activity 
with muscle relaxants and oxygenation improved the therapeutic 
effects of ECT, whereas decreasing the convulsive activity 
with anticonvulsive premedication reduced the therapeutic 
effect . 
Several investigators have attempted to determine whether 
the clinical efficacy of ECT is related to an alteration in 
amine metabolism (Weil-Malherbe , 1955; Havens et al., 1959; 
Cochran and Marbach, 1962; Holmberg, 1963). Increases in 
both plasma .and urinary noradrenaline and adrenaline have been 
demonstrated in unmodified ECT, howeves these alterations 
were diminished when barbiturates or muscle relaxants were 
administered prior to ECT. Rosenblatt et al. , (1960) have 
suggested that the amine blood-CSF barrier becomes more 
permeable to noradrenaline after ECT. Schildkraut et al. 
(1967) showed that ECT lowered the brain levels of tritiated 
noradrenaline and increased the brain levels of normetan-
ephrine-H 3 above those of the control animals. In addition, 
Schildkraut (1975) found increased urinary MHPG levels in 
depressed patients recovering afte r ECT treatment. They 
thus concluded that ECT might act by increasing nor-
adrenaline synthesis and turnover, thereby i ncreasing the 
.... . - 40 -j 
- 40 -
neuronal discharge of noradrenaline onto the receptors. 
This has been confirmed by other investigators (Ebert et al., 
1973; Modigh, 1976a). Noradrenaline-stimulated synthesis 
of cyclic AMP has also been shown to be reduced in rat brain 
tissues after chronic treatment with ECT (Vetulani et al., 
1976). In a recent report, Pandey et al. (1979) observed 
a significant decrease in S-adrenergic sensitivity in the 
rat brain following chronic ECT treatment. This effect was 
shown to be similar to the effects of other antidepressives, 
for example, desipramine (Pandey et al., 1979), doxepin and 
iprindole (Banerjee et al., 1977). However, the question 
of whether this action is related to the antidepressive 
effect of ECT is still unknown. 
The effect of ECT on the serotoninergic nervous system has 
also been investigated in an attempt to verify the indole-
amine hypothesis. Ebert et al. (1973) reported that the 
cerebral concentrations of serotonin, 5-HIAA and tryptophan 
are increased in test animals for a few days following a 
series of electroshocks which might indicate increased 
serotonin turnover. However, the baseline concentration 
of 5-HIAA in human CSF is unaffected after ECT. Some 
depressive patients show a low CSF 5-HIAA response after 
probenecid pretreatment which is said to indicate t educed 
turnover in the CNS (Roos and Sjostrom, 1969; Sjostrom and 
Roos, 1972; van Praag et al., 1970; 1973a). Van Praag (1977a) 
has shown that ECT increases the post-probenecid 5-HIAA 
accumulation in the CSF of these patients, suggesting that 
..... - 41 - / 
- 41 -
ECT has some influence on serotonin turnover. 
1.1.6.4 ~~~E~~£2!~~E~EY: 
Antidepressive drugs have proved to be of considerable 
value in the treatment of depressive disorders. They 
have probably resulted 1n a reduced use of ECT, brought 
about improvement in patients who were chronically ill and 
resistant to other treatment, reduced the need for and 
duration of hospitalization, and made patierits more 
responsive to psychotherapy. 
However a number of factors complicate the evaluation of 
the success rates for the various treatments. 
(1) Depression is often a self-limiting illness and thus 
the statistics on the efficacy of the different drugs are 
often unreliable. There is a high spontaneous r emission 
rate which is said to vary from a median of 3 to 4 months 
among outpatients to a median of 6 to 18 months among in-
patients (Beck, 1973). Therefore many apparently drug-
induced remissions are probably spontaneous. 
(2) Depressed patients often show a nonspecific placebo 
response. It is well known that the response to any drug 
(including a placebo) is dependent upon the patient's 
attitude and expectations. The placebo response has been 
found to vary with the type of drug, the social background 
and educational level of the patient, and whether or not 
the patien t was seen in a clinic or by a private psychiatrist 
(del Giudice, 1970). 
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(3) The population of depressed patients is heterogeneous 
with different subgroups of depressives responding 
selectively to drugs. It has been suggested, for example, 
that patients suffering from "endogenous" depression a re 
particularly responsive to TADs, whereas pa tients with 
" neurotic" and "atypical" dep ressions respond better to 
MAO inhibitors (Sargant, 1961; Sargant and Dally, 1962; 
Crane, 1970). 
Caffey et a1. (1970) compared the efficacy of imipramine 
with thioridazine and found that imipramine was superior 
in "retarded" depression, thioridazine superior in "anxious" 
depression, while both were equally effective in "hostile" 
depression. This selective responsivity to treatment could 
account for the discrepancies in findings among the various 
studies, since the c lin ical population of most s tudies has 
included a heterogeneous group of depressed patients. 
Another major problem with pharmacotherapy arises from the 
delay in clinical activity of the antidepress ive drugs. 
The clinical effects of reserpine, the tricyclic drugs and 
lithium carbonate, take several weeks to become apparent, 
whereas their effects on biogenic amines are immediately 
evident in in vivo animal studies. The reasons for this 
latency in the onset of improvement are not understood . 
Thus, it is evident that the choice of a treatment programme 
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must be individualized according to the particular 
clinical features present, instead of having a standard 
approach that is applied to every depression. 
1.1.6.4.1 Tricyclic Antidepressives: 
Based on controlled trials, it would seem that the tricyclic 
antidepressives (TADs) are currently more effective and 
safer than non-tricyclic drugs in the treatment of 
depression. Beck (1973, review) has summarized the 
controlled studies comparing the tricyclics to a placebo 
and concluded that out of 67 inpatient trials, 42 (63%) 
showed statistically significant improvement . The trend 
appears to be that 50 to 70% of patients are moder ately 
improved while on TAD therapy, whereas 30 to 50% improve 
in placebo groups (Klerman and Paykel , 1970). Patients 
with retardation and other clinical features resembling 
"endogenous" depression (hyposomnia , early morning wakening, 
decreased appetite, mass loss and decreased libido) have 
been shown to be par tic ularly responsive to TAD treatment 
which remains the drug of choice for this condition. 
Moreover , in comparison with other antidepressive treatments, 
the side effects of the tricyclics are far less frequent and 
serious. 
The effec ti veness of imipramine was first described by 
Kuhn (1958) and since then a number of other tricyclic 
compounds have been developed. These include (i) the 
iminodibenzyls (desipramine, trimipramine and clomipramine) 
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and (ii) the dibenzocycloheptenes (amitriptyline, nor-
triptyline, protriptyline and doxepin). In clinical 
studies, the "sedative" tricyclics (amitriptyline, nor-
triptyline, doxepin) have been reported to be particularly 
useful in the treatment of "agitated" depressions (associated 
with anxiety and insomnia), whereas the "stimulant" type of 
antidepressives (imipramine, desipramine, protriptyline) are 
more suitable in "retarded" depressions (Cole and Davis, 
1967; Shepherd et al., 1968). It has also been observed 
that some groups of depressed patients fail to respond to 
amitriptyline (a relatively specific serotonin uptake 
inhibitor) but do respond to imipramine or desipramine, while 
other groups of depressed patients fail to respond to 
imipramine or desipramine (noradrenaline uptake inhibitors) 
but do respond to amitriptyline (Beckman and Goodwin, 1975). 
However, it is not ye t known wh y imipramine, which has 
almost equal effects on both serotonin and noradrenaline 
reuptake, exerts a similar action to desipramine and not 
to amitriptyline in clinical trials. These findings 
support the hypothesis of two distinct biological sub t ypes 
of depression (See section 1.1.4.1) and emphasize the need 
to i dentify those individuals among the heterogeneous depressed 
population who may · be specifically r espons·ive to the differen t 
TADs. 
The most common side effects associated with TAD admin-
istration are related to the anticholinergic action of the 
drug. These include dry mouth, constipation, increased 
perspiration, visual distortions, urinary retention and 
•.••• - 45 - / 
- 45 -
postural hypotension. In addition, it has been reported 
that imipramine administration may intensify an episode of 
mania in manic-depressive patients and could lead to an 
exacerbation of the psychosis in schizophrenic patients 
(Kuhn, 1958; Shepherd et al., 1968). Mild, transient, 
self-limited, hypomania symptomatology has also been 
observed in patients with "endogenous" depressions during 
imipramine treatment (Schildkraut et al., 1966a). 
While the TADs represent an important advance compared to 
previous therapies, their efficacy is limited since they 
require prolonged administration (usually lto 4 weeks) before 
their antidepressive effects can be observed. This is a 
disadvantage, particularly in the treatment of a suicidal 
patient. It was proposed that the delay in therapeutic 
effect be explained by the fact that imipramine must first 
be converted into its active desmethyl metabolite before 
it can be clinically effective. 
The desmethyl derivatives of imipramine and amitriptyline, 
desipramine and nortriptyline respectively, were then 
synthesized in the hope that they would act more rapidly 
than their parent compounds but there is little clinical 
evidence to support this (Shepherd et al., 1968). Further 
research must discover the reasons for this delay in 
therapeutic effect and develop a new antidepressive with 
a more rapid onset of action . 
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1.1.6.4.1.1 Mechanism of Action : 
The precise mechanism of action of the TAOs in alleviating 
depression is unknown but it has been suggested that its 
pharmacological property of blocking the cellular reuptake 
of the biogenic amines (noradrenaline, dopamine and/or 
serotonin) may be important in this respect (Schildkraut, 
1965; Lapin and Oxenkrug, 1969; Mendels et al., 1976; 
Randrup and Braestrup, 1977). 
On nerve stimulation, newly synthesized transmitter is 
released by the process of exocytosis from the storage 
vesicles in the presynaptic neuron (Axelrod, 1972). This 
diffuses across the synaptic cleft and reacts briefly with 
the postsynaptic receptors. The action of the neuro-
transmitter is terminated primarily by reuptake of the 
amine from the synaptic cleft by the presynaptic neurons 
(Cooper et al., 1974). Most of the resorbed transmitter 
is restored in the storage vesicles but some is metabolized 
by the enzyme, monoamine oxidase (MAO), which is located in 
the mitochondria of the nerve cell. Any noradrenaline 
remaining in the synaptic cleft is metabolized to nor-
metanephrine by catechol-O-methyltransferase (COMT). The 
normal process of release and reuptake is illustrated in 
Figure 2A. Figures 3 and 4 illustrate the synthesis and 
metabolism of noradrenaline and serotonin respectively. 
The tricycli cs block t h e r euptake o f biog e n ic aminesfrom 
the synapse and are therefore presumed to increase the 
quantity of functional neurotransmitter at the postsynaptic 
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PRESYNAPTIC NEURON POSTSYNAPTIC NEURON 
Fig. 2A. 
--RELEASE~ 
RECEPTOR 
< ' REUPTAKE --
Schematic Representation of the Normal Process of 
Release, Reuptake and Metabolism of Neurotransmitters. 
COMT, catechol-O- methyltransferase; MAO, monoamine oxidase. 
PRESYNAPTIC NEURON POSTSYNAPTIC NEURON 
Fig. 2B . 
Synaptic cleft 
• • 
• • • 
RECEPTOR 
• • • 
~------
TRICYCLIC ANTI DEPRESSIVES 
Schematic Representation of the Proposed Mechanism of 
Action of the Tricyclic Antidepressives . 
The tricyclic antidepressives block the presynaptic nerve terminal , 
increasing the concentration of neurotransmitter (noradrenaline, 
dopamine or serotonin) at the receptor site and thus potentiating 
its effect. 
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receptor sites. This is illustrated in Figure 2B. 
In 1959, Sigg suggested that imipramine exerts a "sensitizing" 
influence on the adrenergic receptors (Sigg, 1959). This 
was supported by numerous investigators who found imipramine 
potentiated both the response to sympathetic nerve stimu-
lation in several experimental situations as well as many of 
the peripheral effects of exogenously administered nor-
adrenaline in animals and in man (Ryall, 1961; Gershon 
et al., 1962; Sigg et al., 1963; Thoenen et al., 1964). 
The effects of the tricyclics upon the brain metabolism of 
radioactive noradrenaline were then investigated. Glowinski 
and Axelrod (1964) were the first to demonstrate that the 
tricyclic derivatives (imipramine, desipramine and amitrip-
tyline) inhibit the uptake of tritiated noradrenaline in the 
rat brain. Previously, desipramine and imipramine had been 
found to b l ock the uptake of noradrenaline-H' into peripheral 
tissues (Axelrod et al., 1961; Hertting et al. , 1961) and 
brain slices (Dengler et a l . , 1961). Rat brain nor-
metanephrine-H' levels were also shown to be increased by 
imipramine administration (Glowinski and Axelrod, 1965; 
Schildkraut et al ., 1967) . These results were supported 
by cl i nical studies which demonstrated increased nor-
metanephrine levels and decreased VMA levels in the urine 
of patients treated with imipramine (Schildkraut et al ., 
1964; 1965). The decreased VMA excretion was thought 
to be due to the reduced intracellular degradation of 
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noradrenaline by MAO brought about by the ability of the 
tricyclics to prevent the reuptake of extracellular nor-
adrenaline. This, in turn, led to an increased normeta-
nephrine excretion. 
From studies conducted by Haefely et al. (1964) it was 
concluded that the tricyclics exert at least 3 types of 
activity at the peripheral adrenergic synapses: (1) a 
sympathomimetic effect (thought to be due to the release 
of active noradrenaline from its binding sites); (2) in-
hibition of reuptake of noradrenaline from the synaptic 
cleft; and (3) a sympatholytic effect in higher doses. 
The tricyclics' ability to increase monoamine availability 
by blocking reuptake has been confirmed by numerous 
investigators (Ross and Renyi, 1967; Schildkraut et al., 
1969a:; · Lidbrink et al., 1971; Hamberger and Tuck, 1973) 
and it has been hypothesized that this might account for 
its therapeutic effect (Schildkraut, 1965; Bunney and 
Davis, 1965; Mendels et al., 1976). 
The effect of TAD administration on the serotoninergic 
processes was also investigated. Tricyclics were found 
to potentiate the peripheral (Sigg et al., 1963; Gyermek, 
1966) and central effects (Himwich et al., 1961; Gyermek, 
1966) of serotonin. Although tricyclic derivatives showed 
an antiserotonin action on some isolated organs, the 
potentiation of serotonin effects has been proposed to be 
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mo~e ~elevant to its mechanism of action in depression 
(Gye~mek, 1966). Tissue uptake of injected serotonin 
was shown to be inhibited by imipramine administra tion 
thus causing an increase in the concentration of free 
serotonin acting on the ~eceptors (Axelrod and Inscoe, 
1963) . Carls son et al. (196 8) demonstrated that imipramine 
inhibits the cellu lar reuptake of serotonin by serotoninergic 
neurons, while desip~amine and protriptyline are inactive in 
this test . This finding has been supported by othe r worke r s 
(Lidbrink et al., 1971; Hamberger and Tuck, 1973) and some 
authors suggest that the efficacy of the tricyclics is based 
on th is serotonin potentiating property (Coppen, 1967; 
Lapin and Oxenkrug, 1969). In addition, the tricyclics 
have been reported to reduce central seroton i n turnover 
(Schuberth, 1973). This phenomenon, however, may be secondary 
to receptor stimulation and may r esult from feedback 
inhibition of serotonin synthesis. Inhibition of the 
uptake of tryptophan into the neurons by the tricyclic 
compounds (Bruinvels, 1972) is another possible explanation . 
In humans, the tricyclic s (imipramine, amitriptyline and 
clomipramine) have been shown to reduce the post-
probenecid accumulation of 5- HI AA which indicates a 
decreased seroton in turnover (Bowers , 1972b; Post and 
Goodwin , 1974). 
Not all the tricyclic compounds have the same inhibitory 
effect on the reuptake of noradrenaline and serotonin. 
Laboratory studies have demonstrated that desipramine 
... . . - 53 -/ 
- 53-
selectively inhibits the reuptake of noradrenaline (Carlsson 
et al., 1969a; Eckhardt and Maxwell, 1973; Ross and. Renyi, 
1975; Uzan and Le Fur, 1975; Koe, 1976) with little effect 
on serotonin (Carlsson et al., 1969b; Maas, 1975; Ross 
and Renyi, 1975; Uzan and Le Fur, 1975; Koe, 1976). 
Amitriptyline, on the other hand, has been shown to 
selectively inhibit the reuptake of serotonin with little 
effect on noradrenaline reuptake (Carlsson et al., 1969b; 
Haas, 1975; Ross and Renyi, 1975) . Imipramine inhibits 
serotonin and noradrenaline reuptake almost equally, 
although at half the activity of either amitri p tyline or 
desipramine (Maas , 1975) . This is summarized in Table 7. 
The hypothesis that the tricyclics' therapeutic effect be 
attributed to their ability to inhibit the uptake of nor-
adrenaline and/or serotonin has been questioned with the 
discovery of the newer tricyclics, butriptyline and 
iprindole. These drugs have been shown to exhibit a weak 
inhibitory effect on noradrenaline and serotonin reuptake 
(butriptyline: Jaramillo and Greenberg, 1975; iprindole: 
Ross et al., 1971; Fann et al., 1972; Sanghvi and Gershon, 
1975; Horn, 1976) even though they are clinically effective 
antidepressives (butriptyline : Levinson, 1974; iprindole: 
Fann et al., 1972, review; Rickels et al., 1973; Briant 
and George, 1975; Tait and Todrick, 1975). 
More recently the neurotransmitter, dopamine (DA) has been 
implica ted in the aetiology of depression and the TADs' 
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TABLE 7: 
SYNAPTOSOMAL UPTAKE INHIBITION OF NORADRENALINE 
AND SEROTONIN AT CLI NICALLY ACHIEVABLE LEVELS OF 
TRICYCLICS (Maas, 1975) 
Tricyclic Antidepressive Noradr e naline 
Amitriptyline 
Nortriptyline 
Imipramine 
Desipramine 
o = probable lack of activity 
++++ = most active 
0 
++ 
++ 
++++ 
. . ..• - 5 5 - / 
Serotonin 
++++ 
++ 
+++ 
0 
- 55 -
mechanism of action (Randrup et al., 1975, review). 
Amitriptyline and doxepin have been shown to be potent 
inhibitors of the DA sensitive adenyl cyclase (like the 
neuroleptics) while the other tricyclic derivatives were 
moderate or weak inhibitors (Karobath, 1975). Modigh 
(1975) reported that protriptyline administration resulted 
in DA supersensitivity, the duration of which paralleled 
the duration of the antidepressive effect (Modigh, 1976b). 
Initially it was thought that the neuronal uptake of DA 
was not inhibited by the TADs, but more recently, Randrup 
and Braestrup (1977) have shown that the classical tricyclic 
drugs (together with the more recently developed drugs, 
butriptyline and iprindole) all inhibit the uptake of DA 
in crude striatal synaptosomes at concentrations between 
6 5 
10 to 10 M (Table 8). 
All th e clinically effective tricyclics display considerable 
anticholinergic properties both centrally (Sulser et al., 1964; 
ValIant, 1967) and peripherally (Sigg, 1959; vernier et al., 
1962; Sigg et al., 1963) . It has been proposed that the 
blockade of central cholinergic responses may account for 
the drugs' antidepressive effect (Biel et al., 1962; Biel, 
1966; Janowsky et al., 1972b). 
In conclusion, the various tricyclic drugs exert differing 
inhibitory effects on noradrenaline, serotonin and dopamine 
reuptake (see Table 8) and at present, it is not known which 
transmitter is of prime importance for its antidepressive 
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TABLE 8: 
SYNAPTOSOMAL UPTAKE INHIBITION OF BIOGENIC 
AMINES BY ANTIDEPRESS IVE DRUGS. (Randrup 
and Braestrup, 1977) 
Concentration c a using 50 % inhibition 
of uptake ( \.1M) 
Drug 
Dopamine Norad,renaline Serotonin 
Butriptyline 5,2 1,7 10,0 
Trimipramine 6,8 1,0 8,2 
Maprotiline 8,6 0,02 12,0 
Desi pramine 8,7 0,0015 2,0 
Clomipramine 3,8 0,044 0,015 
Nortriptyline 4,4 0,011 0,42 
Protriptyline 4,9 0,003 1,62 
Amitriptyline 5,6 0,02 -
Imipramine 12,5 0,02 0,24 
Dibenzepin 1l3,0 - -
Iprindo1e 7, 9 2,6 10,0 
Mianserin 19,0 0,084 11,0 
Nomifensine 0,10 0,007 6,6 
- Comparative values not available . 
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effect. Some authors believe that the mood-elevating 
action is due to the blockade of serotonin reuptake and 
that activation of motor activity is related to the effect 
on noradrenaline (Lapin and Oxenkrug, 1969; Carlsson, 1976). 
However, it is possible that all 3 of t h e se amine s are 
involved in antidepressive effects and their interactions 
are important. 
1.1.6.4.2 Monoamine Oxidase Inhibitors : 
The monoamine oxidase (MAO) inhib itors constitute the second 
major group of antidepressive drugs. They are subdivided 
according to structure into hydrazine derivatives (phenelzine, 
isocarboxazid and nialamide) and nonhydrazine derivatives 
(tranylcypromine and pargyline). 
Iproniazid was the first compound shown to be effective in 
reversing depressive symptoms (Crane, 1957; Loomer et al., 
1957; Kline, 1958) and since then, the clinical effective-
ness of the MAO inhibitors has been studied fairly 
extensively (Hordern,1965; Cole and Davis, 1967; Davis 
et al., 1967; Shepherd et al., 1968). Discrepancies 
betwee n the various studies hav e been reported which supports 
the suggestion that only a specific subgroup of depressed 
patients may be responsive to ~mo inhibitor treatment (West 
and Dally, 1959; Pare et al., 1962). It has been proposed 
that while "endogenous" dep ressio n s respond particularly 
well to tricyclic antidepressive administration, patients 
with "neurotic" and "atypical" depr e ssions improve more 
. . . .. - 58 - / 
- 58-
with the MAO inhibitors (Sargant, 1961 ; Sargant and Dally, 
1961; Crane, 1970). In addition, it has been found that 
the family members of the responders of MAO inhibitors have a 
tendency to react favourably to such compounds, and 
negatively to TADs which suggests a genetic factor. 
In general/ MAO inhib i tors seem less effective than the TADs. 
The tricyclics were found to be significantly superior in 
9 studies , whereas no study has shown the reverse (Beck, 
1973, review). In add i tion, the side effects associated 
with the MAO inhibitors (dizziness, dry mouth, constipation, 
impotence, orthostatic hypotension and paroxysmal hyper-
tension) were reported to be more numerous and more severe 
than with the tricyclic drugs (Beck , 1973). A potentially 
more serious side effect of MAO inhibition is the hyper-
tensive crises ("the cheese effect") that can occur in 
patients who have ingested food rich in either sympatho-
mimetic amines or their precursors, such as, tyramine 
(Blackwel l , 1963; Blackwell and Mabbitt, 1965; Shepherd 
et al., 1968; Youdim, 1976) . This adverse reaction has 
limited their clin i cal usefulness. 
Because of the variability of clinical response and the 
possibi l ity of toxic side effects, these agents are not 
the first drugs to be prescribed in the treatmen t of 
depression. MAO inhibitors are usually only used if the 
depressed patient has shown a previous favourable reaction 
to them or if treatment with a TAD has failed . 
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1.1.6.4.2.1 Mechanism of Action: 
MAO isoenzymes which are associated with the mitochondria 
of nerve terminals, exist in at least 2 different forms -
type A and type B. The classification is based on 
substrate specificity and sensitivity to inhibition by 
selected inhibitors (Christmas et al., 1972; Sandler and 
Youdim, 197 2 ). The A type enzyme has a substrate preference 
for noradrenaline and serotonin and is selectively inhibited 
by clorgyl j ne. The B type enzyme has a s ubstrate preference 
for S- p henylethylamine and benzylamine and is selectively 
inhibited by deprenyl. Dopamine, tyramine and tryptamine 
are equally good substrates for both forms of the enzyme. 
However, the relative importance of these 2 types of MAO 
in depressive disorders is currently unknown. 
The MAO inhib itor antidepressives inhibit the activity of 
these enzymes (Zeller et al., 1952; Pletscher, 1968) which, 
in turn, causes an increase in the biogenic amines and a 
decrease in their deaminated metabolites within the nerve 
terminal (Kopin, 1964; Pschneidt, 1964). These higher 
concentrations of transmitters are then available for 
release from the presynaptic terminals, following 
stimulation. The degree of inhi bi tion of MAO activity 
has been reported to be related to the clinical anti-
depressive effects (Feldstein et al., 1965; Ravaris et al., 
1976) . The mechanism of action of the MAO inhibitors is 
illustrated in Figure SA . 
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PRESYNAPTIC NEURON POSTSYNAPTIC NEURON 
Fig. SA . 
vesicles 
• 
RECEPTOR 
• • 
COMT 
Schematic Representation of the Mechanism of Action of 
the Monoamine Oxidase Inhibitors. 
The MAO inhibitors block the degradation of the neurotransmitter 
(noradrenaline and serotonin) by MAO. 
COMT, catechol-O-methyltransferase, MAOI, monoamine oxidase inhibitor 
PRESYNAPTIC NEURON POSTSYNAPTIC NEURON 
Fig. SB. 
torage vesicles ® • 
e 0 • RECEPTOR ON • 
Schematic Representation of the Proposed Mechanism of 
Action of the Psychostimulants. 
Psychostimulants (e . g. amphetamine) stimulate the release of 
stored noradrenaline and dopamine, inhibit the reuptake of the 
neurotransmitter from the synaptic cleft and inhibit MAO . 
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It has also been proposed that the MAO i nhibitors b lock 
the reuptake of released noradrenaline into the storage 
vesicles, thereby producing an increased concentration of 
noradrenaline around the adrenergic synapses (Pletsher, 
1966). In addition, the MAO inhibitors have been reported 
to reduce central serotonin turnover (Glowinski et al., 
1972; Schuberth, 1973). This, however, may be a r esult 
of receptor stimulation and subsequent feedback inhibit i on 
of serotonin synthesis. 
Inhibitors of MAO elevate the ' brain levels of both nor-
adrenali ne and serotonin ; which of these amines p l ays 
the major role in these drugs' mechan ism of action is a 
point of contention. Some authors rega rd the increase 
of noradrenali ne as being of primary importance (Pletsche r , 
1964), whereas others suggest the increased serotonin level 
is more cruc ial (Dahlstrom and Fuxe, 1964; Bartonicek , 1966). 
Moreover, the particul ar effec t may vary wi th the MAO inhibitor 
used (Gorkin , 1966) - for example, phenelz ine and nialamide 
inhibit the deamination of serotonin more stro ngly than the 
deamination of tyramine, whereas other MAO inhibitors inhibit 
inacti vation of both amines equally. Chronic t reatment with 
MAO inhibitor drugs has been shown to cause a greater increase 
of brain serotonin than of noradr enaline (Specto r et al ., 
1960; Green et al ., 1962). In addition, the absolute and 
relative incr ease of amines after administration of MAO 
inhibitors, varies from region to r egion of the brain - for 
instance, in the limbic structures of intact rats the ratio 
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of serotonin to noradrenaline is normally 1 : 1, but 4 
hours after tranylcypromine administration this ratio was 
found to be 5 : 1 (Valzelli and Garattini, 1968). 
I nh i b iti on o f MAO h a s bee n li n ke d with t he " PaI se Ne urochemi c al 
Transmitter" theory promulgated by Kopin' et al. (1965). 
This proposes that MAO inhibition will produce an 
accumulation of sympathomimetic metabolites which 
no r mal ly ar e not present in the body, but which have 
sufficient affinity for the adrenerg i c receptor sites to 
displace the regularly presen t neurotransmitters from 
sympathet i c nerve endings. Moreover, sympathetic nerve 
stimulation will rele ase these agents in the same way as 
it does noradrenaline. However, the resultant effect at 
the postsynaptic receptor sites will be greatly diminished, 
since the fa l se neurotransmitters have distinctly weaker 
sympathomimeti c properties (Kopin, 1968; 1971). Normally 
tyramine is rapidly metabolized by MAO so that little oct opamine 
i s formed . However, following MAO inhibition, this acts as a f alse neuro-
transmitter having only one-h undredth the efficacy of nor-
adrenaline at postsynapti c receptor sites (Molinoff and 
Axelrod, 1969; Kopin, 1 971). This has been supported 
by clinical studies which h a ve shown octopamine to accumulate 
in plate lets from depressed patients treated with MAO in-
hibitors (Murphy , 1972). Octopamine has also been fo und 
in plate l ets from patients with endogenous l y r educed MAO 
activity. 
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1.1.6.4.3 Lithium: 
Well-controlled studies have indicated that lithium is 
highly effective in the treatment of manic and hypomanic 
states (Schou, 1959; 1967; Gershon and Yuwiler, 1960; 
Maggs, 1963). More recently it has been suggested that 
lithium maintenance therapy might exert a prophylactic 
effect in the treatment of r ecurrent manic-depress i ve 
disorders (bipolar) and in recurrent depression in which 
no manic episode occurs (unipolar) (Hartigan, 1963; Baastrup 
and Schou, 1967). These authors have reported that lith ium 
maintenance treatment may prevent, delay or alleviate these 
recurrent affective episodes. The efficacy of lithium 
salts in the prophylactic treatment of man ic-depressive 
disorders has , however , been questioned (Blackwell and 
Shepherd, 1968) . Numerous o t her workers have studied 
the efficacy of lithium as a preventative agent in 
depression and the results are conflicting. In 9 
controlled studies lithium was reported to be signifi-
cantly superior to placebo (Angst et al., 1970; Coppen 
et al., 1971a; Schou, 1971) but not significantly superior 
in another . 3 . studies (Fieve et al., 1966; Melia, 1970; 
Polackova et al ., 1971). 
The use of lithium salts in the treatment of depression is 
controversial . Controlled studies inves tigating the 
effectiveness of lithium in the treatment of depression 
have been published and are outlined in Table 9. 
Differences in the response pattern to lithium between 
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TABLE 9: 
TREATMENT OF DEPRESSION WITH LITHIUM 
Number 
of Diagnosis Drugs Used Results Reference 
Patients "-I 
lf1 
12 Acute depression Lithium or placebo No significant Hansen et al. , 
'" 
-difference be- 1959 
tween lithium 
and placebo. 
30 Depression Lithium or placebo Bipolar depressions Goodwin e t al. , 
-responded more 1969 
favourably than 
... unipolar depressions . 
'" 29 Acutely depressed Lithium or imi- Imipramine signifi- Fieve et al. , 
manic-depressives pramine cantly superior -to 19p8 
lithium although both 
groups showed improve-
ment. 
70 Manic-depressives Lithium or imi- Imipramine signifi- Platman, 1970 
pramine cantly superior to 
lithium. 
24 Acute depression Lithium or des- Both exhibited Mendels et al. , 
ipramine similar anti- 1972 b -
depressiv e 
activities. 
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bipolar and unipolar depressive patients have been revealed. 
It has been reported that both the manic and depressive 
phases of bipolar patients respond more favourably to 
lithium than the depressive phase of unipolar patients 
(Hartigan, 1963; Baastrup, 1964; Goodwin et al., 1972; 
Klerman, 197 4 ; Noyes et al., 1974; Prien, 1974). This 
responsiveness to lithium has been used in the classification 
of affective disorders to identify bipolar depressive 
patients (Table 3). 
Although no definite conclusion can be drawn concerning 
lithium's antidepressive effect, there is some evidence 
that lithium may be of value in the treatment of patients 
with recurrent depressions that are resistant to other 
therapies (Dyson and Mendels, 1968; Greenspan et al., 
1968 ; Zall et al., 1968). These lithium responsive 
patients are characterized by a capacity to develop higher 
red blood cell lithium concentrations during treatment 
(~Iallinger et a1. , 1975; Frazer and Mendels, 1977). 
1.1.6.4.3.1 Mechanism of Action: 
The mechanism by which lithium exe rts its psychiatric 
effects is not yet known and it is difficult to determine 
which of the many known lithium effects are relevant to 
its clinical action. 
A number of hypotheses regarding its mode of action have 
been put forward . Coppen et a1. (1962) suggested that 
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lithium exerts its therapeutic effect by replacing sodium 
intracellularly and thereby restoring the resting electro-
lyte balance across the cell membrane. Coppen (1967) and 
Bunney et al. (1972b) hypothesized that the sodium pump 
(which is responsible for removing sodium from the cell) 
is defective in affective illness and l i thium administration 
correc t s t his imbalance. In support of this, lithium 
carbonate treatment of manic patients has been shown to 
be accompanied by decreased residua l sodium levels in 
2 of the 3 studies (Coppen et al., 1967a; Baer et al. , 
1970; Mendels , 1971) . 
It is likely that the intracellular displacement of sodium 
by lithium also has an effect on the electrophysiology of 
the cell (Whybrow and Mendels, 19 69) . The studies of 
Garside et al. (1966) and Barratt et al. (1968) have suggested 
that lithi um administration reduce s CNS excitability. The 
literature was reviewed in detail by Schou (1957). 
An alternat i ve hypothesis suggests that lith i um's thera-
peutic effect is media t ed via the biogenic amines. Af t er 
a transient increase in catecholamine turnover rate 
(Schildkraut, 1973b),lithium has been shown to inhibit 
the release (Baldessarini, 1975) and increase the reuptake 
of catecholamines (noradrenaline and dopamine) at pre-
synaptic neurons (Colburn,et al. , 1967; Baldessarini and 
Yorke , 1970; Kuriyama and Speken, 1 970). Synaptosomes, 
isolated from the brain of rat s and pretreated with li thium, 
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have been shown to take up noradrenaline to a significantly 
greater extent than their controls (Colburn et al., 1967). 
Blood platelets (which have similar membrane functions to 
synaptosomes) from patients treated with lithium carbonate 
also show an increased uptake of noradrenaline (Murphy et al., 
1969) . Lithium has also been shown to interfere with some 
cyclic adenosine monophosphate (c-AMP) mediated hormones to 
stimulate specific adenylate cyclases (Forrest, 1975) which 
are important components of the postsynaptic receptor 
mechanisms in the mediation of responses to catecholamines 
(Forn and Valdecasas, 1971). 
The hypotheses which implicate either biogenic amines or 
electrolytes in the mechanism of lithium are not mutually 
exclusive. Extracellular sodium is required for the 
neuronal uptake of noradrenaline and serotonin, thus in the 
case of a defective sodium pump, the lack of extracellular 
sodium may prevent the uptake mechanism and maintain the 
manic syndrome (Bunney et al., 1972b; Ban, 1977). In 
addition, intracellular sodium has been found to cause a 
steady release of noradrenaline from the synaptic vesicles 
which, in the case of a defective sodium pump, would maintain 
the manic state unless counteracted by lithium administration 
(Bunney et al., 1972b; Mendels et al., 1974). 
An alternative hypothesis on the action mechanism of lithium 
suggests that lithium exerts its therapeutic effect by 
producing a shift in the metabolism of monoamines from 
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extracellular O-methylation to intracellular deamination. 
In favour of this hypothesis are the findings that there 
is a decrease in the urinary excret ion of normetanephrine, 
and an increase in the urinary excretion of VMA and 5- HIAA 
d u ring successful lithium treatment (Schildkraut et al ., 
1967; Mendels et al., 1973). 
Lithium effects on biogenic amines are compatible with the 
catecho lamine hypothesis as long as lithium is considered 
only as an antimanic drug. Current hypotheses, however, 
fail to explain the effectiveness of lithium in the 
prevention of recurrent depression. 
Lithium administration also exerts an effect on indoleamines. 
Knapp and Mandell (1973) have reported that chronic lithium 
treatment increases tryptophan uptake but decreases the 
activity of tryptophan hydroxylase in rat synaptosomes. 
In addition to its effect on the catecholamines and indole-
amines , lithium has been found to decrease both the synthesis 
and release of acetylcholine (Dawes and Vizi , 1973; Vizi, 
1975) as well as increase the synthesis of glutamate and 
d'-aminobutyrate (GABA) (Gottesfeld et al., 1971; 1973). 
In short, the mechanism of action of lithium, according to 
Baldessarini and Lipinski (1975), "has not yet been explained 
by a coherent and convincing body of data or theory, although 
it seems likely that important effects at neuronal and 
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hormonally sensitive membranes are involved. 
1.1.6.4.4 Psychostimulants: 
The psychostimulants, amphetamine, methamphetamine and 
methylphenidate, cause hyperactivity in animals and mood 
elevation , increased alertness and enhanced performance 
in humans (Weiss and Laties, 1962; Innes and Nickerson, 
1965). Amphetamine has been used for many years with 
variable results in the treatment of depression. Although 
the drug has been reported to possess some clinical anti-
depressive activity (Prange, 1975a), it i s generally agreed 
that it has little to offer in the tr eatment of the major 
depressive disorders (Hordern, 1965; Cole and Davis, 1967; 
Davis et al., 1968; Shepherd et al., 1968). Amphetamine 
administration may alleviate the symptoms of mild or 
"reactive" depressions but such beneficial effects are 
often transient and may be accompanied by a number of 
unwanted side effec ts, such as insomnia and nervousness. 
There is also the possibility of tolerance and addiction 
developing and as a result, the drug has limited usefulness 
as an antidepressive (General Practitioner Research Group, 
1964; Davis et al., 1968). In addition, it has been 
observed clinically that after the chronic administration 
of large doses of amphetamine, a "rebound period" of mental 
depression and fatigue develops which has been attributed 
to a temporary deplet ion of noradrenaline stores (McLean 
and McCartney , 1961; Moore and Lariviere, 1963). This 
interpretation is supported by the finding that large doses 
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of amphetamine significantly lower the concentration of 
brain noradrenaline in animals (Smith, 1965). 
The mechanism of action of amphetamine is quite complex as 
it has been reported to have several actions on the nerve 
terminal. It increases the concentration of catecholamines 
(noradrenaline and dopamine) in the synaptic cleft by re~ 
leasing them from the intraneuronal storage vesicles 
(Iversen, 1964; Hanson, 1967). There is also evidence 
that amphetamine blocks the cellular reuptake of the mono-
amines in a similar manner to the TADs (Carlsson et al., 
1966; Rutledge, 1970; Fawcett et al., 1972; Maas, 1975). 
Amphetamine may also inhibit the enzyme, MAO (Costa and 
Garattini, 1970). The proposed mechanisms of action of 
amphetamine are illustrated in Figure 58. 
Amphetamine may, however, have some value in separating 
the various types of depressive disorders. Roberts (1959a; 
1959b) found that patients suffering from "neurotic" 
depression showed a euphoric response after an acute dose 
of methamphetamine, whereas patients with "psychotic" 
depressions experienced dysphoria. Fawcett et al. (1968) 
used a three-day trial of amphetamine to predict which 
depressed patients would respond to the TADs. Those 
patients who exhibited e lation and a temporary improvement 
in depressive symptoms after amphetamine administration, 
have been found to be responsive to subsequent tricyclic 
therapy, whereas those who were unaffected by the amphetamine 
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treatment failed to respond to the tricyclics (Fawcett 
and Siomopoulous , 1971). 
1.1.6.4 . 5 Atypical Antidepressives: 
Although these drugs are clinically effective, they differ 
in bo th chemical structure and pharmacological activi ty 
from the classical TADs or MAO inhibitors. 
1.1.6.4.5.1 Iprindole: 
Iprindole, a tricyclic indole, has been shown in several 
double-blind studies to be an effective antidepressive 
(Johnson and Maden , 1967; Imlah et al., 1968; Sutherland 
et al., 1970) with its clinical efficacy comparable with 
imipramine (Ayd, 1969 ; Fann et al. , 1972, review; Rickels 
et al., 1973; Briant and George, 1975; Tait and Todrick, 
1975) . 
Pha~macologically the drug is neither a strong inhibitor 
of noradrenaline and serotonin reuptake (Ross et al., 1971; 
Fann et a l., 1972; Sanghvi and Gershon, 1975; Horn, 1976; 
Koe, 1976), nor an inhibitor of MAO (Rosloff and Davis, 
1974) . This indicates that its antidepressive activity 
is mediated by a mechanism different from that suggested 
for the classical antidepressives . Iprindole has been 
reported to possess about the same potency in inhibiting 
striatal dopamine uptake as the classical tricyclics 
(Halaris et al., 1975; Randrup and Braestrup, 1977) wh ic h 
may explain its antidepressive effect (Table 8 ) . 
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Noradrenaline-sensitive limbic cyclase activity in rats is 
also reduced after chronic administration of iprindole 
(Vetulani and Sulser, 1975). If the hypothesis that 
some depressed patients may exhibit an increased receptor 
sensitivity to noradrenaline is correct, then iprindole 
(as well as the TADs, MAO inhibitors and ECT) may exert its 
therapeutic effect by this mechanism (Vetulani and Sulser, 
1975; Vetulani et al., 1975). 
1.1.6.4.5.2 Mianserin: 
The tetracyclic compound, mianserin, although pharmacologically 
and biochemically different from the classical TADs, has been 
shown to be an effective antidepressive in man (Wheatley, 
1975; Murphy, 1975; Ghose et al., 1976; Pichot et al., 
1978; Smith et al., 1978). Although the drug inhibits 
the brain uptake of noradrenaline in vitro (Koe, 1976; 
Raiteri et al., 1976), neither biogenic amine uptake 
(Leonard, 1974; Burgess et al., 1978) nor MAO activity 
(Coppen et al., 1978a) is inhibited in vivo. In fact, 
mianserin has been found to be a potent serotonin antagonist 
both centrally and peripherally (Van Riezen , 1972; Jalfre 
et al., 1974; Maj et al., 1976). Moreover , an increase in 
the synthesis and turnover of noradrenaline has been 
demonstrated in animals who were pretreated with mianserin 
both acutely (Kafoe and Leonard, 1973) and chronically 
(Kafoe et al., 1976). This acceleration of noradrenaline 
synthesis has been suggested as a possible mechanism of 
mianserin's antidepressive action (Garver and Davis, 1978) . 
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1.1.6.4.5.3 Nomifensine: 
The antidepressive activity of nomifensine has been confirmed 
by numerous investigators (Franchin, 1973; Madalena et al., 
1973; Pecknold et al., 1975; Acebal et al., 1976). In 
addition to blocking noradrenaline uptake (Samanin et al., 
1975; Koe, 1976), it is also a potent blocker of dopamine 
uptake in the rat brain (Hunt et al., 1974; Randrup and 
Braestrup, 1977; Tuomisto, 1977). This is illustrated 
in Table 8. Serotonin uptake, however is not inhibited 
to any significant extent (Schacht and Heptner, 1974; 
Samanin et al., 1975). 
1.1.6.4. 5 .4 Other Atypical Antidepressives: 
The drugs fenfluramine, maprotiline, toloxatone and 
viloxazine have been shown to possess antidepressive 
activity despite their widely differing mechanisms of 
action (fenfluramine: Murphy et al., 1976; maprotiline: 
Ludiomil Symposium, 1975; Kielholz, 1972; 1973; 1974; 
Briant and George, 1975; toloxatone: Martin, 1973; 
Suttel and Duplan, 1973; viloxazine: Vivalan Symposium, 
1975; Moizeszowicz and Subira, 1977). 
Fenfluramine inhibits the uptake of serotonin into blood 
platelets (IVielosz et al., 1976) and causes the release of 
serotonin from central storage vesicles (Trulson and Jacobs, 
1976) . 
Maprotiline is a stong inhibitor of noradrenaline uptake 
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(Wa1dmeier et a1., 1976) but only has a weak inhibitory 
effect on serotonin uptake (Maitre et a1., 1975; Benesova 
and Benes , 1974). striatal dopamine uptake is also 
inhibited by this drug (Ha1aris et a1., 1975; Randrup 
and Braestrup, 1977). 
To1oxatone, an oxazo1idinone derivative, appears to be a 
relatively specific type A MAO inhibitor (Kan et a1., 1977). 
Vi1oxazine, a S-b1ocker derivative, neither inhibits MAO 
nor b locks the uptake of monoamines in the brain (Ma11ion 
et a l., 1972; Roe, 1976; Lippman and Pugsley, 1976) . 
..... - 75 - / 
- 75 
1.2 BIOCHEMICAL THEORIES OF DEPRESSION: 
1.2.1 Catecholamine Hypothesis: 
In 1965, Schi1dkraut (1965) put forward the "catecholamine 
hypothesis". In essence, this hypothesis postulates that 
depression is associated with an absolute or relative 
deficiency of catecholamines, particularly noradrenaline, 
at functionally important adrenergic receptor sites in the 
bra i n. Elation, or mania, on the other hand, is presumed 
to be associated with an excess of the neurotransmitters. 
The proposal was based on two fundamental observations. 
Reserpine, a drug which is capable of precipitating severe 
depression in some humans (Muller et al., 1955; Harris, 1957), 
lowers both the catecholamine and indoleamine concentrations 
in the brain (Shore, 1962). Iproniazid, a t herapeutically 
effective antidepressive (Crane, 1957; Cole et al., 1961), 
raises the concentration of biogenic amines in the brain 
by blocking the action of MAO (Spector et al., 1960; 1963) . 
Additional pharmacological evidence which supported this 
hypothesis is summarized in Table 10. Largely on the basis 
of this indirect e v idence, other workers supported the 
proposal that an alteration in brain catecholamines may be 
i nvo lved in the pathophysiology of affective disorder s 
(Bunney and Davis, 1965; Coppen, 1967). 
There are, however, numerous problems with the pharmacological 
evidence that supports the catecholamine hypothesis. For 
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TABLE 10: 
PHARMACOLOGICAL OBSERVATIONS CONSISTENT WITH THE CATECHOLAMINE HYPOTHESIS 
(Modified from Schildkraut (1965) and Davis (1970)) 
DRUG 
RESERPINE 
TETRABENAZINE 
MAO INHIBITORS 
TRICYCLIC ANTI-
DEPRESSIVES 
AMPHETAMINE 
ECT 
LITHIUM 
L-DOPA 
PROPRANOLOL 
ACTION 
DEPLETES BRAIN OF NA 
AND 5HT 
DEPLETES BRAIN OF NA 
AND 5HT 
ELEVATES BRAIN LEVELS 
OF NA AND 5HT BY 
BLOCKING MAO 
BLOCKS UPTAKE OF NA 
AND 5HT 
INHIBITS CELLULAR 
UPTAKE AND INACTIVA-
TION OF NA 
RELEASES NA 
INCREASES N~ TURNOVER 
INCREASES NET UPTAKE 
OF NA AND 5HT 
REDUCES RELEASE OF NA 
AND 5HT 
INCREASES NA 
a -ADRENERGIC BLOCKER 
EFFECTS ON 
BEHAVIOUR IN ANIMALS 
SEDATION 
SEDATION 
EXCITEMENT 
PREVENTS AND REVERSES 
RESERPINE-INDUCED 
SEDATION 
EFFECTS ON 
MOOD IN HUMANS 
SEDATION 
CAUSES DEPRESSION 
(in some patients) 
SEDATl'ON 
CAUSES DEPRESSION 
(in some patients) 
RELIEVES DEPRESSION 
PREVENTS RESERPINE- RELIEVES DEPRESSION 
INDUCED SEDATION 
POTENTIATES THE 
EFFECTS OF AMPHETAMINE 
EXCITEMENT 
PREVENTS THE HYPER-
ACTIVITY INDUCED BY 
DMI AND RESERPINE 
EXCITEMENT 
REVERSES RESERPINE 
EFFECTS 
ELATION 
RELIEVES DEPRESSION 
RELIEVES MANIA 
RELIEVES DEPRESSION? 
CAUSES DEPRESSION 
DMI, desipr am i ne ; NA , noradrenaline; 5HT, serotonin; r1AO , monoamine oxidase . 
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example, it is not clear whether the therapeutic effects 
of these agents (reserpine, TAOs, MAO inhibitors, lithium, 
ECT) result from their effects on the catecholamines or on 
serotonin. In addition, the clinical effects of reserpine, 
TAOs and lithium take from several days to weeks to become 
apparent, whereas their effects on biogenic amines are 
immediately evident in in vivo studies. Thus the chronic 
effects of these drugs are probably more complicated. 
Two major research strategies have been employed to test the 
catecholamine hypothesis. One approach, the precursor 
loading technique, consists of administration of the 
catecholamine precursor amino acids and observation of the 
therapeutic response. 
L-DOPA has been used in the treatment of depression with 
mixed results. Pare and Sandler (1959) were the first to 
administer L-DOPA to depressed individuals and they reported 
no therapeutic effect. This has been confirmed by several 
investigators (Klerman et al., 1963; Schildkraut et al., 
1963; Turner and Merlis, 1964; Davis, 1970). In contrast 
Ingvarsson (1965) reported dramatic remissions of long 
standing drug resistant depressions following the 
administration of L-DOPA every other day. Marked improve-
ment was seen within a few hours and relapses occurred on 
discontinuance of the L-DOPA therapy. More recent reports 
by Goodwin et al. (1970) and Matussek et al. (1970) have 
shown that if large doses of L-DOPA are used, with or without 
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a peripheral decarboxylase inhibitor, there is a therapeutic 
response in about one third of the patients, although others 
may deteriorate. Bunney et al. (1971) have reported L-DOPA 
to be particulQrly useful in the treatment of "retarded" 
depressions. This has led to the suggestion that within 
a heterogeneous depressive population, there is a subgroup 
of patients who will respond to L-DOPA therapy. 
There are a number of possible explanations for L-DOPA's 
lack of effect. L-DOPA does not pass through the blood 
brain barrier easily, thus it may be difficult to reach 
therapeutic levels in the brain (Berlter et al., 1966). 
In addition, although L-DOPA treatment leads to increased 
levels of dopamine in the brain, only a small fraction is 
converted to noradrenaline (Glowinski and Iversen, 1966). 
In most studies noradrenaline brain levels are either 
unchanged or are lower following L-DOPA administration 
(Butcher and Engel, 1967; Iversen, 1967; Everett and 
Borcherding, 1970), although the turnover of noradrenaline 
may be increased (Dairman and Udenfriend, 1971). Another 
complication of L-DOPA treatment is that the metabolic 
response to the drug is not confined to the catecholamine 
system. L-DOPA has been reported to decrease rat brain 
serotonin in a dose-dependent manner (Everett and Borcherding, 
1970) . The behavioural responses of animals to L-DOPA can 
be prevented by PCPA which suggests that serotonin is 
necessary for the drug's behavioural response (Carroll, 
1971). Decreased serotonin synthesis has also been observed 
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in depressed patients following L-DOPA administration 
(Goodwin et al., 1971; Dunner and Goodwin, 1972) . 
Platelet serotonin content has also been found to decrease 
significantly during L-DOPA treatment (Murphy, 1972). A 
number of mechanisms purporting to explain the above findings 
have been put forward and are discussed in detail by Carroll 
(1971) and Murphy (1972). 
The negative results following L-DOPA administration 
challenge the adequacy of the catecholamine hypothesis of 
depression. The results suggest functional interactions 
between catecholamines and indoleamines at the cellular 
level which, in turn, underlies the need for combined study 
of the different neurotransmitter systems instead of narrow 
adherence to one system. 
Another more direct approach for confirming the catecholamine 
hypothesis involves measuring the postmortem catecholamine 
metabolites in the brain and the body fluids of patients 
with affective illnesses. 
Raised urinary noradrenaline levels have been reported in 
depressed patients (Curtis et al., 1960). However, this 
has also been seen in mania (Strom-Olsen and Weil-Malherbe, 
1958), schizophrenia (Mattock et al., 1967) and in a 
psychotically depressed population (Bunney et al., 1967). 
In addition, Bliss and co-workers (1966) found a reduction 
in cerebral noradrenaline concentration when animals were 
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subjected to a variety of stresses. The above results led 
Whybrow and Mendels (1969) to conclude that disturbances in 
peripheral noradrenaline levels represent a general response 
to stress rather than aetiologic disruption of amine 
metabolism. In addition, there is evidence to suggest 
that turmoil, psychosis as well as muscular activity may 
be associated with alterations in the excretion of nor-
adrenaline and its metabolites (Sachar et al . , 1963; 
Schildkraut et al., 1965; Nelson et al., 1966; Bunney 
et al., 1967). 
The most direct test of the catecholamine hypothesis would 
be the measurement of noradrenaline levels in the human 
brain. However, these studies are obviously limited. 
Shaw et al. (1967) and Bourne et al. (1968) examined the 
brains of depressed patients who had committed suicide and 
observed no marked difference in noradrenaline levels when 
compared with a control group who died from other causes. 
Dencker et al. (1966a) and Moses and Robins (1975) also found 
no difference in the brain noradrenaline levels of depressed 
patients . 
MHPG has been shown to be the major metabolite of nor-
adrenaline in the brains of many different species including 
man (Glowinski et al., 1965; Rutledge and Jonason, 1967; 
Schanberg et al., 1968a; 1968b; wilk and Watson, 1973). 
It has, therefore, been suggested that the amount of MHPG 
excreted in the urine may reflect central noradrenaline 
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metabolism (Maas and Landis, 1967; Schanberg et al., 1968a). 
In a pilot study, it was reported that a heterogeneous 
group of depressed individuals excreted significantly less 
MHPG into urine than did a healthy control group, whereas 
the quantities of urinary normetanephrine and metanephrine 
excreted by these two groups were similar (Maas et al., 1968). 
Since then numerous investigators have shown the levels of 
urinary MHPG to be relatively lower during depression and 
higher during mania or hypomania than after clinical 
remissions (Greenspan et al., 1970; Schildkraut et al., 
1971 ; 1972; Bond et al., 1972; Watson et al., 1972; 
Jones et al., 1973). However, this was not confirmed by 
Bunney et al. (1972a) and Shopsin et al. (1973b). In addition, 
one should interpret urinary MHPG levels with caution, since 
these levels may be a function of activity (Ebert et al., 
1972) or stress (Rubin et al., 1970; Maas et al., 1971). 
Maas et al. (1968; 1972) observed that not all depressed 
patients excrete low levels of MHPG and proposed the existence 
of various subgroups of depressives, those excreting normal, 
less than normal or greater than normal quantities of MHPG. 
In support of this, Schildkraut et al. (1977) reported 
significantly lower MHPG excretion in "schizoaffective" 
and "bipolar manic-depressive" depressions than in "unipolar 
chronic characterological" and "non-specific" depressions . 
(The diagnostic criteria for this classification of depressive 
disorders were based on clinical picture and are described in 
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a previous paper (Schildkraut and Klein, 1975». On the 
basis of these findings, they have proposed that examination 
of MHPG levels may provide a biochemical basis for classify-
ing the different types of depressions (Section 1.1.4.1). 
Recent studies of MHPG levels in the CSF of depressed 
patients confirm the existence of subgroups of depressed 
patients, since Gordon and Oliver (1971) a nd Post et al . 
(1973) reported a significant decrease in MHPG in the 
depressed group while Shaw et al. 
(1973) and Shopsin et al. (1973a) did not. In addition, 
Goodwin (1976) found that th e concentration of MHPG in the 
CSF of bipolar depressed patients was lower than in 
unipolar depressive patients. 
Therefore, although the pharmacological evidence supporting 
the catecholamine hypothesis is indirect and indefinite, 
th e more recent clinical findings provide evidence that 
alteration in central noradrenaline metabolism may be of 
importance in the underlying pathophysiology of at least 
some types of depressive disorders. 
l.2.2 Indoleamine Hypo thesis: 
The indoleamine hypothesis of depressive disorders is a 
variation of the catecholamine hypothesis, which states 
that depression is associated with a deficiency of brain 
seroton in (Lapin and Oxenkrug, 1969) . 
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Since reserpine decreases brain serotonin concentrations 
as well as brain noradrenaline levels, and since most 
antidepressive drugs (tricyclics, MAO inhibitors) that 
increase noradrenaline concentrations usually also increase 
serotonin concentrations, the question of whether mood states 
are related to changes in the concentration of serotonin or 
noradrenaline has remained unanswered to date. There are, 
however, a number of findings which suggest that serotonin 
may be of major importance in the aetiology of depressive 
disorders. 
Treatment with TADs has been shown to reduce brain serotonin 
turnover (Goodwin and Post, 1974). These findings are 
consistent with those of Bowers (1972a) as well as those 
from animal studies demonstrating that imipramine decreases 
brain 5-HIAA when administered with probenecid (Bruinvel?, 
1972), decreases serotonin dep~etion after synthesis 
inhibition (Corrodi and Fuxe, 1968; 1969; Bruinvels, 
1972) and retards the disappearance of labelled serotonin 
from the brain (Schildkraut et al., 1969b). In addition, 
there is evidence that treatment with imipramine in usual 
therapeutic doses significantly decreases the concentration 
of 5- HIAA in human spinal fluid (Papeschi and McClure, 1971). 
Imipramine therefore apparently decreases CNS turnover of 
serotonin. Another point in favour of the above hypothesis 
is the observation that elevation of serotonin occurs 
several weeks after the onset of treatment with MAO inhibitors 
coinciding with the time at which the antidepressive effect 
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occurs (McClean et al., 1965). Modification of serotonin 
levels may thus be relevant to the treatment of depression. 
Van Praag (1977a) reported an increased 5-HIAA accumulation 
in CSF following probenecid treatment on the day ECT was 
administered. Moreover, patients who had shown a low 
5-HlAA response prior to therap~ showed a normal response 
1 week after a successful ECT course. Therefore ECT also 
seems to influence serotonin turnover in a direction to be 
expected on the basis of the indoleamine hypothesis. 
There have been two major st~ategies employed to test more 
directly the relationship between serotonin and affective 
disorders. One strategy is to manipulate the level of 
serotonin pharmacologically using serotonin precursors. 
There is no consensus on the efficacy of the serotonin 
precursor, I-tryptophan, in depression. Some authors 
have reported I-tryptophan to be as effective as imipramine 
(Broadhurst, 1970; Coppen and Noguera, 1970; Coppen et al., 
1972a) and ECT (Coppen et al ., 1967b) in the treatment of 
depression. These studies, however, are open to serious 
questions since no placebo 
the study was not double-blind. 
group was included and 
L-tryptophan has also been 
found useful in depression by Cocheme (1970) and van Praag 
and Korf (1970). The apparent prophylaxis by I-tryptophan 
of an annual episode of depression has also been reported 
(Hertz and Sulman, 1968). Other investigators, however, 
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have not confirmed these findings (Bowers, 1970 ; Carroll 
et al., 1970; Bunney et al., 1971; Carroll, 1971; Murphy 
e t al., 1973). Use of tryptophanpyrrolase inhibitors, such 
as allopurinol and nicotinamide, has been suggested as 
adjuncts in the treatment of depression (Curzon, 1969). 
These drugs would protect tryptophan from excessive 
degradat ion along the irreversible pyrrolase-catalysed 
kynurenine pathway and thus favour its passage to the brain 
where it can form serotonin. In a preliminary study 
(Chouinard et al., 1977), nicotinamide has been used 
successfully in combination with l-tryptophan, all the 
depressed patients showing significant improvement over a 
4-week period. 
A study indicating l-tryptophan's ability to potentiate the 
antidepressive effect of a MAO inhi bitor more positively 
connects indoleamines with depression. This potentiation 
was initially demonstrated by Coppen et al. (1963) and has 
been replicated by other workers (Pare, 1963; Glassman and 
Platman, 1969; Van Praag, 1970). Van Praag (1962), 
however, had previously been unable to demonstrate this 
potentiation, either in terms of intensity or of rapidity 
of the antidepressive effect. Van Praag and Korf (1971a) 
in order to explain the variability of the reported results, 
proposed that there is a serotonin deficient subgroup of 
depressed patients who respond to l-tryptophan . The 
combination of l-tryptophan with clomipramine has also 
been reported to produce a more intensive antidepressive 
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effect than clomipramine alone (W§linder g1 ~. / 1975) . 
The immediate metabolic precursor of serotonin, 5-hydroxy-
tryptophan (5-HTP), has also been tri ed alone and in 
combination with MAO inhibitors in the treatment of 
depression but with inconclusive results. 5-HTP alone 
has been reported b¥ 2 groups of investigators (Sano/ 1972; 
Takahashi et al. / 1973b) to be an effective treatment for 
some dep ressed patients. In other studies , this anti-
depressive activity was demonstrated in only a subgroup of 
the depressed population (Persson and Roos, 1967; Brodie 
et al ., 1973). In addition, it has been demonstrated that 
patients who exhibit decreased accumulation of 5-HIAA 
following probenecid administration respond to 5- HTP 
treatment while those exhibiting higher accumulations do 
not (Van Praag et al. / 1972). Where other inves tigators 
have failed to demonstrate a significant antidepressive 
effect with 5- HTP (Pare and Sandler, 1959; Kline et al., 
1964; Glassman and Jaffe, 1969), the discrepancies might 
be explained by the proposal that only those patients with 
decreased serotonin turnover respond to 5-HTP (Van Praag 
e t al., 1973b). 
A single report (Kline and Sacks, 1963) indicates that the 
effects of MAO inhibitors are potentiated by 5-HTP, while 
other reports show no beneficial effects from this 
combination (Pare and Sandler, 1959; Glassman, 1969). 
In normal test subjects, however, 5-HTP has been observed 
to exert a positive influence on mood level (Trimble et al., 
1975) . 
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There are, unfortunately, limitations to the strategy of 
testing theindoleaminehypothesis by the use of precursors,since 
these agents also have effects on other systems. Tryptophan 
raises central serotonin levels but may also alter the levels 
of other transmitters. 5-HTP is taken up not only into the 
serotoninergic neurons but also into the catecholaminergic 
neurons (Van ~raag, 1977a). 
Murphy et al. (1976) tested fenfluramine, a serotonin releaser 
in depressed pa t ients . They reported that there was improve-
ment in a majority of the bipolar depressives after a few 
weeks of treatment but not in the unipolar cases. Moreover, 
there are indications that 4-chloramphetamines, compounds 
which potentiate central serotonin activity, behave like 
true antidepressives (Van Praag and Korf, 1973a; 1976). 
If the indoleamine hypothesis is correct , then drugs which 
decrease serotonin brain levels should cause depression. 
There is evidence that PCPA, which inhibits tryptophan 
hydroxylase and lowers the brain concentration of serotonin, 
can produce depressive symptoms in subjects without a 
previous history of depression (Bunney et al., 1969). 
-- --
More recently, Shopsin and co-workers reported that PCPA 
abolished the therapeutic effect of imipramine (1974) and 
tranylcypromine (1976) within a few days. PCPA administra-
tion caused the patients to revert to the depressed state, 
whereas its withdrawal permitted the re-establishment of 
mental well- being . This finding points to an important 
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role of serotonin, although it should be borne in mind that 
this drug may also have effects other than reduction of 
serotonin formation . 
Methysergide, a specific antagonist of serotonin, has been 
reported to be effective in the treatment of mania (Dewhurst, 
1968b), however, this has been disputed by Coppen et al. 
(1969 ) . 
Thus the results obtained from pharmacological studies using 
drugs which potentiate or diminish serotoninergic activity, 
lend support to the hypothesis that a deficiency in indole-
amines in the CNS plays an important aetiological role in 
the pathogenesis of at least some depressive disorders. 
A more direct way of testing the indoleamine hypothesis is 
by direct measurement of serotonin and its metabolites in 
the biological fluids of depressed patients. The 
concentration of 5-HIAA in the CNS is related to the amount 
of serotonin metabolized in the CNS and consequently, the 
5-HlAA concentration is considered to be an indication of 
the amount of serotonin degraded in the CNS. An argument 
in favour of this is that procedures that stimulate 
~dministration of serotonin precursors) or inhibit (PCPA 
administration) central serotonin synthesis elicit an 
increase or decrease, respecti vely, in the 5-HIAA concentra-
tion in the CSF (Chase, 1972; Dunner and Goodwin, 1972; 
Van Praag et al., 1973b). 
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Numerous investigators have reported lowered levels of 
5-HIAA in the lumbar CSF of depressive and manic patients, 
while others have been unable to confirm these findings. 
A summary of the work down in this field is presented in 
Table 11. The low 5-HlAA levels can be interpreted as 
arising from a defect in the synthesis of brain serotonin 
or a slower rate of its release and metabolism. This 
abnormality has been shown to persist even after apparent 
full recovery (Coppen et al., 1972b; Mendels et al., 1972a). 
It is therefore suggested that serotonin deficiency 
determines the patients' predisposition to depression and 
mania, while other factors may be involved in triggering 
the affective illness (Prange et al., 1974). 
The variable results in many reports of spinal fluid 5-HlAA 
levels in depression might be explained by several factors. 
Post et al. (1973) demonstrated that 5-HIAA levels are 
correlated with motor activity. This relationship had 
previously been noted by Fotherby et al. (1963) and Bowers 
et al. (1969). Variability might also result from different 
amounts being removed during the spinal tap (Siever et al., 
1975) and age (Bowers and Gerbode, 1968; ~sberg et al., 
1973) . These discrepancies might also be based on 
differences in the nature of the control group, differences 
in the procedure for collection of the CSF or other factors 
such as drugs and diet (Goodwin and Post, 1973). A recent 
study was controlled for age of the subject, amount of 
fluid removed and the time of day of the test and again 
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TABLE 11: 
AFFECTIVE 
I LLNESS 
DEPRESSION 
MANIA 
RESULTS OF STUDIES OF CSF 5-HIAA CONCENTRATIONS IN AFFECTIVE ILLNESS 
MEAN 5-HIM LEVEL WITHOUT PROBENECID MEAN 5-HIAA LEVEL WITH PROBENECID 
I1JiI NOR-1AL IJJiJ NOR-1AL 
Ashcroft et al., 1966 Fotherby e t al., 1963 Roos and Sjostrom, 1969 Bowers, 1972b. 
Dencker et al., 1966b Bowers et al., 1969 Sjostrom and Roos, 1972 Goodwin and Post, 
Van Praag et al., 1970 RooS and Sjostrom, Van Praag and Korf, 1973b 1973 
Van Praag and Korf, 1969 Van Praag et al., 1970; 
1971a Papeschi and McClure, 1973a 
Coppen et al., 1972 b 1971 
McLeod and McLeod, Sjostrom and RooS, 
1972 1972 
Mendels et al., 1972a Goodwin and Post, 1973 
Coppen, 1973 
Dencker et al., 1966b Ashcroft et al., 1966 
Coppenetal., 1972b Bowers et al., 1969 
Coppen, 1973 Roos and Sjostrom, 
1969 
Goodwin and Post, 
1973 
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significantly lower CSF 5-HIAA concentrations were seen 
in depressed patients when compared to controls (Coppen, 
1973) . 
The probenecid technique .(Van Praag et al., 1973a) has 
refined spinal fluid studies and has increased the 
reliability of these determinations (Van Praag, 1977a). 
Probenecid inhibits the active transport OD serotonin from 
the CNS to the bloodstream (Neff .et a~., 1967) and thus it 
has been assumed that the rate of 5-HIAA accumulation 
following probenecid administration is proportional to the 
turnover rate of serotonin in the brain. The accumulation 
of 5-HIAA with time following probenecid administration has 
been reported to be lower in depressed patients than in 
control subjects, although this has not been confirmed by 
all investigators (Table 11). 
There are, however, also complications with the probenecid 
test. It is possible that the level of probenecid achieved 
differs from patient to patient or that a given level of 
probenecid produces different levels of transport inhibition 
(Zarcone et al., 1977) . Moreover, it is also possible that 
probenecid may affect serotonin metabolism directly (Korf 
et al., 1972). 
~sberg et al. (1976) measured the 5-HIAA concentration in 
the CSF of 68 depressed patients and demonstrated that this 
measurement is distributed bimodally . In these patients, 
.•.•• - 92 -/ 
- 92 -
29% had less than 15 ng/ml of 5-HIAA and a significant 
correlation between the severity of the depression and 
5-HIAA concentration in this low level subgroup was 
observed. These results support the hypothesis of a 
subgroup of depressed patients with low CSF 5-HIAA levels 
(Section 1.1.4.1). ~sberg's bimodal distribution may 
explain the difficulties investigators have in establishing 
significant differences in 5-HIAA levels in the CSF, with 
or without probenecid. In other words, if a patient group 
included 2 kinds of different modal values and these were 
pooled, there would be little hope of detecting differences. 
The proposed bimodal distribution of 5-HIAA values has been 
supported by Goodwin (1976) and Van Praag (1977b). Kripke 
(1976), however, suggested that bimodal disturbances should 
not be postulated until the possibility that a diurnal 
rhythm has shifted out of place, has been ruled out. 
Several investigators have measured the urinary excretion 
of 5-HIAA in depressed patients. Pare and Sandler (1959) 
and Van Praag and Leijnse (1963) reported that those 
depressed patients who responded to iproniazid had a lower 
initial urinary excretion of 5-HIAA than those who did not 
respond. Burgermeister et al. (1963), however, could not 
replicate these findings . 
Studies on tryptam i ne excretion in depressed patients have 
shown that urinary tryptamine levels can be either increased 
(McNamee et al., 1972) or decreased (Rodnight, 1961; Coppen et al., 
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1965a) in depressive disorders. However, since diet was 
not standardized and classification of depressive disorders 
received little attention; these findings cannot be 
regarded as very significant (Van Praag , 1977a). 
Another method for biochemical investigation of patients 
with depression involves the assay of levels of 
serotonin and 5-HIAA in the brains of suicide victims. 
Early studies suggested that either serotonin (Shaw et al., 
1967; Pare et al., 1969) or 5-HIAA (Bourne et al . , 1968) 
was decreased in the brainstem of suicide victims as 
compared to a control group whose deaths were from other 
causes. In a more recent study, Lloyd et al. (1974) 
found that serotonin, but not 5-HIAA, was lower in certain 
raphe nuclei (the dorsal nucleus and the inferior central 
nucleus) of suicide victims than in controls. 
Limitations of this strategy, however, are numerous. For 
example, it is difficult to obtain reliable diagnostic data 
on these subejcts , the victims' nutritional state as well as 
their drug history is often uncertain, the time of day when 
they committed suicide is often difficult to determine and 
so forth. Moreover, the dUration of the interval between 
death and postmortem examination is a factor that is 
difficult to standardize. 
The above data on serotonin metabolism (postmortem and CSF 
studies) in depressed patients, although not unequivocal , 
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provide strong ev idence suggesting a disturbance of 
either serotonin synthesis or turnover in depressive 
disorders. 
There are also natural and iatrogenic states that seem to 
involve serotonin deficiency and these cause mental 
depression. Patients with Parkinson's disease who receive 
L-DOPA sometimes become depressed and this has been 
attributed to interference with the intestinal absorption 
of tryptophan by competition between the two amino acids 
(Lehmann, 1973) or to the excessive formation of DA in the 
brain which, in turn, displaces the serotonin from its 
storage sites (Birkmayer and Neumayer , 1972). "Natural" 
diseases such as carcinoid syndrome and regional enteritis 
cause sero t onin depletion and the depression occuring with 
these has been reported to be relieved by l-tryptophan 
administration (Lehmann, 1972; Johansson et al., 1973). 
since both the b l ood platelets and eNS serotonin synaptosomes 
share common biochemical as well as many morphological 
characteristics, the blood p latelets have been used as an 
easily obtainable model of serotoninergic neurons. The 
uptake of serotonin into platelets of depressed patients 
has been shown to be decreased (Tuomisto and Tukiainen, 
1976; Ehsanullah and Mulgir igama, 1979) and the capacity 
of serotonin transport through the platelet membrane has 
been reported to be impaired in some depressed patients, 
the impairment being independent of the psychiatric status 
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of the patient (Coppen et al . , 1978b). 
The above results are far from unequivocal but overall, 
are more in favour of than against the indoleamine 
hypothesis. The evidence points to an abnormality in 
serotonin metabolism in both mania and depression, but 
it seems that clinical recovery is not accompanied by any 
change in this abnormality. This suggests that these 
changes in serotonin and possibly other amines, are only 
part of the chemical pathology and may be a necessary 
predisposition that requires another factor - perhaps 
endocrinological - to produce the clinical picture of 
depression and mania (Coppen, 1972) . 
1.2.3 Dopamine Hypothesis: 
Recently DA has also been implicated in depression (Randrup 
et al., 1975, review). Support for this hypothesis has 
come from the findings that most of the TADs as well as 
some newer antidepressives (iprindole, maprotiline, mianserin, 
nomifensine) are fairly potent inhibitors of DA uptake in rat 
brain synaptosomes (Randrup and Braestrup, 1977). A 
comparison of the inhibitory effects of the various anti-
depressives on DA , noradrenaline and serotonin reuptake is 
shown in Table 8. In addition, piribedil, a DA receptor 
agonist, has been reported to be effective in the reversal 
of depressive symptoms in some patients (Post et al., 1978). 
Nomifensine, an antidepressive drug which is a dopamine 
agonist (Costall et al., 1975; Schacht et al . , 1977) as 
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well as an inhibitor of noradrenaline reuptake (Schachtet 
al., 1977) has been found to be particularly useful in 
depressed patients with psychomotor retardation (van Scheyen 
et al., 1977). The efficacy of L-DOPA, the immediate 
precursor of DA, in depression is controversial and is 
reviewed in Section 1. 2 . 1. At best, L-DOPA seems to be 
effective in the treatment of only a few retarded, depressed 
patients (Bunney et al., 1971). 
An indirect piece of evidence from neuroendocrinology 
pointing to deficient dopaminergic mechanisms in the hypo-
thalamus of depressed patients is the subnormal 
GH response to insulin-induced hypog lycaemia seen 
in some depressives (Section 1.2.9.2 .2)(Casper et al., 1977). 
Post et al. (1973 ) reviewed the stud i es measuring the 
concentration of homovanillic acid (HVA) , the main degradation 
product of DA , in the CSF of depressed patients. Some 
i nvest iga~ors have reported slightly lower (Nordin et al., 
1971) or definitely lower (Sjostrom, 1973) HVA levels in 
the CSF of depressed patients than of controls, while others 
have found no significant difference from the control group 
(van Praag and Korf, 1971b; Goodwin et al., 1973; van Praag 
et al . , 1973a). Probenecid inhibits the active transport 
of HVA from the CSF and the amount of HVA accumulating after 
probenecid administration is believed to reflect the rate 
of DA turnover. Post and Goodwin (1975) using the probenecid 
method concluded that, while the baseline concentrations of 
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HVA were not abnormal among manic-depressive patients, the 
rate of increase of HVA during probenecid administration 
was definitely below normal . This finding has been 
confirmed by numerous investigators (Roos and Sjostrom, 
1960; Nordin et al., 1971; van Praag and Korf, 1971b; 
Sjostrom and Roos, 1972; Sjostrom, 1973; Goodwin et al., 
1973; van Praag et al., 1973a; Post and Goodwin, 1975). 
These observations suggest that there may be a deficiency 
of DA synthesis or turnover in the state of depression. 
A point against this hypothesis, however, is the observation 
that ECT (Nordin et al., 1971), as well as various anti-
depressive drugs, seem to have little or no effect upon 
the accumulation of HVA in the probenecid test (Sourkes, 
1977). In addition, motor activity has been shown to 
affect HVA levels in the CSF (Post et al., 1973). 
As with noradrenaline, no significant changes in the 
concentration of DA in various parts of the brain of 
depressive suicides has been reported (Moses and Robins, 
1975) . 
The above findings thus suggest that DA may also playa 
role in depressive disorders, particularly in the motor 
component of depression. 
1.2.4 Permissive Amine Hypothesis: 
This hypothesis, originally proposed by Kety (1971) and 
developed by Prange and his co-workers (1974), states that 
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a central serotonin deficiency indicates a vulnerability 
to affective illness, but in itself is not sufficient for 
its cause. In addition, a change in catecholamine levels 
is needed to produce the clinical syndrome, l owered 
catecholamines correlating with depression and increased 
catecholamines with mania. A comparison between this 
proposal and the other biogenic amine hypotheses is outlined 
in Table 12. 
The permissive amine hypothesis supports the view that 
depression and mania are on a continuum rather than being 
polar opposi t es . This model, originally proposed by Court 
(1968 ), suggests that mania and depression share a similar 
biological dysfunction, with mania representing a more 
severe deviation from normal mood. 
Support for this continuum model comes from the observation 
that both depression and mania may show some response to 
t he same antidepressive therapies. ECT is widely used in 
both states. Imipramine, a clinically effective anti-
depressive, has been reported by one investigator to be 
useful in the treatment of mania (Akimoto et al., 1960) . 
Moreover, lithium, an effective treatment for mania, has 
been shown to have some therapeutic efficacy in depression 
(Goodwin et al., 1969). In addition, some drugs, such as 
cortisone, can precipitate episodes of either depression 
or mania - sometimes in the same individual (Fawcett and 
Bunney, 1967) . 
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TABLE 12: 
BIOGENIC AMINE HYOPTHESES OF DEPRESSIVE 
ILLNESSES: COMPARISON 
HYPOTHESIS 
CATEJ:HOU\MINE 
INDOLEAMINE 
PERMISSIVE 
AMINE 
HYPOl'HESIS 
PREDISPOSITION 
Unspecified 
Unspecified 
----.--- ~-
.. . ~ 
~ CATHECHOLAMINES 
INDOLEAMINES 
NORMAL 
DEPRESSION MANIA 
Unspecified 
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Electrolyte abnormalities have been reported to deviate 
from normal in the same direction in mania and depression 
(Coppen, 1965). In a review of the evidence, Whybrow and 
Mendels (1969) proposed that mania and depression are 
neurophysiologically very similar, both representing "an 
unstable state of CNS hyperexcitability" . In addition, 
\ 
the clinical observation of depression during mania (Kotin 
and Goodwin, 1972) can only be explained by a continuum 
model. 
Since there is data implicating a deficiency of catechol-
amines and indoleamines in depression as well as increased 
catecholamine levels in mania (Section 1.2.1, 1.2.2 and 
1.2.3), only evidence suggesting decreased indoleamine 
activity in mania is necessary to verify the permissive 
amine hypothesis. 
L-tryptophan has been reported to be useful in mania (Prange 
et al., 1974) and depression (Coppen et al., 1967b; 1972; 
van Praag and Korf, 1970). Prange et al. (1974) proposed 
that I-tryptophan exerts its antimanic effect by correcting 
the postulated indole amine deficit while only slightly 
reducing the catecholamine level. Lithium not only 
decreases catecholamine levels (Schildkraut et al., 1966b) 
but also increases serotoninergic activity (Sheard and 
Aghajanian, 1970; Tagliamonte et al . , 1971; Knapp and 
Mandell, 1973), which, according to this hypothesis, would 
account for its effective antimanic activity. This 
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hypothesis would also explain why L-DOPA precipitates 
mania in some individuals (Murphy et al., 1971), while 
not being a particularly effective antidepressive (Bunney 
et al . , 1970). L-DOPA has been shown to decrease 5-HIAA 
levels in the CSF of depressed patients (Goodwin et al., 
1971~ a decrease which would aggravate the already deficient 
indoleamine system ~ 
Prange et al. (1974) believe that if this hypothesis were 
true in the strictest sense, a carefully adjusted dose of 
I-tryptophan would not only cure depression and mania but 
also prevent their recurrence. This, however, has not been 
reported. Thus, even though this hypothesis probably 
represents only half the story, it, unlike the previous 
biogenic amine hypotheses, deals with the interrelations 
of amines and is of heuristic value in providing further 
stimulus for research. 
1.2.5 Kynurenine Hypothesis: 
There is ample evidence for defective serotonin synthesis 
and metabolism as well as abnormally high adrenocortical 
secretion in some groups of depressed patients (Section 
1.2.2 and 1.2.9.2.1). A possible link between these two 
conditions has been proposed (Lapin and Oxenkrug, 1969; 
Curzon, 1969; Curzon and Bridges, 1970). 
Tryptophan is known to be metabolised by several pathways. 
Less than 3% of dietary tryptophan is converted to serotonin, 
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its formation being r e gulated by the enzyme, tr ypt ophan 
hydroxylase. A quantitatively more important route 
involves the formation of nicotinic acid which is regulated 
by the liver enzyme, tryptophan pyrrolase, via the kynurenine 
intermediate. The metabolic pathway is presented in Fig. 6. 
The activity of liver pyrrolase has been reported to be 
increased by hydroxycorticosteroids (Knox, 1951; Knox and 
Auerbach, 1955; Shan et al., 1968; Curzon, 1969; Young 
and Sourkes, 1977). This observation led to p o s tulation 
of the hypothesis that the raised plasma cortisol levels seen 
in depressed patients, may induce tryptophan pyrrolase which, 
in turn, may directly divert tryptophan away from serotonin 
formation (thereby lowering brain serotonin levels) and 
instead, increase metabolism along the tryptophan nicotinic 
acid pathway (Curzon, 1969; Curzon and Bridges, 1970). 
Thus depression is proposed to be associated with a decreased 
utilization of tryptophan in the formation of serotonin with 
a consequent increased utilization of tryptophan as a 
substrate for kynurenine formation. 
Direct investigation of this relationship between pyrrolase 
activity and brain serotonin metabolism requires determinat ion 
of brain serotonin. Rat brain serotonin l evels were shown 
to decrease (maximally by 30%) after a single intraperitoneal 
injection of 5 mg/kg hydrocortisone (Curzon and Green, 1968). 
This reduction was s hown to be associated with a comparable 
fall of 5-HIAA levels which indicated decreased serotonin 
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synthesis. In this study, it was also noted that the 
injection of pyrrolase inhibitors (allopurinol and yohimbe) 
nullified hydrocortisone's effect in reducing serotonin. 
Furthermore, a-methyl tryptophan , which causes pyrrolase 
activity to increase, also led to a fall of brain serotonin. 
Studies using human brains are obviously impossible. How-
ever, indirect evidence comes from the observation that a 
group of female patients suffering from "endogenous" 
depression excreted significantly greater amounts of kynurenine 
and 3-hydroxykynurenine than the female controls (Curzon and 
Bridges, 1970). As already mentioned, this fall in brain 
serotonin could be explained by the diversion of tryptophan. 
However, another explanation is possible. Injection of 
kynurenine or other tryptophan metabolites formed subsequent 
to pyrrolase action causes brain serotonin levels to fall 
(Curzon and Green, 1968). Therefore, increased formation 
of these substances due to increased pyrrolase activity may 
be involved in the mechanism by which brain serotonin levels 
diminish. 
Lapin and Oxenkrug (1969) proposed that the depression of 
brain serotonin levels may result in weakening of the 
inhibitory processes on the amygdaloid complex. In man, 
activation of this area has been reported to increase plasma 
cortisol levels, presumably by stimulating the anterior 
pituitary to produce more ACTH. Thus a vicious circle 
would be set up - low serotonin brain levels would lead 
to activation of the amygdaloid complex, increased formation 
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o f hyd roxy c o rticos teroi ds and i nc reased a c tivity o f tr yp t opha n 
pyrrolase, which, in turn, would "shunt" the degradation 
of tryptophan away from serotonin to kynurenine. This 
is illustrated in Fig. 7. 
If this hypothesis were true, treatment of depressive 
disorders would involve attacking the links in the chain. 
Serotonin precursors would perhaps be effective in restoring 
the serotonin brain levels. Chronic administration of 
imipramine or desipramine has been found to inhibit liver 
tryptophan pyrrolase activity in mice (Paracchi, 1967) 
which suggests that this action could be a component of 
their antidepressive effect. According to this hypothesis, 
pyrrolase inhibitors (nicotinamide and allopurinol) would be 
of use in the treatment of depression (Curz o n, 1969). These 
drugs would inhibit the degradation of tryptophan along the 
pyrrolase-catalysed kynurenine pathway ther e by increasing 
the formation of brain serotonin. In support of the theory 
Chouinard et al. (1977) reported that the combination of 
I-tryptophan and nicotinamide has an enhanced antidepressive 
effect in some depressed patients. 
A numb e r of questions involving the kynurenine hypothesis, 
however, are still unresolved. Firstly there is the 
question of whether the activation of tryptophan pyrrolase 
is sufficiently marked to draw a substantial amount of 
tryptophan away from serotonin synthesis. It may bein a c ute 
experiments involving rats (Curzon and Green, 1968), but it 
•..•. - 106 - / 
LOWERING OF INTENSITY 
OF SEROTONINERGIC 
PROCESSES 
RELEASE OF AMYGDALOID 
INHIBITION 
- 106 -
KYNURENINE PATHWAY 
(therefore decrease in 
brain serotonin levels) 
STIMULATION OF TRYPTOPHAN 
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Fig. 7. The Kynurenine Hypothesis and Sequence of Events 
Proposed by Lapin and Oxenkrug (1969) . 
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is not known whether this mechanism is also involved in 
depressed patients. A drawing off of available tryptophan, 
howeve~ seems unlikely since the pyrrolase pathway is only 
one of the important metabolic pathways of tryptophan. 
Moreover, as noted by van Praag (1977a), the correlation 
between cortisol and plasmajCSF tryptophan has not been 
studied in depressed patients . Furthermore, normal CSF 
tryptophan levels have been reported in depressions 
(Ashcroft et a1., 1973b). Thus at this stage, the kynurenine 
hypothesis is mere speculation. 
1.2.6 Tryptamine Hypothesis: 
As an alternative to the monoamine theory, Dewhurst (1968a) 
proposed a hypothesis to account for the role of noradrenaline 
and serotonin in terms of central receptors. 
central monoamines into two distinct groups: 
He classified 
excitant 
amines (type A) and depressant amines (type C). 
Type A amines have a general formula R.CH,CH,NH, where R 
is a fat-soluble planar hydrocarbon, such as indolyl or 
phenyl. These amines, of which tryptamine is the most 
potent, produce behavioural and physiological excitation 
in immature chicks, probably by activation of specific 
central receptors. Depressant amines (type C) have a 
general structure R'CH(OH)CH,.NH.CH, where R' is polar, 
for example, catechol. Such amines, of which adrenaline 
is the most potent, produce drowsiness and sleep in the 
immature chick. 
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Dewhurst (1968a) proposed that some forms of depressive 
illness are caused by a deficiency of type A amines or 
insensitivity of the type A receptor, and some forms of 
mania are caused by an excess of type A amines or increased 
sensitivity of the type A receptor. He explained the 
efficacy of some antidepressive treatments in terms of 
this theory. Inhibitors of MAO principally increase 
tryptamine (type A amine). Amphetamine acts directly on 
the brain type A receptors. Tryptophan is the precursor 
of tryptamine, which could explain its antidepressive 
effect. In some studies methysergide, a specific competitive 
antagonist of the type A receptor (Dewhurst and Marley, 1965), 
has been claimed to be able to control manic disorders 
(Dewhurst, 1968b). Although these findings provide support 
for the above hypothesis, objections to it remain. For 
example, adrenaline does not produce sedation in man, but 
excitation. Moreover, this theory suggests that nor-
adrenaline and serotonin have opposing actions in man, 
however, this is probably an oversimplification. It is 
more likely that they have both excitatory and inhibitory 
effects in different areas of the brain and that satisfactory 
treatment of affective disorders depends on restoring the 
normal balance of neurotransmitters. In addition, this 
theory does not take other transmitter substances, such as 
dopamine, into consideration. 
1.2.7 False Neurotransmitter Theory: 
Murphy (1972) proposed that the state of decreased central 
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adrenergic activi ty during depression could be due to the 
effects of endogenously produced false transmitters, instead 
of resulting from a reserpine-like depletion of central 
biogenic amines as has been previously hypothesized 
(Schildkraut, 1965). 
Although no definite role for false central neurotransmitters 
has been established, there is evidence to suggest that they 
may be involved in depressive disorders. Administration of 
the precursor of the false transmitter, a -methyldopa, to 
hypertensive patients has been found to precipitate depressive 
reactions and suicidal behaviour, particularly in those 
individuals with a history of depressive episodes (Fullerton 
and Morton-Jenkins, 1963; Smirk, 1963; McKinney and Kane, 
1967). Octopamine, a false transmitter with one-hundredth 
the efficacy of noradrenaline, has been reported to 
accumulate in platelets from depressives treated with MAO 
inhibitors (Murphy, 1972). In the same study octopamine 
was found in the platelets of patients with endogenously 
reduced MAO activity. 
Thus preliminary reports indicate that false neurotransmitters 
may be important in affective disorders, the exact function of 
which needs further eva luation . 
1.2 . 8 Cholinergic-Adrenergic Hypothesis : 
It is possible that brain amine systems other than those 
previously discussed, are involved in the genesis of affective 
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disorders. Janowsky ~ al. (1972a; 1972b; 1973a; 1973b) 
have postulated that the cholinergic nervous system is also 
involved in the regulation of affect. They have suggested 
that a balance between adrenergic and cholinergic factors 
exists in the brain areas which regulate affect and have 
hypothesized that depression is a disease of central 
cho l inergic predominance and mania a disease of central 
adrenergic (or serotoninergic) predominance. In other 
words,high biogenic amine levels and low acetylcholine (Ach) 
levels are associated with mania, while low catecholamine 
levels and high Ach levels are associated with depression. 
There is both direct and indirect evidence suggesting the 
involvement of cholinergic activity in the aetiology of 
depression. 
Reserpine, which can produce depression in hypertensive 
patients, has central cholinomimetic properties in both 
animals (Bogdanski et al., 1961) and man (Goodman and Gilman, 
1975). According to the above hypothesis, reserpine would 
be expected to shift the adrenergic-cholinergic balance to 
a cholinergic predominance. It is interesting to note tha t 
u-methylparatyrosine (AMPT) which specifically blocks 
catecholamine synthesis without altering central Ach levels, 
has not been reported to produce depression in hypertensive 
patients (Charalampous and Brown, 1967). 
The TAD drugs have central anticholinergic effects (Janowsky 
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et al., 1972b). In man, these drugs cause a toxic, 
confusional state characterized by agitation, disorientation, 
loss of short-term memory and hallucinations which can be 
reversed by physostigmine. In addition, imipramine has 
been shown to block the increase in central cholinerg ic 
activity occuring with reserpine administration (Sulser 
et al., 1964) and to antagonize physostigmine- induced 
suppression of operant behaviour in pigeons (Vallant, 1967). 
Thus the tricyclics block central cholinergic activity, as 
well as increasing functionally available neurotransmitters, 
shifting the adrenergic-cholinergic balance towards an 
adrenergic predominance. 
Numerous workers have reported data from animal studies 
which indicate that central cholinergic activation causes 
depressant inhibitory effects, while anticholinergic agents 
or adrenergic stimulation causes behavioural activation and 
arousal (Carlton, 1963; Vallant, 1967; Fibiger et al., 
1970). For example, brain self-stimulation (Jung and 
Boyd, 1966) and locomotor activity (Fibiger et al., 1970) 
--
are inhibited by centrally active cholinomimetic agents. 
Centrally acting anticholinergic drugs block these 
cholinomimetic effects (Jung and Boyd, 1966; Vallant, 
1967) and have themselves been shown to increase locomotor 
activity and self-stimulation (Stein, 1964). 
The most convincing direct evidence that central cholinergic 
activity plays a significant role in the regulation of affect, 
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however, comes from studies of the effects of centrally 
active cholinomimetic agents in man. Patients, who have 
a pre-exist ing depression, have bee n reported to experience 
worsening of their symptoms after physostigmine (Janowsky, 
1972b, 1973a; Modestin et al., 1973) and choline 
administration (Tamminga et al., 1976). Moreover, several 
studies have reported that depression is a complication of 
poisoning with cholinesterase-inhibitor insecticides 
(Rowntree et al., 1959, Gershon and Shaw, 1961, Bowers 
et al., 1964). Severe depression has also been seen in 
patients treated with physostigmine while on a marih uana-
induced "high" (El-Yousef et al., 1973). Physostigmine 
administered to methylphenidate-stimulated humans has been 
shown to cause a dramatic decrease in methylphenidate 
activation (Janowsky et al., 1972b). These workers have 
proposed that physostigmine acts by increasing central Ach 
levels so as to balance the increase in central adr energic 
activity caused by methylphenidate. 
Physostigmine has also been reported to exert an antimanic 
effect (Janowsky et al., 1972a; 1972b, Carroll et al., 
1973). Janowsky et al. (1972a, 1972b) demonstrated that 
an acute dose of physostigmine caused a rapid decrease in 
the manic state which was converted to a state of psychomotor 
retarded depression. 
The above finding s support the hypothesis that the major 
affective disorders result from an imbalance between 
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cholinergic and aminergic neurotransmission in the CNS. 
1.2.9 Biochemical Abnormalities in Depression: 
1.2.9.1 ~~§~!E9~y!§_~e~2E~~~i!i§§: 
Electrolytes playa vital role in the normal functioning of 
the nervous system. The resting potential is dependent on 
the ratio of the concentration of potassium inside and out-
side the cell, while the action potential is dependent on 
the ratio of the concentration of intracellular to extra-
cellular sodium. Electrolytes also play an important role 
in the synthesis, storage, release and inactivation of the 
neurotransmitters. Thus it is conceivable that abnormalities 
in electrolyte distribution and metabolism ~ se or through 
interaction with the biogenic amine systems, could lead to 
altered neuronal functioning that could underlie depressive 
disorders. 
1.2.9.1.1 Sodium: 
Schottstaedt and co-workers (1956) reported a reduction in 
the urinary excretion of sodium during depressive episodes. 
Other early studies also found a retention of sodium in 
depressed patients (Russell, 1960; Anderson and Dawson, 
1963) . More recently radioisotope techniques have been 
used to study electrolyte metabolism in affective disorders 
(Coppen, 1965; Shaw, 1966). Gibbons (1960) observed a 
decrease in exchangeable sodium after recovery from a 
depressive illness, although exchangeable potassium showed 
no significant alteration. These results led to the 
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hypothesis that during depression sodium is retained, with 
total body sodium increasing until recover y occurs, by which 
time the excess sodium has been excreted. 
Subsequent studies by Coppen and Shaw (Coppen and Shaw, 1963; 
Coppen, 1965; Coppen et al., 1965b; 1966; Shaw, 1966) how-
ever, strongly indicate that there is no change in total 
body sodium, but that during depression th e re is a re-
distribution of sodium within the body. For example, a 
significant increase in residual sodium (which represents 
intracellular sodium together with a small amount of 
exchangeable bone sodium) was demonstrated in both depressed 
(Coppen and Shaw, 1963) and manic patients (Coppen et al., 
1966) . The magnitude of the increase was 50 % in depression 
and 200% in mania, levels returning to normal after recovery. 
In addition, total body potassium and intracellular potassium 
were found to be low in depression but this did not change 
with clinical recovery. 
The rate of entry of radioactive sodium from the blood to 
the CSF was investigated by Coppen (1960). He reported a 
reduced entry rate in severly depressed patients when 
compared with normal subjects, schizophrenic patients and · 
patients who had rec ove red from a depressive disorder. 
Shaw et al . (1969) found that the brains of depressed 
patients who had committed suicide had an increased water 
content and reduced sodium concentration as compared to 
brains from subjec ts who died of natural causes. 
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Changes in sodium could arise in several ways. The 
increased sodium retention observed in the above studies 
may be secondary to the elevated cortisol seen in 
depression (Gibbons, 1963; Durele and Schildkraut, 1966; 
Baer et al., 1969). Sodium distribution is also affected 
by progesterone, aldosterone and ADH. Therefore it is 
important to know whether these abnormalities are primary 
to affective disorders or secondary to changes in gluco-
corticoids and mineralocorticoids, or in adrenergic 
functioning (Shaw, 1966). 
Based largely on the data from Coppen's laboratory (Coppen 
and Shaw, 1963; Coppen et al., 1966), Whybrow and Mendels 
(196~ review) hypothesized that there is an unstable 
hyperexcitability of the CNS in depression. They suggested 
that states of central arousal could result from intra-
neuronal sodium accumulation with a consequent lowering of 
the resting potential and hyperexcitability. 
Clinical evidence to support the proposal that electrolytes 
do playa role in the pathogenesis of affective disorders 
comes from the finding that lithium appears to have a 
prophylactic value in reducing the incidence and severity 
of depressive disorders (Section 1.1.6.4.3). Lithium is 
believed to exert its therapeutic effect by replacing 
sodium intracellularly, thereby re-establishing the "resting" 
electrolyte balance across the cell membrane (Coppen et al., 
1962; 1965b; Bunney et al., 1972b) . 
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It has been proposed that the disturbance in biogenic 
amines seen in depressed patients (Sections 1.2.1 and 1.2.2) 
could secondarily result from intraneuronal sodium 
accumulation, since the transport and release of monoamine 
neurotransmitters across the presynaptic membrane is 
p artially determined by the distribution of electrolytes 
intra- and extraneuronally (Bogdanski et al., 1968; Maas, 
1972; White and Paton, 1972). Transport of electrolytes 
across the presynaptic membrane involves Na+/K+ dependent 
adenosine triphosphatase (ATPa se ) and the carrier protein. 
A deficiency (could be a genetic deficiency) in either the 
enzyme or the carrier would interfere with the transport 
of electrolytes and thus the transport of biogenic amines . 
Bunney et al. (1972b) hypothesized that increased intra-
cellular sodium could decrease the intracellular release 
of noradrenaline from its carrier transport protein, thereby 
decreasing net noradrenaline transport. Additional support 
for a defective transport system comes from investigators 
+ + 
who have demonstrated reduced erythrocyte Na /K ATPase 
activity in patients suffering from depressive illness 
(Naylor et al., 1973; Hokin-Nyverson et al., 1974; Hesketh 
et al., 1977). Previous studies by Naylor and co-workers 
(197 0a; 1970b; 1971) showed that the mean erythrocyte 
sodium concentration as well as active sodium transport 
was lower in depressive females in comparison to that of a 
control group. 
Pandey et al. (1976) and Mendels et al. (1977) found that 
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the ability to extrude lithium ions from red blood cells 
is impaired in many manic patients and some first degree 
relatives. Reduced platelet serotonin uptake and 
accumulation has also been observed in some depressives 
(Tuomisto and Tukiainen, 1976; Coppen et al., 1978b). 
Thus current evidence suggests that there is a subgroup 
of depressed patients who have an abnormality, possibly 
genetic, in some property of the cell membrane that 
regulates electrolyte distribution. This hypothesis is 
not incompatible with the biogenic amine hypotheses of 
affective disorders since it is possible that an abnormality 
in one system may be responsible for changes in other systems. 
Thus an impairment of the ionic fluxes responsible for 
depolarization and repolarization of the neurons, could 
disrupt critical neurotransmitter levels which, in turn, 
may lead to depressive symptomatology. 
1.2.9.1.2 Magnesium: 
Cade (1964) reported considerably elevated total plasma 
magnesium levels in depressed patients both before and 
after recovery. Frizel et al. (1969), however, found total 
plasma magnesium to be significantly lowered in depressed 
patients which increased significantly with recovery. 
Ionized magnesium, however, did not differ between the 
control and depressed group, and since it is presumably 
ionized magnesium that is physiologically active, the authors 
concluded that it was unlikely that magnesium was involved in 
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the pathophysiology of depression. 
1.2.9.1.3 Calcium: 
Calcium plays a role in regulating sodium and potassium 
flux across the cell membrane. There is evidence to 
suggest that this ion may be involved in affective disorders. 
Severe depression or catatonic stupor has often been observed 
in hypercalcaemic disorderu, for example, hyperparathyroidism 
(Mandel, 1960; Hockaday et al., 1966; Petersen, 1968) and 
vitamin D intoxication (Andersen et al., 1968). 
In an early study, Flach (1966) found a reduced calcium 
excretion in the urine of depressed patients who had imppoved 
as compared with a small rise in urinary calcium excretion in 
those patients who did not respond to the treatment. He 
thus suggested that clinical improvement is associated with 
calcium retention. 
Carman and Wyatt (1977) in a review of the evidence reported 
that a decrease in extracellular calcium levels reduces the 
activity of tyrosine hydroxylase and tryptophan hydroxylase, 
and increases the activity of acetylcholinesterase, COMT 
and adenylate cyclase. Reduced extracellular calcium 
thus diminishes neurotransmitter release, precursor uptake 
and transmitter uptake. 
Lowering calcium levels in the CSF produces behavioural 
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excitation in several animal species (Pappenheimer et al., 
1962; Veale and Myers, 1971), whereas increasing the calcium 
concentration in the CSF produces sedation or catatonic states 
(Marquardt and Riemschneider, 1951; Feldberg and Sherwood, 
1957) . In addition, a decrease in calcium levels in the 
CSF has been associated with the antidepressive response to 
ECT (Carman et al., 1974) and sleep deprivation (Jimerson 
et al., 1976), while CSF calcium levels remained unaltered 
when no antidepressive response was evident. 
Thus, even though no definite role for calcium has been 
shown to date, there is evidence to suggest it may be a 
factor in affective disorders. 
1.2.9.2 Neuroendocrine Abnormalities: 
----------------------------
1.2.9.2.1 Hypothalamic-pituitary-adrenal cortical (HPA) 
system: 
Associations between affective disorders and diseases of 
the HPA axis have been noted by many clinicians (Michael 
and Gibbons, 1963; Rubin and Mandell, 1966; Whybrow and 
Hurwitz, 1976). Addison in his original description of 
hypoadrenalism, included mental depression among the clinical 
symptoms. Since then numerous workers have confirmed that 
symptoms such as depression, apathy, insomnia, apprehension 
and sleep disturbances are associated with Addison's disease . 
(Engel and Margolin, 1941; Cleghorn, 1951). A significant 
proportion of patients with hyperadrenalism, Cushing's 
s y ndrome, or under long term treatment with ACTH or cortisol 
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have also been found to exhibit profound mental changes 
such as euphoria, depression and overt psychosis (Bo rman 
and Schmallenberg, 1951; Glaser, 1953; Cobb, 1960). 
Although euphoria has been reported, depression is a more 
common finding in chronio cases (Fawcett and Bunney, 1967). 
These findings seem contradictory but might be explained 
by the fact that in both Addison's disease and some forms of 
Cush i ng ' s d i sease , p ituitary ACTH l evels can be raised. This 
clinical association of mood changes with abnormalities of 
adrenal function raised the question of the role of gluco-
cortico id s in affective disorders. 
Many workers have shown that the production (or secretion) 
rate of cortisol is elevated in most patients suffering from 
depression (Gibbons, 1964; 1966; Carpenter and Bunney , 1971; 
Sachar et al., 1971a; 1973b). Carroll (1972), in a rev iew 
of the evidence, reported that the plasma cortisol levels of 
depressed patients are usually elevated over that of normal 
patients. These plasma cortisol levels provide an indirect 
indication of the rate of release of ACTH from the anterior 
pituitary. Similar findings have been observed by many 
other investigators (for example, Gibbons and McHugh, 1962; 
Michael and Gibbons, 1963; Rubin and Mandell, 1966). 
However, it should be noted that in most studies there are 
usually a number of patients who do not show any significant 
alteration in cortisol levels. In a review, Carroll and 
Mendels (1976) concluded that the adrenal cortex of depressed 
patients respond s normally to ACTH which thus suggests that 
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the high cortisol secretion rate observed, reflects 
increased ACTH release rather than exaggerated adrenal 
cortical responsiveness to ACTH. 
Researchers studying CSF cortisol levels in depressed 
patients have reported conflicting results. Some authors 
have demonstrated a deficiency in brain cortisol (McClure 
and Cleghorn, 1968; 1970; Carpenter and Bunney, 1971; 
Coppen et al., 1971), while others have found elevated CSF 
cortisol levels in depressed subjects (Carroll, 1972; 
Carroll and Mendels, 1976). The latter finding would be 
in keeping with the elevation of plasma cortisol levels 
described above. Urinary fDee cortisol excretion has also 
been reported to be elevated in most of the depressed 
patients studied (Ferguson et al., 1964; Carroll, 1976). 
All these findings (elevated plasma free and total cortisol, 
normal plasma corticosteroid-binding globulin capacity 
(King, 1973), elevated CSF cortisol and elevated urinary 
free cortisol excretion) suggest that there is increased 
exposure of peripheral tissues and the CNS to free cortisol 
in depressed patients. It is therefore surprising that 
cortisol levels have been found to be lower than normal in 
the suicide brains of depressed patients (Brooksbank et al., 
1972; 1973). These findings, however, cannot be evaluated 
properly since not only are suicide brain studies fraught 
with difficulties of interpretation, but also because little 
is known about the rate of postmortem decay of cortisol in 
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nervous tissue (Carroll and Mendels, 1976). 
Initially attempts were made to suggest an aetiological 
role for the steroids in depression. This interest diminished 
however, when it was known that cortisol levels could be 
elevated in a number of conditions that invol ve stress s uch 
as combat, examinations and hospitalization. Thus it was 
proposed that the elevated cortisol plasma levels found in 
some depressives, probably reflect a non-specific stress 
response which is secondary to the psychic distress of the 
disorder (Brooksbank and Coppen, 1967; Sachar, 1967). Even 
though the hypersecretion of cortisol may only be a secondary 
effect of certain depressive disorders, Curzon (1969) suggested 
that the elevated cortisol secretion may not simply be a stress 
response, but may reflect "apparent limbic dysfunction, along 
with disturbances in mood, affect, appetite, sleep, aggressive 
and sexual drives and autonomic nervous system activity". 
The HPA axis of man exhibits a definite circadian variation 
in spontaneous activity (Doe et al., 1956; Kobberling and 
von zur Muhlen, 1974). Instead of operating continuously 
with a minute-to-minute feedback control, the HPA axis is 
activated in an episodic manner which is interspersed by 
per iods of "total adrenocortical qui escence" (Hellman et al., 
1970; Krieger et al., 1971). During most of the day the 
brain exerts an inhibitory influence on the HPA axis, with 
a relaxation in this inhibition being observed mainly 
during the morning peak of cortisol secretory episodes 
(Carroll, 1972). 
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The diurnal rhythm of plasma cortisol levels persists in 
most depressed patients (where rhythm is defined as morning 
values being higher than night values). However, the 
elevation of evening plasma cortisol levels over control 
values is usually much greater than the elevation of 
morning values i.e . night values are more abnormal than 
are morning values (Doig et al., 1966; McClure, 1966; 
Knapp et al., 1967; Fullerton et al., 1968). In other 
words, morning plasma cortisol levels of depressed patients 
are generally within the normal range, whereas the levels 
measured during the night lie in the pathological range. 
Sachar et al. (1973b) studied the diurnal rhythm of cortisol 
secretion in depressives using the venous catheter technique 
(Hellman et al., 1970), and found a circadian HPA disturbance . 
These patients were shown to have an increased number of 
secretory episodes, increased total cortisol secretion and 
increased time per day during which cortisol secretion was 
occuring. Of particular interest was the fact that active 
cortisol secretion was observed during the late evening and 
early morning hours when cortisol secretion is minimal in 
normal subjects. They proposed that these findings indicated 
a failure of the normal CNS circadian inhibitory influences 
on ACTH-cortisol release. These results have been 
replicated by Carroll and his co-workers (Carroll and 
Mendels, 1976) and this has led to the hypothesis that "the 
essential neuroendocrine lesion ln depression appears to be 
a disinhibition of the HPA axis". 
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A number of standard clinical tests of HPA function has 
been used to provide additional evidence of central neuro-
endocrine dysfunction in depressed patients. 
Lysine-8-vasopressin (LVP), by a yet undefined mechanism, 
causes a rapid increase in plasma cortisol levels in normal 
subjects. Jakobson et al. (1969) and Carroll (1972) have 
observ ed that some depressed patients fail to respond 
normally to LVP, which suggests an impairment of the central 
mechanisms mediating the HPA response to LVP . 
An intravenous injection of insulin produces a rapid fall 
in blood glucose levels followed by a large HPA activation. 
Some depressed patients have been found to have impaired 
responses to insulin- induced hypoglycaemia (Carroll, 
1969; 1972; Perez-Reyes, 1972), while other depressives 
have been shown to respond in a similar manner to normal 
subjects (Sachar et al., 1971b ; Endo et al., 1974) . 
In normal subjects a midnight dose of dexamethasone (2 mg) 
suppresses plasma cortisol levels maximally for at least 
24 hours (McHardy-Young et al., 1967). Numerous 
investigators have reported that depressed patients fail 
to show normal suppression of plasma cortisol levels after 
dexamethasone administration (Butler and Besser, 1968; 
Carroll et al., 1968; Platman and Fieve, 1968; Carpenter 
and Bunney, 1971; Stokes, 1972; Endo et al., 1974; 
Carroll and Mendels, 1976) but this has not been confirmed 
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by all workers (Shopsin and Gershon, 1971; Verghese et al., 
1973) . The abnormality of dexamethasone suppression 
observed by Carroll et al. (1968) in a group of depressed 
patients , was shown to be correlated with the severity of 
the depressive illness as well as with the physiological 
symptoms (Carroll, 1972). 
Studies by Carroll (1972) and Carroll and Mendels (1976) have 
indicated that although some depressed patients had initial 
suppression of HPA function following dexamethasone 
administration, this was followed by escape from suppression 
abnormally early. In addition, they have found that with 
increasing severity of depression, escape from suppression 
occurs earlier on the post dexamethasone day. On the basis 
of these results they have proposed that the abnormality 
previously called "nonsuppression" is really an early 
escape from suppression and that it is a graded phenomenon 
rather than an all-or-none event. Carroll and Mendels 
(1976) proposed that the above abnormalities seen in 
depressed patients, reflect the same basic disturbance 
of HPA function as described by Sachar et al. (1973b). 
To summarize, Addison's disease, diencephalic Cushing's 
disease and primary depressive illness have been shown to 
share all the common features of mood disorder and 
disinhibition of the central HPA mechanisms. In addition, 
the limbic areas involved in HPA regulation (hippocampus, 
amygdala, septal region, midbrain) are closely associated 
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with the limbic sites which regulate mood and emotions. 
Thus experimental evidence s uggests that depressive states 
may be a result of suprahypophyseal brain dysfunction which 
amongst other things causes stimulation of the anterior 
pituitary. 
1.2.9 . 2.2 Hypothalamic-pituitary-growth hormone system: 
Another important neuroendocrine system to be studied in 
affective disorders is th e hypo thalamic-pituitary-growth-hormone 
system. Various stimuli are able to increase the secretion 
of growth hormone (GH), including slow-wave sleep, L-DOPA, 
apomorphine, ACTH fragment 1-24 and amphetamine, but the 
most widely used clinical test procedure is insulin-induced 
hypoglycaemia. 
Rel ease of GH is thought to be regulated at least in part by 
the central nor adrenergic system, since adrenergic blockers, 
such as phentolamine, reduce such insulin-induced release 
(Martin, 1976). Basa l GH levels are normal in depressed 
patients and the GH response to slow-wave s leep, L-DOPA, 
apomorphine and ACTH fragment 1-24 has been shown to be within the 
normal range (Carroll and Mendels, 1976). However, in 
many depressed patients, the GH r esponse to insulin-induced 
hypoglycaemia (lIueller et al., 1969; Sachar et al.: 1971b ; 
Carroll, 1972) and to amphetamine administration (Langer 
et al., 1976) is deficient. Garver et al. (1975; 1976) 
reported a correlation between diminished GH response and 
diminished urinary MHPG levels in some depressed patients. 
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This suggests that the depressives who show evidence of 
reduced noradrenaline turnover , also exhibit a functional 
deficit in noradrenaline neurotransmission. Amphetamine 
causes release of both noradrenaline and dopamine. However, 
since the GH responses to L-DOPA and apomorphine were shown 
to be unimpaired (Frazer, 1975), the low GH responses to 
amphetamine support the hypothesis of deficient central 
noradrenaline systems in a group of depressed patients 
(Garver , 1979) . 
The above findings are consistent with the catecholamine 
hypothes i s of depression. However, serotonin (Bivens 
et al., 1973) as well as somatostatin (Besser, 1974) may 
-- --
also playa role in mediating the GH response . 
1.2.9.2. 3 Hypothalamic-pituitary-thyroid sys tem: 
Thyroid dysfunction i s associated with changes in mood. 
Numerous investigators have reported a marked depression 
'of mood in patients suffering from hypothyroid i sm (Whybrow 
e t al., 1969 , review; Whybrow and Ferrell, 1974; Whybrow 
and Hurwitz, 1976). 
L-triiodothyronine (T,) has been reported to potentiate 
the act i on of the TAOs in women with pr i mary depression 
(Pr ange et al . , 1969; 1976). They have hypothesized that 
this may be due to a hormone-mediated increase in receptor 
site sensitivity (Section 1 . 2.11) . 
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Thyrotropin-releasing hormone (TRH) is a tripeptide that 
controls the secretion of thyroid-stimulating hormone (TSH). 
In some studies TRH administration has been found effective 
in depressed patients (Kastin et al ., 1972a; Prange et al., 
1972), although other investigators have reported no anti-
depressive effect (Takahashi et al., 1973a; Ehrensing et al., 
1974; Gorden, 1975; Hollister et al., 1975a); 
Itil (1976) has shown TRH to have CEEG (computer-analyzed 
electroencephalogram) profiles similar to the psychostimulant, 
g-amphetamine, which could account for its occasional anti-
depressive effect. 
Thus although there is no consensus regarding the efficacy 
of TRH in depression, it has been suggested that the TSH 
rise induced by TRH may be a diagnostic aid, since every 
study measuring the TSH response to TRH has found a lowered 
response in a subgroup of depressed patients (Kastin et al., 
1972a; Prange et al., 1972; Takahashi et al. , 1973a; 
Ehrensing et al., 1974; Itil et al., 1975). This has led 
to the suggestion that they may be a subgroup of depressed 
patients in whom TRH acts as a mood elevator. Prange 
{1975b)reviewed the patterns of pituitary responses to TRH 
in 12 studies involving 153 depressed patients and concluded 
that a diminished TSH response occurs in about 50% of the 
depressives. Moreover, this response deficit seems to be 
unrelated to the type and severity of the depressive 
disorder. 
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At present, it is not clear why there is a diminished 
TSH response in depressed patients, although high cortisol 
levels have been i mplicated. In addition, it is not yet 
known whether the deficit in TSH response is related to the 
state of being depressed or to predisposition to a depressive 
disorder. 
1.2.10 Sex Steroids: 
Research has not ye t succeeded in relating depression to 
any specific hormone. There is, however, evidence suggesting 
that the sex steroids may playa role. 
Clinical depressions occur more frequently in W0men than in 
men . Published surveys show the sex ratios to be between 
2:1 and 3:1 (Weissman and Paykel, 1974). The reason for 
the predomillance of female depressives, however, need not 
be hormonal. Social factors could be important, for 
example , "the tendency in our culture for tearfulness and 
helplessness to be regarded as feminine manifestations that 
cannot be acknowledged by males" (Weissman and Paykel, 1974). 
Furthermore, it has been suggested that alcohol may be used 
by males in an attempt to alleviate depression, and as an 
alternative to psychiatric treatment (Winokur et al ., 1970; 
1971) . The higher rate of alcoholism seen among men 
s upports this suggestion. 
Weissman and Paykel (1974) have cited additional evidence 
which suggests a link between sex hormones and depressiYe 
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disorders. 11inor feelings of depression are a common part 
of the premenstrual syndrome. Depression is also common in 
the first few days after childbirth (postpartum period) when 
major hormonal changes occur . Furthermore, depression also 
occurs in both men and women during the involutional period 
(menopause) which is also characterized by significant 
hormonal changes. Research by Rosenthal (1968) and 
Winokur (1973), however, has questioned whether there is, 
in fact, an increase in the occurrence of depressions around 
menopause. Daykin et al . (1966) have suggested that these 
depressions may be more related to psychological causes 
such as changes in social status , departure of children 
from home etc. Another piece of suggestive evidence is 
that oral contraceptives both cause and relieve depressive 
symptomatology (Section 1.2.12.2). 
Sex steroids have variable effects on neurotransmitters. 
The administration of steroids of the oestrogen and nor-
testosterone type utilized as contraceptives has been 
reported to modify the uptake and turnover of catecholamines 
in the hypothalamic median eminence (Fuxe et al. , 1973). 
In addition, these drugs have a marked effect on centra l 
DA metabolism (Greengrass and Tonge, 1973 ; 1974; Jori 
and Dolfini, 1976). Endogenous ovarian steroids also 
influence the metabolism of monoamines in the brain (Stefano 
et al., 1965; Fuxe et al., 1973; Greengrass and Tonge, 1974; 
Wirz-Justice et al., 1974). 
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Testosterone has been reported to exer t catecholamine-like 
effects on brain function (Broverma nn et al., 1968; Stenn 
et al. , 1972). It has also been shown that testosterone 
directly inhibits MAO activity in plasma (Klaiber et al . , 
196 7) . Thus it has been speculated that testosterone might 
exer t its catecholaminergic effect through an elevation of 
brain catecholamine l evels as a result of MAO inhibition. 
Testosterone has been found to be effective in the treatment 
of depression, particularly in climateric depression in 
males (Bleuler, 1954 ; Klaiber et al., 1975). This a nti-
depressive effect could be explained by its MAO inhibitory 
effects. Sachar et al. (1973a) however, have reported that 
the mean plasma testosterone level of depressed male patients 
is not significantl y changed after recovery from illness. 
Itil et aL (1974) examined the CEEG profiles of patients 
receiving 2 sex stero i ds . Mesterolone, an androgen , was 
shown to resemble the psychostimulant, ~- amphetamine in low 
doses, while in high and very high doses it had an effect 
similar to the " stimulant" TADs. The CEEG prof i le of 
patients receiv ing low doses of cyproterone acetate, an 
antiandrogen, was similar to the "sedative" TADs, whereas 
in high doses the profile was similar to that of an 
anxiolytic. On the basis of these r esults, mesterolone 
and cyproterone acetate were evaluated in a clinical trial. 
Mesterolone was shown to be dramatically effective in some 
male depressives while having no effect in others. The 
r eason for this discrepancy in unknown. Itil et al. (1974) 
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proposed that mesterolone's antidepressive effect could be 
r e lated to th e general MAO inhibitory effects of androgens. 
Low doses of cyproterone acetate were reported to be effective 
in male anxiety and high doses were found useful in the relief 
of the female premenstrual syndrome. 
The above study is the most positive to date in which a 
role for sex steroids in affective illness has been implied. 
The study, however, was small and uncontrolled and therefore, 
double-blind controlled trials are needed to verify these 
results. 
1.2.11 Adrenergic Receptor Abnormalities: 
Altered neuronal transmission in depression may result not 
only from alteration in transmitter availability but also 
from alteration in postsynaptic receptor sensitivity. 
Recent research has offered some support for this concept 
of an altered receptor sensitivity in depressive disorders. 
The chronic administration of TADs and MAO inhibitors or 
ECT has been shown to cause a reduction of noradrenaline-
sensitive limbic cyclase activity (Vetulani and Sulser, 
1975; Vetulani et al., 1975). Since this effect closely 
parallels the time course of the clinical antidepressive 
response, these authors proposed it to be the most relevant 
mechanism of action of the antidepressives. Moreover, 
iprindole, which neither inhibits the uptake of nor-
adrenaline or serotonin nor inhibits MAO (Fann et al., 1972; 
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Rosloff and Davis, 1974), also causes a similar reduction 
of limbic cyclase activity (Vetulani and Sulser, 1975). 
This pharmacological evidence suggests that depression might 
be accompanied by an i ncreased receptor sensitivity to 
noradrenaline which could be corrected by the reduction of 
noradrenaline-sensitive limbic cyclase activity produced by 
antidepressive ther apy. 
Supersensitive nor adrenergic receptors could be expected 
to cause feedback inhibition of noradrenaline synthesis, 
which might explain the diminished urinary MHPG levels 
observed in some depressed patients (Maas, 1968; Jones 
et al., 1973; Schildkraut et al., 1977) . This hypothesis 
is thus not inconsistent with the reports which suggest a 
noradrenaline depression subtype (Maas, 1975; Garver, 1979). 
In contrast, Ashcroft (1972) and Prange et al . (1972) suggest 
impaired sensit ivity of the postsynaptic receptor in 
depressive disorders. This is supported by the finding 
that thyroid hormone (TH), which affects receptor sensitivity, 
enhances the antidepressive action of the tricyclics (Prange 
et al., 1969; 1970 ; Coppen et al., 197~; Wheatley, 1972). 
In addition, a deficient GH response to clonidine (Matussek 
et al., 1977) is observed in some depressed patients, 
suggesting diminished a-adrenergic receptor sensitivity. 
These conflicting reports emphasize the need for further 
study of receptor function in affective states . 
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1.2.12 Vitamin Abnormalities: 
1.2.12.1 ~21~~~_Q~ii~i~~~Y: 
Hunter et al . (1967) found a high incidence of low serum 
folate concentrations in patients suffering from various 
psychiatric syndromes. A large number of patients in 
this study, however, took alcohol and/or barbiturates to 
exce s s or were on anticonvulsant therapy, which could partly 
account for this result. Carney (1967) and Reynolds et al . 
(1970) also reported that a sUbstantial proportion of 
patients suffering from affective disorders had low serum 
folic acid levels. 
Although the relationship of folic acid deficiency to 
depression is not yet clear, a possible link with the 
biogenic amine theories of depression has been postulated 
(Reynolds et al., 1970). Since pteridine cofactor is 
necessary in the hydroxylation of tyrosine (Udenfriend, 
1966) and tryptophan (Lovenberg et al., 1968), the propos ed 
folic acid deficiency could interfere with this rate-limiting 
hydroxylation step in the synthesis of the catecholamines or 
serotonin. 
1.2.12.2 ~YEi92~i~~_Q~fi~i~~~Y: 
The enzymes kynureninase and kynureninase aminotransferase, 
which convert 3-hydroxykynureni ne to 3 hydroxyanthranilic 
acid and xanthurenic acid respectively, are pyridoxal-
phosphate-dependent (Fig. 6) . Pyridoxine deficiency 
results in an elevated urinary excretion of kynurenine, 
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3-hydroxykynurenine and xanthurenic acid, apparently because 
kynureninase is more sensitive to a lack of available co-
enzymes (Ogasawara et al., 1962). Pyridoxine deficiency 
has been implicated in depression. 
Clinically it has been known for a considerable time that 
oral contraceptive intake can lead to depression. A survey 
of the literature (British Medical Journal, 1969) showed the 
frequency of this side effect to vary between 2 and 30 %. 
Nilsson and Solvell (1967) conducted a controlled trial 
and reported that 12% of the test patients complained of 
tiredness and/or depression. Oral contraceptive 
administration has been shown to induce a state of pyridoxine 
deficiency (Salkeld et al., 1973) with a consequent increase 
in the urinary excretion of these abnormal tryptophan 
metabolites (kynur e nine, 3-hydroxykynurenine a nd 
xanthurenic acid) (Brown et al., 1969; Rose, 1969; Briggs, 
1976) . It has been reported that the oestrogenic component 
of the oral contraceptive induces tryptophan pyrrolase which 
results in altered tryptophan metabolism (Rose, 1969; 
Salkeld et al., 1973; Sauberlick, 1975). According to 
the kynurenine hypothesis (Section 1.2.5) induction of 
tryptophan pyrrolase would decrease brain serotonin levels 
which, in turn, could cause depression. Another proposed 
mechanism is that pyridoxine deficiency in the brain would 
lead to low 5-HTP decarboxylase activity and thus to low 
brain serotonin and depression. In support of this, 
Nistico and Preziosi (1970) found that rats injected with 
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an oral contraceptive for 10 days showed a significant 
fall of brain serotonin with high pyrrolase activity. 
Pyridoxine supplements have been reported to restore the 
tryptophan metabolite levels to normal (Brown et al., 1969; 
Rose, 1969; Salkeld et al., 1973 ; Briggs, 1976). In 
addition, supplementary pyridoxine has been shown to 
relieve the depression in women taking oral contraceptives 
(Winston, 1973; Leeton, 1974). 
The above findings thus indicate that pyridoxine deficiency 
may well contribute to the state of mental depression. 
However, the exact nature of the relationship is currently 
unknown . 
1.2.13 Abnormal Glucose Utilization: 
One of the earliest biochemical changes noted in depressive 
d isorders was a decrease of glucose tolerance indicating an 
inhibition of glucose utilization (van Praag and Leijnse, 
1965) . Moreover, this change was reported to persist for 
some time after clinical recovery (Pryce, 1958). 
Treatment of depressed patients with MAO inhibitors has 
bee n found to improve their glucose utilization. The fact 
that MAO inhibitors potentiate insulin's effects could 
account for this observation (Weil-Malherbe, 1970). How 
abnormal glucose utilization is linked to depression remains 
unknown however . 
. .... - 137 - j 
- 137 -
1. 3 MELATONIN: 
1.3.1 Introduction: 
In 1958, Lerner and his co-workers isolated the melanophore-
lightening principle from bovine pineals and identified its 
structure as N- acetyl- 5-me tho xy tr y ptamine (melatonin) . 
Melatonin is found in the pineal, brain and eye of amphibians 
(Quay , 1965a; Cardinali and Rosner, 1971). I n mammals, this 
hormone is s y nthesized primarily in the pineal gland (Wurtman 
et al., 1968~, its synthesis undergoing diurnal variati ons in 
--
response to the photoper iod (Section 1.3.4) . 
1.3.2 Physiology and Pharmacology: 
Melatonin is a highly lipophilic compound that is uncharged 
at physiological pH and which enters the b rain with little 
difficulty . 
Melatonin has a unique tissue distribution: most of the 
indole present at any time is located within its pineal 
organ. The amounts of melatonin present in the pineal are 
very small (D,S to 7 ng in the rat pineal) and they fluctuate 
according to the photoperiod (Lynch, 1971). 
There is indirect evidence that melatonin is actually 
secreted from the pineal since it is found in human plasma 
and urine and is also present in tissues that lack the 
enzymes necessary to synthesize it (Lerner et al., 1959). 
However, it is not yet known whether melatonin is secreted 
into the bloodstream or into the CSF . The e lectron 
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microscopic and histological evidence is in favour o f 
secretion into a rich capillary network that surrounds 
the pineal cells (Kappers, 1971). On the other hand, 
there is as good evidence suggesting secretion into the 
CSF. Anton-Tay and Wurtman (1969) showed that the indole 
concentrates .in the bra in a 100 times better if it i s 
placed in the CSF instead of in the circulation. Thus, 
in determining the effects of exogenously-administered 
melatoni~ the dose and route of administration are of 
particular importance since 100 ~g of intravenously-
administered melatonin would be equivalent to about 1 ~g of 
the hormone introduced into the CSF. 
If isotopically labelled melatonin is injected into the 
venous blood, the hormone enters all tissues, including 
the brain (Kopin et al . , 1961; Wurtman et al., 1964b). If 
labelled melatonin is placed into the CSF, it is concentrated 
within several brain areas, especially by the hypothalamus 
and midbrain (Anton-Tay and Wurtman, 1969; Cardinali et 
al., 1973). Both brain regions are considered possible 
sites of action of melatonin. In a recent paper, Cohen 
et al. (1978), using specific binding techniques, p resented 
evidence for the existence of a specific cytoplasmic 
melatonin receptor. Radioactive melatonin binding was 
detected in animal and human ovarian tissue as well as in 
the testis, uterus, skin, liver and eye of the rodent 
species. These binding areas correlated well with those 
already mentioned in th e study by Wurtman et al. (1964b) . 
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Melatonin is detectable in rat and human plasma during the 
dark period of the day (Lynch and Wurtman, 1972). Most of 
the hormone in plasma (60-80%) is bound to serum albumin 
(Cardinali et al., 1972). Circulating radioactive 
melatonin disappears rapidly from the blood and is mostly 
inactivated by 6-hydroxylation within the liver, followed 
by conjugation and excretion as the sulphate or glucuronide 
(Kopin et al., 1960; 1961). Cardinali et al. (1973) 
showed that 'H-melatonin taken up from the CSF also 
disappears very rapidly from the brain. They reported 
that its delay curve exhibits 2 major components, an early 
phase lasting 20 minutes (hal f-life about 5 minutes) and a 
slower phase lasting 20 to 180 minutes (half-life about 40 
minutes). A major fraction of brain melatonin was shown 
to be metabolized to undefined water-soluble metabolites. 
In addition, Hirata et al. (1974) have shown that melatonin 
in the brain is also metabolized by an enzyme that cleaves 
the indole nucleus (Fig . 8). 
1.3.3 Synthesis of Melatonin: 
The synthesis of melatonin from tryptophan is shown in 
Fig. 8. 
The biosynthesis of melatonin is initiated by the uptake of 
the amino acid try ptophan from the circulating blood . Once 
within the pineal, some of the tr y ptophan is utilized for 
the synthesis of pineal proteins, while a larger fraction 
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is converted to serotonin (Wurtman et al., 1968c). 
Th e first step in melatonin's biosynthesis is hydroxylation 
which is catalysed by the enzyme, tryptophan hydroxylase 
(Lovenberg et al., 1967), and requires the presence of 
oxygen, ferrous iron and a reduced pteridine cofactor 
(Lovenberg et al., 1968). Next, 5-HTP is decarboxylated 
to form serotonin, which is found in very high concentrations 
in the pineal (Giarman and Day, 1959). This step is 
pyridoxal-phosphate-dependent. Part of the serotonin is 
oxidized to 5-HIAA by MAO and part is converted into 
me latonin (Fig. 8). 
In mammals serotonin-N-acetyltransferase (SNAT) ac·tivity 
is found in many organs besides the pineal, whereas 
hydroxyindole-O-methyltransferase (HIOMT) activity has been 
reported to be confined to the pineal gland (Ax elrod and 
Weissbach, 1961; Axelrod et al., 1961a). the retina 
(Cardinali and Rosner, 1971) and the harder ian gland 
(Vlahakes and Wurtman, 1972). However, it remains to be 
demonstrated that the mammalian retina or harderian gland 
actually synthesizes melatonin in vivo or that such melatonin 
is released. In a recent paper, however, Raikhlin and 
Kvetnoy (1976) presented evidence suggesting that melatonin 
is synthesized in the enterochromaffine cells of the gastro-
inte stinal tract . 
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1.3.3.2 Neural Control: 
Exposure of rats to constant illumination has been shown 
to reduce the activity of pineal HIOMT (Wurtman et al., 1963), 
SNAT (Klein and Weller, 1.970) and melatonin content in the 
pineal (Ralph et al., 1971) . Making a number of discrete 
neural transections in various brain areas of the rat, 
Wurtman et al. (1968b) established the pathway by which light 
reaches the pineal:retina + inferior accessory optic tract 
+ medial forebrain bundle + preganglionic sympathetic nerves 
+ superior cervical ganglion + postganglionic sympathetic 
nerves + pineal gland (Fig. 9). 
Noradrenaline (Axelrod et al., 1969) or cAMP (Shein and 
Wurtman, 1970) added to rat pineal gland cultures stimulated 
melatonin synthesis from I'C-labelled tryptophan and enhanced 
the cellular uptake of labelled tryptophan . This stimulation 
of melatonin synthesis was shown to be blocked by propranolol 
but not by phenoxybenzamine (Wurtman et al., 1971). In 
addition, adenyl cyclase activity (Weiss and Costa, 1968) 
and cAMP content (Strada et al., 1972) of the rat pineal 
were increased by noradrenaline. 
Based on these results, it has been proposed that in response 
to information received from the retina, the sympathetic 
nerves release noradrenaline, which then acts at S-adrenergic 
receptor sites in the pineal to activate the adenyl cyclase 
system which, in turn, triggers HIOMT activity and melatonin 
synthesis. 
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However, there is the possibility that the neural signal 
is generated by factors other than light, since the daily 
rhythms in pineal HIOMT and SNAT activity as well as 
melatonin content persist in continuous darkness (Section 
1.3.4). 
1.3.3.3 ~e~!2E§_~!!~~!!~9_~~~e!9~!~_§y~!g~§!§: 
Not only environmental lighting affects the pineal. 
Melatonin synthesis has been shown to be activated by stress 
and hypoglycaemia (Lynch et a1., 1973a; Sampson, 1975). 
Lynch et al. (1973a) showed that animals immobilized for 
several hours or made hypoglycaemic by the administration 
of insulin, exhibit a marked elevation of pineal melatonin 
as well as increased SNAT activity even while maintained 
in a environment of continuous illumination. 
1.3. 3.3. 1 Drug Effects: 
Since melatonin formation is stimulated by the release of 
noradrenaline from the sympathetic nerves innervating the 
pineal, it is conceivable that catecholaminergic drugs and 
hormones that influence the release of noradrenaline will 
affect melatonin synthesis. 
Several investigators have shown that the rate at wh i ch 
cultured rat pineals synthesize 14e-melatonin from labelled 
14e-tryptophan is increased by catecholaminergic drugs, 
such as d-noradrenaline , l-epinephrine, dopamine, tyramine, 
octopamine, tryptamine (Axelrod et al., 1969). The MAO 
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inhibitor, pheniprazine (Axelrod et al., 1969) . and harmine 
(Klein and Rowe, 1970) have also been reported to increase 
melatonin synthesis. 
A variety of psychotomimetic agents have also been shown to 
increase the production of melatonin. These include 
dimethyltryptamine, bufotenine, mescaline, lysergic acid 
diethylamide (LSD) and dimethoxyphenylethylamine (Hartl~y 
and Smith, 1973) as well as amphetamine (Backstrom and 
Wetterberg, 1973) and cocaine (Holtz et al., 1974). On 
the other hand, neuroleptics have been found to decrease 
this synthesis (Hartley et al., 1972). A possible relation-
ship between these drug effects, melatonin and schizophrenia 
is discussed in Section 1.3.8.3.1. 
In rats, L-DOPA administration increased the activity of 
pineal SNAT and HIOMT and caused a rapid acceleration of 
the synthesis and secretion of melatonin (Lynch et al., 1973b). 
The mechanism by which L-DOPA acts probably involves eit.her 
the release of noradrenaline from the pineal sympathetic 
nerve t.erminals or its conversion to DA which act.s directly 
on the pineal parenchymal cells to stimulate melatonin 
synthesis (Minneman and Wurtman, 1976). 
Numerous compounds have been shown to affect pineal HIOMT 
and SNAT activity, thereby indirectly influencing melatonin 
production. 
(1976) . 
These are reviewed by Minneman and Wurtman, 
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1.3.3.3.2 Effects of Sex Hormones: 
Although there is much literature on the effect of melatonin 
on gonadal function, little is known about the mechanism 
that relates gonadal function to changes in pineal melatonin 
levels. 
wurtman et al. (1965) showed that pineal HIOMT activity can 
be correlated with stages of the rat oestrous cycle. 
Enzyme activity was found to be twice as great in meta-
oestrous and di-oestrous than during pro-oestrous or oestrous. 
weiss and Crayton (1970a; 1970b) demonstrated that sex 
hormones influence the response of pineal adenyl cyclase 
to catecholamines. Noradrenaline stimulated pineal adenyl 
cyclase activity to a greater extent in male than in female 
rats. Ovariectomy increased the noradrenaline-induced 
activation of adenyl cyclase whereas oestrogen treatment 
had the opposite effect. Testosterone and progesterone 
were without effect in this system. The authors therefore 
suggested that the reciprocal relationship that exists 
between the pineal and ovary involves the adenyl cyclase-
cAMP system. 
Pineal HIOMT activity has also been shown to be affected 
by gonadal steroids. Oestrogen has been reported to both 
increase (Cardinali et al. I 1974a) and decrease (Nagle et al. I 
1972a) this activity in rats. Moreover, progesterone 
decreased HIOMT activity (Houssay and Barcelo, 1972), 
whereas testosterone administration produced a dose-dependent 
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variation in enzyme activity (Nagle et al., 1974). 
Cardinali et al. (1975a) reported that superior cervical 
ganglionectomy decreases the pineal uptake of both oestradiol 
and testosterone. It was thus suggested that sympathetic 
transmission plays a role in the effects of these hormones 
on the pineal. 
Further evidence suggesting that the pineal gland is a target 
organ for sex hormones, is the observation that labelled 'H-
oestradiol concentrates within the rat pineal following 
intraperitoneal injection (Neuspiller et al., 1972). In 
a study conducted by Rosner et al. (1971), pineal 'H-oestradiol 
concentrations were shown to be twice those found in the 
uterus. The above observations suggest that an oestradiol 
"receptor" may be present in the pinealocytes. 
1.3.4 Diurnal Rhythms in the Pineal: 
The activity of rat pineal SNAT undergoes a 24-hour rhythm 
which is in phase with changes in HIOMT activity, noradrenaline 
and melatonin secretion but is 180 0 out of phase with the 
pineal serotonin rhythm. Its activity is more than 15 times 
higher at night than during the day (Klein and Weller, 1970). 
The rhythm persists in complete darkness or in blinded 
animals (Klein and Weller, 1970) but can be suppressed by 
maintaining the animals in constant light (Klein and Weller, 
1970), removing the superior cervical ganglion which sends 
nerve fibres to the pineal, or deafferentation of this 
ganglion (Klein et al., 1971). Pineal SNAT rhythmicity thus 
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appears to be endogenous, although dependent on the 
sympathetic neural input and subject to modificatio n by 
external lighting conditions. 
Pineal serotonin content also shows diurnal changes with 
highest levels during the daylight (peak at midday) and 
falling rapidly with the onset of darkness (Quay , 1963; 
Snyder et al., 1965). Like the SNAT rhythm, the serotonin 
rhythm is endogenous although cued by environmental li gh ting 
conditions (Synder et al., 1965; 1967). 
HIOMT activity shows a diurnal rhythm similar to SNAT activ ity 
(Wurtman et al., 196~; Axelrod et al., 1965) but its 
variability is much less pronounced and is, therefore, not 
thought to have a major rate-limiting role in melatonin 
synthesis. This rhythm also persists when animals are 
placed in constant darkness (Nagle et al . , 1972b ). 
Pineal noradrenaline also has a diurnal rhythm corresponding 
to the photoperiod (Wurtman et al., 1967). This rhythm is 
180 0 out of phase with serotonin and in contrast to 
serotonin, is not endogenous, since it is readily abolished 
by continuous light or darkness. 
A ci rcadian rhythm in rat pineal melatonin has also been 
observed. During the day melatonin levels are low but at 
night, values 7 to 10 times th e day levels are reached (Quay, 
1964; Lynch, 1971) . 
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Persistence of this rhythm in constant darkness (Ralph et al., 
1971) suggests that pineal melatonin production is influenced 
by extrapineal circadian oscillators which, in turn, appear 
to influence pineal responsiveness to alterations in 
environmental light . Melatonin concentration in the blood 
has been shown to follow a similar rhythmic pattern in 
chickens (Pang et al., 1974; Pelham, 1975)· , sheep (Rollang 
and Niswender, 1976) calves (Hedlund et al., 1977) and 
humans (Vaughan et al., 1976). In addition, Vaughan et al. 
(1976) showed that 5-HIAA excretion followed a cycle similar 
. to that of blood melatonin. Comparable diurnal changes in 
urinary melatonin have been demonstrated in man (Lynch et al., 
1975) . Jimerson et al. (1977) measured the urinary melatonin 
rhythms in depressed and normal patients and found similar 
diurnC'.l rhythms. Moreover, following 1 nigh t' s sleep 
deprivation, the diurnal rhythm in mela t on i n excretion 
remained unchanged. Similarly , Vaughan et al. (1976) observed 
a continuation of the melatonin rhythm for 2! days following 
the onset of constant light. This suggests that neither 
sleep nor darkness governs the rhythm of melatonin excretion. 
These findings are incons i stent with previous studies in 
rats showing rapid light-induced suppression of the nocturnal 
rise in pineal melatonin synthesis (Wurtman et al., 1963 ; 
Axelrod et al., 1965). However, in a recent study using 
rats, Lynch (1977) reported that 1 night's exposure to 
continuous light failed to decrease the nocturnal rise in 
urinary melatonin excretion, in agreement with the human 
data . 
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Based on experimental evidence, Klein and Weller (1970) put 
forward the following hypothesis to explain the diurnal 
rhythm of the pineal compounds. The initial event is a 
dark-induced release of noradrenaline from the sympathetic 
nerve endings. No radrenaline stimulates adenyl cyclase in 
the pinealocytes, resulting in an increase in cAMP production 
whic~ in turn, stimulates SNAT (Section 1.3.3.2). A rapid 
rise in SNAT at night produces a decrease in serotonin 
concentration and results in elevated levels of N-acetyl-
serotonin and melatonin. It was sugges ted that pineal 
serotonin probably decreases because serotonin production 
cannot keep pace with the increased rate of acetylation. 
Thus, apparently it is the cycles in the activity of SNAT 
which are responsible for the cycles observed in serotonin, 
N-acetylserotonin and melatonin. 
There has been a suggestion that melatonin itself may 
contribute to the maintenance of rhythmic changes in the 
pineal (Fiske and Huppert, 1968) . These authors found 
that when melatonin was administered in the middle of the 
light per iod, the characteristic diurnal changes in serotonin 
were suppressed , whereas melatonin injected at the beginning 
of the dark period had no significant effect. 
Circadian rhythms have been observed in such functions as 
body temperature, adrenocortical secretion, sleep, motor 
activity and eating behaviour. It has been proposed that the 
mammalian pineal may function as a "biological clock" which 
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delivers time signals generated by environmental lighting 
conditions to centres in the brain that mediate other 
biological rhythms (Wurtman and Axelrod, 1965). Research , 
at present, is directed towards discove ring which organs 
"watch the pineal clock". 
1.3.5 Endocrine Effects: 
1.3.5.1 ~i~~i~~~Y_~~~~9_§~9_~~~~9~~~~Ei~_§~9~~~i~~: 
The reports of investigations on the effects of melatonin 
administration on blood and pitui tary levels of lutein izing 
hormone (LH) and follicle-stimulating hormone (FSH) are 
conflicting (Table 13). 
In an early study, Adams et al. (1965) repor ted an increase 
in the pituitary LH content following the administration of 
melatonin to immature rats which suggested LH suppression. 
Other investigators, however, have failed to detect any 
change in pituitary LH levels (Debeljuk, 1969; Debeljuk 
et al., 1970; Roche et al., 1970). Subsequent research 
demonstrated that the implantation of melatonin into 
selective brain areas, such as the median eminence and the 
reticular formation of the brain stem, suppressed the post-
castration rise in pituitary LH content (Fraschini et al., 
1968; 1971) . Likewise the castration-induced rise in 
serum LH was suppressed by melatonin in some studies 
(Roche et al., 1970; Fraschini et al., 1971) but not in 
others (Talbot and Reiter, 1973). 
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TABLE 13: 
THE EFFECT OF MELATONIN ON La AND FSH MEASUREMENTS 
(Modified from Reiter et !!., 197sa) 
Ul FSH 
SPOCIES S'" Am; = lWl'E l<XlEL Pl TUITAXi BUXJO PI'IULTARY BtDJI) RErnlElCFS 
Rat F 21-35 1001191 S.C. Prepubertal t (blocked .J - - - Jl.dams~~ •• 1965 
day old day Daily injection p..Ibertal deop) 
Rat M 25-44 IOo-SOOllg! S.C. Imnature No effect - No effect - Debeljuk. 1969 
day old day Constant light 
Daily injection 
Rat M 21-25 300)Jg/ SystEmic lmTIature No effect - , - Debeljuk ~ ~., 
day old day Daily injection 1970 
Sheep F Adult 2OOO11g/ I.V. Ollar iectany then No effect , - - ax:he ~&. , 1910 
day daily injectiaJ 
day 15-30 
... t M Adult J.mg/week s.c. castrated No effect No effect No effect No effect Talbot aoo Reiter, 
bee~ax 1973 
implants 
Rat F )0-58 lO1l9/ I.P. lnIMture - - - • Sorrentino, 1968 day old day Daily injection 
.. t F Adult JO)Jg/day loP. Adult, 00 
- -
- • Daily injection 
day cr.18 
Rat F Imnature l.500)J9/ I.P. lIm'Iature, Pro--
-
+oyulatory - - Reiter and 
day oestrous R>IS surge Sorrentino, 1971 
irduced 
ovulation 
Rat F Adult 1250-5000 Intra- Pro-oestrous 
-
+ovulatory - - Ying and I"iske, 
"9 cardiac: c:yc:lic surge 1972 
ovul ation 
Rat M Adult small Pituitar y Castrated ~ effect - - - F'raschini et a1., 
"""",t in 1968; 197r-
ooooa 
butter 
Rat M Adult 
""'U ~~:nrce anount in Castrated • • No effect -
ooooa 
butter 
Rat M Adult Small ~ticular • 
, 
-
-
"""",t in formation 
cocoa 
butte< 
Rat M Adult 1-5°1-19 III Acute - • 
, , Koo1beri ~~., 
Ventricle injection 1971 
, 
f, female; ~1{, follicle-stimulating hontale; I . P. , intraperitoneal, LV., intravenouSt I.H, luteinizing honnone; 101, male; 
FMS, pregnant mateis senft; 00, unilateral ovariectany . 
- canparative figures not available. 
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Melatonin administration has also been reported to decrease 
pituitary mass among untreated (Narang et al., 1967 ; 
Vaughan et al., 1971), light-exposed (Debeljuk, 1969) and 
castrated rat s (Debeljuk et al., 1970). DeProspo and 
Hurley (197ffi), however, did not observe any effect on 
pituitary mass. 
In addition , melatonin administration has been shown to block 
the pre-ovulatory surge in serum LH (Reiter and Sorrentino, 
1971; Ying and Fiske, 1972) as well as decrease serum FSH 
(Sorrentino, 1968; Kamberi et al., 1971). 
A possible mechanism explaining the above effects has been 
p roposed by Moszkowska et a1. (1973). These investigators 
fou nd that microinjections of melatonin into the rat lateral 
ventricle resulted in a significant decrease in hypothalamic 
releasing factor (RF) levels, particularly FSH-RF content . 
It was, therefor e , suggested that melatonin may act by 
decreasing the synthesis or release of the gonadotropin 
RFs in the hypothalamus. This hypothesis was supported by 
the studies of Kamberi et al. (1970) who showed that melatonin 
injected directly into the pituitary gland had no effect on 
serum LH levels. In contrast, the mor e r e c ent reports by 
Martin and co-workers (Martin and Klein, 1976; Martin et 
al., 1977) have demonstrated that melatonin can act directly 
on the neonatal pituitary gland and suppress the response to 
LH releasing hormone (LH-RH) which, in turn, suppresses 
pituitary LH release . It is possible , however , that 
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melatonin acts both on the hypothalo~us to inhibit LH-RH 
secretion and on the pituitary to suppress the stimulatory 
effect of the hypothalamic hormone on LH release. 
1. 3 . 5.2 Gonads: 
Melatonin ' s antigonadal effects have been well- reported but 
are not the subject of this study. For excellent reviews, 
the reader is referred to Reiter et al. (1975a) and Minneman 
and Wurtman (1976). 
1.3.5.3 Adrenal Glands: 
--------------
1.3.5.3.1 Glucocorticoids: 
Studies investigating the effect of melatonin administration 
on ACTH secretion and corticosterone levels are conflicting. 
Following reports on the inhibitory effect of pineal 
materia l on adrenal function (Kinson and Singer, 1967ai 
1967b ), Gromova et a!. (1967a; 1967b) found that corticosterone 
production increased significantly after melatonin treatment 
(200 ~g/IOO g BW) . This effect disappeared following 
hypophysectomy which suggested that melatonin has a 
stimulatory effect on pituitary ACTH. Fraschini et al. 
(1968), however, observed decreased adrenal mass following 
intrahypothalamic implantation of melatonin, whilst Barchas 
et a l. (1969) reported no alteration in corticoste rone or 
ACTH blood levels after either acute or chronic administration 
of melatonin. 
In order to increase the amount of melatonin gaining access 
... . . - 155 -/ 
- 155 -
to the neuroendocrine axis, De Prospo and Hurley (197la) 
injected melatonin (100 ~g/day) into the lateral cerebral 
ventricles of female rats for 10 days . Judging from the 
normal adrenal mass observed in the melatonin-treated 
animals, this treatment also failed to depress the pituitary-
adrenal axis. 
Despite reports to the contrary, Motta et al. (1971) 
demonstrated that an acute intraventricular injection of 
melatonin caused a marked reduction of plasma cortisol 
levels in normal male rats. Further experiments indicated 
that melatonin also suppresses stress-induced corticosterone 
production. However, following reserpine pretreatment, the 
corticosterone response was unaffected by melatonin treat-
ment. These results support the proposal that ACTH is 
under inhibitory control by a central adrenergic mechanism 
(Giuliani et al., 1966) and suggest that melatonin might 
act via this inhibitory mechanism. A central action of 
melatonin is supported by the in vitro evidence that, when 
the hormone is added to pituitary incubates, it does not 
change ACTH secretion (Jouan and Samperez, 1965). 
Melatonin has also been shown to alter the synthesis of 
corticoids in incubated adrenal slices (Giordano et al., 
1967; 1970). 
In a recent paper, Ogle and Kitay (1977) demonstrated that 
daily intraperitoneal administration of melatonin (2 x 50 ~g/ 
day) for 1 week stimulated adrenal 5 a-reductase activity 
.. . .. - 156 -/ 
- 156 -
in ovariectomized and hypophysectomized rats. This finding 
suggests that melatonin may playa role in the physiological 
regulation of adrenal steroidogenesis. 
1.3.5.3.2 Aldosterone: 
Although numerous investigators have studied the influence 
of the pineal and pinealectomy on aldosterone production 
(Reiter and Fraschini, 1969, review; Reiter et al., 1975a; 
review), only 1 report concerning me latonin's effect on 
this variable is presently available. Gromova et al. (1967a; 
1967b) reported that acute administration of melatonin 
significantly reduced aldosterone production, while 
hypophysectomy abolished this effect. 
Melatonin administration has been reported to inhibit thyro id 
function though the results are far from uniform. Baschieri 
e t al. (1963) noted a highly significant depression of 1311 
uptake by the thyroid after daily subcutaneous injections of 
melatonin. This finding was confirmed by Reiter et al. (1965). 
Baschieri et al. (1963) also demonstrated that melatonin 
blocked the thyroid hyperplasia caused by methylthiouracil. 
These authors concluded that melatonin might interfere with 
either the release or production of TSH. De Prospo et al. 
(1968; 1969) also reported depression of l311 uptake 
following melatonin administration which they found unrelated 
to the inhibitory effect of melatonin on gonadal secretion. 
In contrast, Thieblot et al. (1966) showed that administration 
of melatonin (100 ~g/day) led to gland changes normally 
associated with increased activity, whilst Naber et al. (1969) 
found melatonin to have neither stimulatory nor depressant 
effects on 1 311 uptake into the thyroid. 
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The TH secretion rate in rats was also shown to be inhibited 
by chronic melatonin administration (Narang et al., 1967). 
The animals , however, became progressively l ess sensitive 
to melatonin with advancing age. 
Several investigators have attempted to identify the site 
of action of melatonin on the hypo t hal amic-pituitary-thyro id 
axis (De Prospo and Hurley, 1971b; Panda and Turner, 1968). 
Panda and Turner (1968) observed that daily administration 
of melatonin (100 ~g/day) to rats for 10 days, increased 
their TSH levels which was associated with an increase in 
the DNA content of the thyroid. As a result of their 
findings, the authors concluded that melatonin acts directly 
on the thyroid to inhibit either the synthesis or release of TH. 
1.3.5. 5 Growth Hormone: 
Smythe and Lazarus (1973) showed that melatonin administration 
blocked the GH response to serotonin while 5-HTP administration 
enhanced it. This action could explain melatonin's well-
known inhibitory effect on growth. In a subsequent study 
(1974a), these authors demonstrated a reduced GH response 
to insulin-induced hypoglycaemia in 10 subjects following 
oral administration of melatonin. Initially. howeve~ a 
significant elevation of serum GR levels was observed. 
This increase in serum GH levels was aga in demonstrated in 
a later experiment (Smythe and Lazarus, 1974b). On the 
basis of these results, the authors suggested that the 
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ability of melatonin to increase serum GH in man is due to 
interaction with serotonin receptor sites in the hypothalamus 
which, in turn, mediates th e release of GH from the pituitary. 
They proposed that once melatonin had occupied the serotonin 
receptors and had displac ed any serotonin present, it acted 
as a competitive inhibitor of serotonin and consequently 
blocked GH stimulation via serotoninergic pathways. 
The ability of melatonin to block serotonin effec ts has also 
been demonstrated in vitro in s everal t ypes of smooth muscle 
(Rahamimoff et al., 1965; Quastel and Rahamimoff, 1965). 
1.3.5 . 6 ~§!~Q2~Y!§:~!i~~!~!i~g_~2£~2~§_~Q9_~§!~Q2~Y!§: 
~!i~~!~!iQg_~2£~2Q§_g~!§~§§~!~~i9i!i~9_~~~!2£: 
The significance of melanocyte-stimulating hormone (MSH) in 
mammals has been reviewed in detail by Thody (1977). The 
possible relationship between MSH, MSH release-inhibiting 
factor (MIF) and melatonin is briefly discussed here. 
In an early s tudy , Kastin and Schally (1967) reported that 
melatonin administration decreased the MSH content of the 
rat pituitary gland. They suggested that the release of 
MSH from rat pituitaries is stimulated by an increased 
concentration of circulating melatonin and inhibited by 
raised levels of circulating MSH . The exact mechanism by 
which melatonin stimulates MSH secretion was not known, 
although they proposed that the hormone might act by 
inhibiting MIF or by direct action on the pituitary. A 
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possible interaction between the pineal gland, hypothalamus 
and pituitary involving melatonin , MSH and MIF is suggested 
in a later paper by Kastin et al. (1972b). 
Tilders and Smelik (1975), however, found no changes in MSH 
content of the rat pituitary gland following melatonin 
administrat ion. Furthermore, melatonin had no effect on 
the diurnal variation of pituitary MSH levels (Tilders, 1973) 
and it was therefore concluded that t his rhythm as well as 
resting MSH levels was not controlled by melatonin (Tilders 
and Smel i k, 1975). 
1.3 .5 .6.1 Effect on Mood: 
In animals MSH administration produces an exaggerated response 
to noxious stimuli (Kastin et al . , 1973; Stratton et al., 
1973) and in man, pr oduces feelings of ner vousness, anxiety 
and motor restlessness (Kastin et al., 1968). Since 
melatonin and MSH have been shown to exert opposing actions 
on frog skin colour (Kastin and Ross, 1965; Kastin and 
Schally, 1966), rat pituitary MSH release (Kastin and 
Schally, 1967) rat thyroid (Baschieri et al . , 1963; Bowers 
et al., 1964) and melanocyte-lightening activity in the rat 
(Kastin et al., 1972), it is possible that melatonin may have 
an antianxiety or antidepressive effect on mood (Section 1,3.10). 
Further support for this suggestion comes from studies 
investigating the antidepressive effect of MIF; MIF is a 
peptide, isolated from hypothalamic tissue, which antagonizes 
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the ac tion of MSH by inhibiting the latter's release from 
the pituitary (Celis et al., 1971; Kastin et al., 1971). 
This peptide has been reported to be effect i ve in the DOPA 
response potentiation test (Plotnikoff et sl., 1971), a 
test for screening possible antidepress ives (Everett, 1966). 
In another animal model of depression, oral administration 
of the peptide reversed the sedative effects of deserpidine 
in mice and monkeys (Plotnikoff et al., 1973). In a double-
blind study, Ehrensing and Kastin (1974) investigated the 
efficacy of MIF in female depressives and reported MIF to 
be more effective than placebo in 4 of the 5 patients. 
Itil (1976) using CEEG profiles reported that MIF exhib its 
bimoda l effects, in low dosages CNS depression and in high 
doses CNS stimulation. This response, however, was 
subject to biological variability, subjects with ~-background 
activity showed a marked response to MIF, whereas those with a 
~-pattern showed no significant response. 
1. 3.5 .7 Prolactin: 
Melatonin administration has been shown to increase the 
concentration of prolactin in the blood . Following an 
injection of melatonin into the rat cerebra l ventricles, 
Kamberi et al. (1971) reported increased prolactin release 
into the circulation. since this effect was not obtained 
when melatonin was injected directly into the anterior 
pitu itary, these investigators suggested that melatonin 
might b lock the release of prolactin inhibiting factor 
(dopamine) from the hypothalamus, which, in turn, would 
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explain the observed elevation in p lasma prolactin levels. 
This finding has been confirmed by Lu and Meites (1973). 
1.3. 5 .8 Glucose Metabolism: 
--- ---------------
Pinealectomy creates a paradiabetic state with low glucose 
tole rance , hyperg lycaemia and a rise in insulin levels , 
whilst administration of pineal extracts leads to increased 
glucose tolerance and hypoglycaemia (Milcu et al., 1971, 
review). It has been suggested that these effec ts can 
be explained e ither by direct action on the panc r eas, 
possibly mediated v ia serotoninergic mechanisms, or by 
indirect acti on involving altered adrenocorticosteroid 
p rod uct ion. Thus, although th e pineal gland clearly plays 
a role in glucose metabolism, the function of me l ato n in is 
less clear. 
1.3.6 Central Metabolic Effects: 
Melatonin administration has been shown to influence t he 
metabolism of var ious central neurotransmitters. 
1.3.6.1 Serotonin: 
Anton-Tay e t al. (1968) reported that melatonin (500 ~g) 
administered intraperitoneally to rats caused an increase in 
brain serotonin content, especially in the midbrain and hypo-
thalamus , 1 hour after administration. These were the 
sites in the brain at which circulating 3H-melatonin was 
shown to be most concentrated (Section 1.3.2). Piezzi and 
Wurtman (1970) showed that melatonin administration ( 1 mg/kg 
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I.P. per day) for 5 days resulted in a significant increase 
in the serotonin concentration of the pars intermedia without 
influencing the concentration of serotonin in the other areas 
of the pituitary. Clinical studies have indicated increased 
5-HIAA levels in the urine of Parkinsonian patients (Anton-
Tay, 1974) as also in the CSF of depressed patients (Carmen 
et al., 1976) following the administration of melatonin, 
which again suggests increased serotoninergic activity. 
Additional effects of melatonin administration on serotonin 
and catecholamine release and uptake are discussed in Section 
1.3.6.4. 
1. 3 . 6. 2 GABA : 
Intraperitoneal injection of melatonin (50 ~g/kg) increased 
the hypothalamic concentration of GAB A twofold, as well as 
significantly increasing its concentration in the rat cerebral 
cortex 2 hours after administration (Anton-Tay, 1971). 
1.3.6.3 ~YEi99~~~_~E9§PE9~i~~§~ : 
Pyridoxal phosphokinase catalyzes the formation of pyridoxal 
phosphate in the brain (McCormick and Snell, 1959). py ridoxal 
phosphate is the prosthetic group of the enzyme, aromatic 
L-amino acid decarboxylase, and this is essential for the 
synthesis of DA, serotonin and GABA (Roberts et al., 1958; 
Lovenberg et al., 1962). 
Anton-Tay et al. (1970) reported that intraperitoneal injections 
of melatonin (0,25 to 4 mg/kg) gave rise to a rapid increase 
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in the activity of rat brain pyridoxal phosphokinase, 90 
minutes after administration. This effect was dose-related. 
Following a single dose of melatonin (200 ~g/kg) a good 
correlation between the changes in pyridoxal kinase activity 
and serotonin levels was noted. The above data led Anton-
Tay et al. (1970) to propose that the biochemical effects of 
melatonin administration (i.e. increased serotonin and GABA 
brain levels) might be related to its effect on pyridoxal 
phosphokinase. Since melatonin had no effect on pyridoxa l 
phosphokinase activity in vitro, the authors suggested that 
melatonin enhanced the enzyme's activity in vivo by increasing 
its de novo synthesis. This is supported by the finding that 
2 mg/kg of actinomycin was able to block the effects of 
melatonin (Anton-Tay, 1971) . 
1.3.6.4 Catecholamines: 
--------------
Cotzias et al. (1971a) found no significant alteration in 
brain DA content of mice following an intraperitoneal injection 
of melatonin (400 mg/kg). Previously Anton-Tay et al. (1968) 
had reported no changes in noradrenaline levels in brain 
tissue after melatonin administration. wendel et al. (1974), 
however, dosed rats with either an intraarterial or intra-
cisternal injection of melatonin and found significant 
increases in DA and noradrenaline levels in the rat brain. An 
intraarterial injection of melatonin (250 ~g/g ) nearly doubled 
the DA content and significantly increased the noradrenaline 
concentration 1 hour following administration . Melatonin 
injected intracisternally to circumvent the blood brain 
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barrier, also caused significant increases in both DA and 
noradrenaline levels. The elevated levels were noted 
within 15 minutes after hormone administration, rose to a 
maximum between 30 minutes and 1 hour and returned to control 
levels approximately 2 hours later. 
These authors suggested that the failure of the previous 
workers to demonstrate an effect of melatonin on catecholamine 
l evels may have been due to its rapid conversion to 6-hydroxy-
melatonin following intraperitoneal administration. 
In addition, melatonin has been shown to non-competitively 
inhibit the uptake of noradrenaline, serotonin, DA and 
glutamate into synaptosome-rich homogenates of the rat hypo-
thalamus (Cardinali et al., 1975b ). This effect was dose-
dependent. Noradrenaline, serotonin, DA and glutamate 
accumulation fell by 43, 69 , 48 and 32 % respective ly following 
administration of 0,5 mM melatonin and by 60, 82 , 66 and 55 % 
respectively following 1,0 mM melatonin. Transmitter release 
evoked by increasing [ K+j to 30 mM was also augmented by 
melatonin in a dose-dependent manner. Noradrenaline, serotoni n , 
DA and glutamate release was increased by 9 , 25, 12 and 4% 
(0,5 mM) and by 22, 34, 19 and 11% (1,0 mM), respecti vel y. 
The results suggested that melatonin interferes more easily 
with transmitter uptake and release in serotonin- than in 
catecholamine-containing neurons. This proposal was supported 
in a subsequent report by Cardinali (1975) who showed that 
melatonin-treated rats exhibited a depressed hypothalamic 
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serotonin uptake whilst the uptake and accumulation of nor-
adrenaline, DA and glutamate was unaffected. 
1.3 .6.5 ~E9!~~~_§Y~!b~§~§: 
Melatonin administration has been reported to decrease protein 
synthesis (Orsi et al., 1973; Cardinali et al., 1974b) and 
microtubule protein content (Cardinali and Freire, 1975). 
Brain microtubule protein (Thoa e t al., 1972) or actin-
like protein (Nicklas et al., 1973; 1974) has been implicated 
in the process of neurotransmitter uptake and release by the 
nerve endings. Cardinali et al. (1975b), therefore, speculated 
that melatonin may affect transmitter uptake and release by 
interacting with brain microtubule or actin-like protein. 
1. 3.7 Behavioural Effects: 
1.3.7.1 §1~~E_9~9_~1~£!E9EbY§~9199~£91_~b9~g~§: 
Several investigators have evaluated the effect of melatonin 
a dmi nistration on sleep and EEG patterns in a variety of 
animal species. Marczynski et al. (1964) implanted melatonin 
into the hypothalamus of cats and reported the appearance of 
behavioural and EEG signs of sleep. Systemic administration 
of the hormone into young chicks was also found to induce 
sleep (Barchas e t al., 1967; Hishikawa et a l., 1969) and 
EEG desynchronization (Hishikawa et al., 1969) . 
Likewise, melatonin administration has been shown to induce 
and prolong sleep in healthy human subjects. In an early 
study, Lerner and Case (1960) gave a patient 200 mg of 
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melatonin intravenously and observed mild sedation. Anton-
Tay et a1. (1971) administered an acute dose of melatonin 
(1,25 mg/kg) to 11 healthy volunteers and reported cortical 
deactivation, sleep and an increase of EEG alpha activity. 
In a more extensive study, these authors showed Phase II 
enhancement, Phase IV shortening and an increase in rapid 
eye movement (REM) sleep (Anton-Tay, 1974). Cramer et a1. 
(1974), however, did not observe any significant changes 
in total s leeping time or s l eep stage percentages although 
sleep onset time was reduced by 50%. These findings led 
them to conclude that "melatonin-induced sleep strikingly 
resembles natural sleep". This has been confirmed by another 
group using EEG studies (Hollister et al., 1975a). 
On the other hand, pinealectomy led to increased cortical EEG 
activity (Nir et al., 1969). 
The above data suggest that melatonin among other factors may 
play a neurohumoral role in modulating the state of wakefulness 
and sleep. A proposed mechanism of action is discussed in 
Section 1. 3.9. 
1.3.7.2 ~~E9!~~E~~§_f9~§~~!~~!9~: 
Additional support for the sedative role of melatonin has been 
presented by Barchas et a1. (1967) who demonstrated a potentia-
tion of hexobarbital sleeping time in mice following a systemic 
injection of melatonin (25 mg/kg I.P.). This inhibitory effect 
on the CNS had been previously shown by Arutyunyan et a1. (1964), 
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who found that melatonin potentiated the effect of the 
somnifacients, sodium hexenal and chloral hydrate. In 
addition, Martini and Fioretti (1971) reported that intra-
ventricular injections of melatonin prolonged the effect of 
pentobarbitone and that this effect was dose-related. 
Since melatonin is metabolized by the same liver enzymes which 
metabolize barbiturates (Kopin et al., 1961), it has been 
suggested by Axelrod (1971) that prolongation of the sleeping 
time by melatonin might be due to the hormone blocking the 
metabolism of the barbiturate. 
Furthermore, Nir (1971) has demonstrated that the electro-
phy siological reaction of the rat brain to lethal doses of 
pentobarbitone is different after pinealectomy. In the sham-
operated and intact controls death occurred within 7 to 10 
minutes, while in the pinealectomized rats it was delayed 
until at least the fifteenth minute. These results, therefore, 
suggest that pinealectomy decreases the lethality of 
barbiturates which is consistent with Axelrod's hypothesis 
(1971). 
1.3,7.3 Avoidance Behaviour: 
A study evaluating the effect of melatonin administration on 
avoidance behaviour in rats as well as a review of previous 
reports i s presented in Chapter 2 . 
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1.3.7.4 ~!!~~!_~~_~~~9~9!9E_~~!iYi~y: 
Numerous investigators have studied the influence of the pineal 
gland and melatonin on the locomotor activity of many animal 
species under a variety of experimental conditions. 
Gaston and Menaker (1968) studied the effects of pinealectomy 
on the locomotor activity rhythm of the house sparrow (Passer 
domesticus) in different environmental lighting conditions . They 
found that when pinealectomized birds were exposed to light-
dark cycles, synchronization of rhythmic aspects of their 
locomotor activity with changes in the photoperiod did not 
differ from those of the sham-operated control birds. However, 
when the birds from which the pineal had been removed, . were 
kept in constant darkness, their rhythm of locomotor activity 
was abolished. The control birds, on the other hand, continued 
to exhibit rhythmic activity patterns. From these observations 
the authors concluded that the pineal of the sparrow is 
essential for the persistence of the circadian locomotor 
rhythm in constant conditions and consequently they suggested 
that the pineal may be an important component of the endogenous 
time measuring system ("biological clock") which serves to 
correlate activity rhythms with periodic changes in the 
external environment. These studies have been partially 
replicated in the iguanid lizard (Sceloporus olivaceus) by 
Underwood and Menaker (1970). 
The laboratory rat has been used extensively to study pineal 
involvement in locomotor activity levels and rhythm with mixed 
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results. The effect of pinealectomy and melatonin administra-
tion on rat locomotor activity 1S summarized in Tables 14 and 
15. In an early study, Reiss et al. (1963) reported that the 
neonatal pinealectomy of both male and female rats resulted, 
12 weeks later, in increased treadwheel activity during a 
2-hour test period. This experiment, however, suffered 
serious methodological problems including the lack of a sham-
operated control group. I n a later experiment Reiss et al. 
(1967) studied the pineals of normal male rats microscopically 
and found that the "slow runners" exhibited a greater pineal 
cell density, suggesting greater hormone production, than the 
"fast runners". Wong and Whiteside (1968) found that daily 
intraperitoneal injections of melatonin (10 Vg/rat) 
significantly decreased the wheel-running activity of food-
deprived male rats during a 2-hour test period for the first 
5 days of testing. However, these differences were small and 
the curves of increasing activity over time appeared very 
similar in the 2 groups. 
All these early studies, therefore, suggested that pineal 
functioning retards the total level of motor activity in the 
rat. This conclusion,however, is inconsistent with the more 
recent finding that pineal activity, specifically melatonin 
production, as well as rat locomotor activity is higher at 
night. 
Recen t, better-controlled experiments relating pineal 
function and rat motor activity have contradicted these 
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TABLE 14: 
EFFECT OF PINEALECTOMY ON RAT LOCOMOTOR ACTIVITY 
PLnealectal1y Species Sex A.e Lighting Test period Othe, Results Reference conditims ard apparatus conditions 
Neonatal (2-4 Sprague- Male' u_. - 2 hours i n a Lack of ~ FE rats were Reiss et al . , 
days uter Dawley fBMle tread\.lheel opeuted no[e lCtive 1963 --
birth) CDIltrol group 
Postpubertal long- Male ZS weeks Continuous Tested in an No effect:. on Quay. 1968 
E.V~s light then activity wheel activity 
CXlI'ltinuous for 5 rronths rhythrs 
da<k 
Ebstpubertal Sprague- Male 25 weeks L2L:l2O Activity ro effect on Remley et al., 
Dawley (14 days) recorded twice wheel running 1969 --
then daily in activity 
constant activity 
illunination wheels 
Postpubertal Local 51 FaMle 28 weeks Varied Tested in an No effect on Quay. 1970a 
strain lighting activity Mlee1 activity 
conditions for a ~ar levels or 
rhytl'lt\a 
Neonatal (2-4 Wistar Male 7 wee'" 8L; 16D 1 haul: in a Food- No effect on Relkin, 1970a 
di1}t; after strain t reaiMleel deprived activity 
birth ) or levels 
post pubertal 
Nronaral (2-, Wistat" Male 6 ~ks 8L! l6D I bou, in a Food- No effect on Relkin. 1970b 
days after strain ",e deprived 
' .. m birth) or performance 
plStpubeptal. 
NeOnatal (24 Holtzman FBMle 13 weeks 14L: 100 1 month in PE rats showed Ki rel et ~. , 
hrs after and then activity reduced motor 1970 
birth) Charles 10L:140 cages activity. A!rv 
River synchronize to 
.u. t.rain new light:-dark 
cycles II'Ore 
readily 
Neonatal (2-3 Charles FBMle 12 weeks Constant 3-minute test PE rats were Sampson and 
days after River darkness peeioo in an Il'Ore active Bigelow, 1971 
birth) strain open-field in the open 
box field 
PostfAlbeetal Sprague- hale 
- lSL: 9D 1 day in PE rats showed Karppanen ~ 
Da.wlt- activity increased !!. , 1973 
cages activity in 
the darkness i 
PO:. t/:JUbf. r tal R-Am~ter- Female 
-
12L: 120 3-minute test No effect on Kovacs !! ~. , 
dam period in an open-field 1973 
albino open-field activity 
box 
PrefUbertal Sprague- Fenole 
- 14L: 100 2-mi nute test Rats were Pinea1ectony Sackman and (22 dayel Dawle} period in an reooered reversed Reiter, 1977 
after birth) open-field blind and hyperactivi ty 
box arosoic 
PEf pinea1ectanized 
- not refOrted 
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TABLE 15: 
EFFECT OF MELATONIN ADMINISTRATION ON RAT LOCOMOTOR ACTIVITY 
Melatonin Dose Species Sex Age Lighting Test period Other Results 
and Duration conditions and apparatus conditions 
10 Jl9/rat daily wistar Male 9 weeks - 2 hours per Deprived of Melatonin 
for 2 weeks albino day in an food decreased 
activity wheel acti vi ty f(x 
the first 5 
days of testing 
100 Jlg/ rat daily Charles Female 12 weeks Constant 3-rninute test Administered No effect on 
for 2 weeks River darkness period on day to PE and exploratory 
strai n following the control rats activity in 
final injection the open-field 
in an open-
field box 
200 Jl9/rat daily Sprague- Male - Constant Daily 3-rninut e Administered No effect on 
for 13 days Dawley illt.nnination test period in to hypophy- acti vity 
an activity sectanized 
cage and control 
rats 
50 Jlg/rat and R-Arnster- Male - 12L:12D 3-minute test No effect on 
100 Jlg/rat for dam period in an open-field 
3 days albino open-field box activity 
Weekl y S.C. Sprague- Female 3 weeks 14L:IOD 2-minute test Administered Reversed 
impl ants (1 mg Dawley period in an to blind- hyper acti vi ty 
melatonin) for open-field box anosmic rats 
4 weeks 
PE, pinealectomized; S.C. , subcutaneous. 
- not reported 
Reference 
Wong and 
Whiteside, 
1967 
Sampson and 
Bigel oo, 1971 
Kasti n et al. , 
1973 
Kovacs et al., 
1973 
Sackman and 
Rei ter, 1977 
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earlier reports. For example, Remley et al. (1969) 
demonstrated that the total activity of male rats which had 
been pinealectomized as adults, did not differ significantly 
from sham-operated controls, either during light-dark cycles 
or during constant illumination. These findings were confirmed 
by Relkin (1970ai 1970b) who showed that neither prepubertal 
nor postpuberta l pinealectomy affected the treadwheel-running 
activity (1970a) or maze performance (1970b) of adult male 
rats that had been deprived of food . 
Quay in a series of well~controlled studies demonstrated that 
pinealectomy did not influence the wheel-running activity 
rhythms of either male rats kept in constant conditions 
(1965 b; 1968) or of female rats under varied environmental 
lighting conditions (1970a). The total level of wheel-
running activity of adult female rats was also shown to be 
unaffected by pinealectomy (1970a). Quay , however, found 
that following reversal of the photoperiod, pinealectomy 
affected the shifting of the daily start of the rat's activity 
phase (1970a; 1970b). The direction of this effect of 
pinealectomy on shifting the activity phase was reported to 
change with age - initially pinealectomized rats phase-shifted 
more rapidly than their controls, however, at early adulthood, 
this difference reversed and the pinealectomized animals phase-
shifted more slowl y (1972). In addition,he showed that the 
activity levels of pinealectomized rats synchronized to the 
new light-dark cycles more rapidly than those of the control 
animals. 
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Kincl et al. (1970) replicated these findings using neonatally 
pinealectomized female rats. Neonatal pinealectomy was also 
reported to reduce the spontaneous motor activity of female 
rats and this was said to be independent of the oestrous 
cycle. These authors thus suggested that the p ineal gland 
acts as a " brake" which adjusts the activity of nocturnal 
animals in response to changing photoperiod , and, in the 
absence of such a "brake", rapid adjustment of motor activity 
to light changes occurs. 
Sampson and Bigelow (1971) supported the work of Kincl et al. 
(1970) by showing that female rats which had been p inealectomized 
2 to 3 days after birth, exhibited more exploratory activity in 
the open field than either sham-operated or unope rated litter-
mate controls. Daily injections of aqueou s pineal extract for 
2 weeks reversed this effect, while similar treatment with 
melatonin (100 ~g/rat) had no significant effect on this 
behavioural variable. 
In a study performed by Kastin et al. (1973) a single injection 
of melatonin (200 ~g/rat) had no significant effect on the motor 
activity of intact or hypophysectomized male rats under 
conditions of constant illumination. Kovacs et al. (1973) 
reported that neither melatonin (50 ~g/rat and 100 ~g/rat) nor 
pinealectomy had any effect on exploratory activity in the open 
field. Karppanen et al. (1973) demonstrated that during a 
15-hour-light:9-hour-dark schedule pinealectomized male rats 
showed increased motor activity in the dark. In addition, 
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oxypertine (a methoxyindole resembling melatonin) was shown 
to reduce locomotor activity in pinealectomized rats less 
than in unoperated controls. 
In a recent report, Sackman and Reiter (1977) found that 
pinealectomy or weekly implants of melatonin (1 mg/rat) 
reduced the hyperactivity produced in blind-anosmic female 
rats. In this case pi nealectomy and melatonin implants 
acted similarly in reducing hyperactivity which supports the 
suggestion that chronic treatment of rats with melatonin leads 
to functional pinealectomy (Reiter et al., 1975b). 
The influence of the pineal and melatonin on rat locomotor 
activity i s thus not clear cut. In order to demonstrate 
the complex relationship between pineal acti vi ty and motor 
activity , it is essential that experiments be well-controlled 
in terms of photoperiod, sex, age and species of the animal. 
The above findings show that the pineal gland ~ se does not 
exert a direct control over motor activity. Were this the 
case, pinealectomy would render the rodents either 
continuously active or continuously inactive. The pineal 
has, however, been implicated indirectly in the circadian 
control of spontaneous locomotor activity (Kincl et al., 1970, 
Quay, 1970 b ). Melatonin also does not exert a simple effect 
on locomotor activity and conflicting reports have been 
published. Since serotonin is concerned with the control 
of sleep, the inhibitor y effect of melatonin on motor activity 
reported by some workers, might be due to th e drug's effect on 
the serotoninergic mechanisms of the midbrain and hypothalamus . 
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1.3.7.5 ~~y£~~!~~~~~!i£_~!!~£!?: 
Abnormal methylation has long been implicated in the aetiology 
of schizophrenia (Osmond and Smythies, 1952; Kety, 1965) . 
It has been hypothesized that enzyme systems involved in 
transmethylation reactions are defective in schizophrenic 
patients, which, in turn, allows for the b uild-up of toxic 
levels of pyschotomimetics in t he brain. HIOMT is a methylating 
enzyme and it has been suggested that this enzyme may be 
congenitally defective in schizophrenics (Greiner, 1970). 
Since the func ti on of HIOMT is Oto catalyse the forma tion of 
melatonin, this indole has been implicated in the d isease (McIsaac 
et al., 1961; Jones -et al., 1969). It was suggested that melatonin 
might unde rg o a cyclic dehydratiorr to form 10-methoxyharmala~ a 
psychotomimetic compound. There is indirect evidence 
supporting the concept that melatonin may be associated with 
schizophrenia. In animal studies, haloperidol (Nay lor and 
Olley, 1969), a drug used in the treatment of the disease, 
and LSD (Drab et al., 1971), a psychotomimetic, have been 
shown to be concentrated in the rat pineal gland. In addition, 
Hartley et al. (1972) reported the inhibition of pineal HIOMT 
by haloperidol and fluphenazine in vitro. Moreover, in a 
subsequent paper, it was shown that psychotomimetic drugs 
activate HIOMT activity in vivo (Hartley and Smith, 1973). 
On the basis of these results, the authors proposed that the 
ability of haloperidol and fluphenazine to inhibit pineal HIOMT 
activity and melatonin synthesis may account for the 
beneficial action of these drugs in the treatment of 
schizophrenia . Unfortunately , however, there have been few 
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clinical studies to substantiate this hypothesis (Section 
1.3.8.3.1). 
1.3.8 Clinical Studies: 
1.3.8.1 ~~E~~!_§~~j~~!§: 
Numerous investigators have administered melatonin to normal 
healthy volunteers. A summary of these studies and the 
psychological effects of melatonin administration is outlined 
in Table 16. Common effects of melatonin treatment seem to 
be sedation (Section 1.3.7.1), tranquilization and a general 
feeling of well-being. Cutaneous flush, abdominal cramps , 
diarrhoea, scotoma lucidum and migraine headaches have also 
been noted in occasional patients. 
se roto ninergic ac t ivity. 
1 . 3.8.2 ~~~E~!~9~~~!_9~~~E9~E§: 
1 . 3.8 . 2.1 Epilepsy : 
These effects suggest 
Anton-Tay et al. (1971) administered melatonin to 3 epileptic 
patients and reported the same well-being and elation seen in 
normal subjects. Recordings of the EEG showed a reduction in 
the electrical activity over the temporal lobe, depression of 
paroxysmal activity and increase in REM sleep . The observed 
rise in the convulsive threshold suggested a deactivation of 
the subcortical structures that integrate the general seizure 
(Penfield and Jasper, 1964) . Melatonin, therefore, may be 
of use in the treatment of epilepsy, however, further studies 
are needed to confirm this suggestion. 
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TABLE 16: 
Study 
Lerner and 
Case, 1960 
Anton-Tay et 
al., 1971-
Anton-Tay et 
al., 1974-
Cramer et al., 
1974 
Smythe and 
Lazarus, 1974 
Hollister et 
al., 1975a-
Norlund and 
Lerner, 1975 
PSYCHOLOGICAL EFFECTS OF MELATONIN ADMINISTERED TO NORMAL SUBJECTS 
(Modified from Carman et al. (1976)} 
NLUnber 
of Subjects 
2 
15 
6 
15 
10 
6 
Length of 
Study (days) 
1 
1 
6 
1 
1 
28 
Peak Daily 
Dose (mg) 
200 
125 
1000 
50 
1000 
1,25 
1000 
Route of 
Administration 
IntravenQUs 
Intravenous 
Oral 
Intravenous 
Oral 
Oral 
Psychological Effects 
Mild sedation 
Sleep induction, elation, visual 
imagery 
Sleep EEG effects, increased 
REM sleep, increased phase 2 
and decreased phase 4 
Immediate sedation, decreased 
psychomotor activity, shortened 
sleep latency, increased 
emotional stability noted on 
the day following bedtime 
infusion 
Behaviour not reported 
Sleep EEG effects 
Sedaticn 
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1.3.8.2.2 Parkinsonism: 
Studies investigating the efficacy of melatonin in the treat-
ment of Parkinsonism are conflicting. Anton-Tay et al. (1971) 
administered 1,2 g of melatonin daily to 2 Parkinsonians for 
4 weeks and reported a striking improvement in their clinical 
picture. Rigidity and tremor improved and in addition, both 
reported a general feeling of well-being associated with an 
improvement in the performance of daily tasks. In both cases, 
placebo substitution led to overall deterioration. These 
beneficial effects of melatonin administration have been 
replicated ln a study by Anton-Tay and Fernandez-Guardiola 
(1976) but have not been confirmed by other investigators. 
Papavasiliou et al. (1972) reported that various oral doses of 
melatonin had no effect on the signs of Parkinsonism in 11 
patients suffering from the disease . Shaw et al. (1973) 
administered 1 g of melatonin daily for 4 weeks to 4 Parkin-
sonian patients and likewise reported no change in the 
disabilities. Cotzias et al. (1971b), however, showed that 
melatonin admi.nistration controlled the tremor of 1 Parkin-
sonian patient. 
1.3.8.2.3 Huntington's Chorea: 
In a single study, Carmen et al. (1976) reported that 2 patients 
suffering from Huntington's chorea showed depression and 
psychomotor retardation following melatonin administration . 
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1.3.8.3 ~§Y~Di~!!i~_~i§2!9§!§: 
1.3.8.3.1 Schizophrenia: 
In a small study, Jones et aI.· (1969) investigated the metaoolism of 
melatonin in 3 schizophrenic and 2 non-schizophrenic patients. Although 
they reported a somewhat higher excretion of an unidentified 
acidic metabolite by the schizophrenic patients, no mention 
was made of the behavioural or possible therapeutic effects 
of melatonin on the subjects. 
In contrast to melatonin, aqueous extracts of pineal glands 
have been shown to produce clinical improvement in some patients 
with chronic schizophrenia (Altschule, 1957; Eldred et al., 
1961; Bigelow, 1974). 
1.3.8.3.2 Depression: 
To date, only 1 study by Carman et al. (1976) has investigated 
the effects of melatonin administration in depressed patients. 
Melatonin was administered in varying amount s either orally 
or by intravenous infusion. During therapy, depression ratings 
increased and this was accompanied by a loss of sleep and mass 
and a drop in oral temperature. Melatonin, however, was shown 
to increase the 5-HIAA and calcium levels in the CSF in 3 of 
the 4 patients studied. 
1 . 3.9 Proposed Mechanism of Action on the CNS: 
The exact mechanism of action of melatonin on the CNS is 
unknown, although various theories have been proposed. 
Melatonin might elevate brain neurotransmitter l eve ls by 
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stimulating synthesis, inhibiting release, enhancing reuptake 
or by inhibiting the intraneuronal or extraneuronal metabolism 
of the transmitter. Anton-Tay et al. (1970) proposed that the 
increased concentration of serotonin and GAB A observed in the 
midbrain and hypothalamus following melatonin administration 
could be explained by the hormone's effect on pyridoxal 
phosphokinase activity (Section 1.3.6 . 3). 
Another explanation involving cAMP has been put forward. 
This is schematically outlined in Fig. 10 . Anton-Tay (1974) 
hypothesized that the changes in brain cAMP observed after 
melatonin administration (Ortega et al., 1974) suggest that 
the hormone acts on at least 2 different kinds of receptors, 
one located in the midbrain, the other in the cerebellum. 
He proposed that the midbrain receptor responds to melatonin 
by a decrease in cAMP level while the cerebellum receptor 
produces an increase of nucleotide in response to the hormone. 
Following melatonin administration, maximal changes in cAMP 
levels are seen after 10 minutes, in pyridoxal phosphokinase 
activity after 45 minutes and in midbrain serotonin 
concentration after 60 minutes. Thus, although the 
physiological role of cAMP in the eNS is not clear, the above 
sequence of metabolic events induced by melatonin suggests a 
causal relationship between them. 
Anton-Tay (1974) also postulated other mechanisms. He 
suggested that melatonin might compete with serotonin at 
receptor sites in the telencephalon, causing an increased 
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Fig. 10. 
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synthesis of the monoamine in the midbrain. Melatonin 
may also act on other brain systems, for example, the 
hypothalamus. The fact that the hypothalamus shows a rich 
uptake of melatonin (Anton-Tay and Wurtman, 1969) and that 
hypothalamic levels of melatonin remain unaltered after 
pinealectomy (Green et al., 1972) support this assumption. 
The above actions of melatonin on the midbrain and cerebellum 
would explain the variety of effects observed after its 
administration. since the serotoninergic neurons of the 
midbrain have axons projecting to the hypothalamus and limbic 
system through the medial forebrain bundle, it is possible that 
the neuroendocrine and behavioural effects of melatonin could 
be mediated by the activation of these serotoninergic pathways. 
Similarly, activation of the neural pathways that leave the 
cerebellum and enter the red nucleus and reticular formation 
may explain the observed changes in sleep pattern and 
convuls ive threshold . 
Electrical stimulation of the cerebel l um has been reported to 
depress convulsive activity (Dow et al., 1962) and it is 
possible that melatonin triggers the same mechanism. In 
addition, increased neuronal activity of the red nucleus is 
followed by depression of the spinal monosynaptic reflex 
through the rubrospinal tract (Fernandez-Guardiola et al., 
1964), a mechan ism that could account for the effects of 
melatonin on the tremor of Parkinson's disease. These 
postulations, however, remain to be verified by other researchers . 
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1.3.10 Melatonin as an Antidepressive?: 
There is a lot of circumstantial evidence suggesting that 
melatonin may be therapeutically effective in depressive 
disorders. 
The hypothalamus is involved in the regulation of a variety 
of functions known to be disturbed in depression, such as 
appetite, sleep, libido and hormone secretion and this brain 
area has been proposed as the site of action of melatonin. 
Labelled melatonin whether injected intravenously or intra-
ventricularly has been shown to concentrate largely in the 
brain limbic structures (involved in mood regulation) and 
the hypothalamus (Wurtman et al., 1964b; Anton-Tay and Wurtman, 
1969; Cardinali et al., 1973). In addition, Kappers et al. 
(1974) have provided evidence suggesting that the anti-
gonadotropic effects of melatonin are mediated by the 
hypothalamus. 
In depression sleep is frequently reduced and melatonin has 
been reported to induce and prolong sleep in animals and man 
(Section 1.3.7.1). 
A deficiency of brain catecholamines and/or serotonin has long 
been implicated in the aetiology of depressive disorders 
(Sections 1.2 . 1, 1.2.2 and 1.2.3) . Melatonin, on the other 
hand, has been shown to increase the content of these mono-
amines, especially serotonin, in the brain (Anton-Tay et al., 
1968; Anton-Tay, 1971; Wendel et al., 1974; Cardinali, 1975; 
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Cardinali et al., 1975). In addition, 5-HIAA levels in the 
urine (Anton-Tay, 1 974) and CSF (Carman et a l. , 1976) 
are increased in depressives and Parkinsonian patients 
following melatonin administration. 
Rei t er and his co-workers (Reiter and Morgan, 1972; Reiter 
et al., 1972) found that when the pineal was removed from 
immature rats which had previously been either thyropara-
thyroidectomized or parathyroidectomized , most of the animals 
experienced severe convulsive seizures. Miline (1 971) 
showed that pineal ectomized rats were more sensitive to lowered 
environmental temperatures than control animal s. On the basis 
of these results and simi l ar experimen t s, Sampson (1975) 
proposed that "pin eal functioning protects the organism 
against stress" . However, the exact role of melaton i n in 
these experimental situations is unclear. 
MSH, an antagonist of melatonin (Cotzias et a1., 197Jb) causes 
an exaggerated response to noxious stimuli in animals and 
feelings of nervousness and anxiety i n humans (Section 1.3.5.6. 1). 
Conversely, MIF has been shown to be more effecti ve than 
placebo in depressed patients (Ehrensing and Kastin, 1974) . 
The above findings suggest that melatonin could be an anti-
depressive. Currently, only 1 study has tested this 
hypothesis. Carman et a1. (1976) adm i nistered melatonin to 
6 depressed patients and reported an "exacerbation of the 
symptoms of dysphoria" in all the depressives (Section 1.3.8.3. 2) . 
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In the light of the findings of Anton- Tay (1971) and Cardinali 
(1975), these results seem paradoxical . As a possible 
explanation, Watson and Madden (1977) proposed that melatonin's 
effect on the GABA neurons may outweigh the monoamine increases. 
In addition, 4 of the 6 patients used in Carman's study had been 
diagnosed as suffering from "retarded" depressions and in view 
of melatonin's known depressant and sedative effect on the 
CNS (Sections 1.3.7.1 and 1.3.7.2), the results are not 
surprising. Moreover, since this was a small study, this 
author suggests that melatonin should be evaluated in a 
larger group of depressives, preferably using patients suffering 
from "agitated" depressions, before a definite conclusion 
regarding melatonin's antidep r ess ive effect i s drawn. 
The above findings and discrepancies have prompted the 
investigation of the effects of melatonin in current animal 
models of depression. This study was undertaken not only 
to evaluate melatonin as a possible antidepressive but also 
to determine whether the newer pharmacological models of 
depression are, in fact, viable models for the screening of 
"antidepressives" of unknown merit and mechanism of action . 
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1.4 ANIMAL MODELS OF DEPRESSION: 
1 . 4.1 Need for an Animal Model of Depression: 
No satisfactory experimental animal model of depression 
exists at present. Depression in man is a poorly defined 
entity and an animal model would help in clarifying the 
clinical phenomenon. Moreover, the theories relating the 
monoamines and other biological variables to depression are 
based on limited and indirect evidence and a model would 
allow this relationship to be studied directly. In an 
animal model, the social and environmental variables thought 
to be important in depression could be systematically 
manipulated and their relationship to depression clarified, 
since there is only a limited opportunity to control these 
variables in humans. An experimental model could also 
provide a system in which potential antidepressive treatments 
could be evaluated. 
Any animal model of a human affective disorder , however, is 
limited by the relative inability of animals to communicate 
with us as well as by our tendency to anthropomorphise. 
MCKinney and Bunney (1969) proposed that a model meet th e 
following minimum requirements: the symptoms of the induced 
animal depression shoul d be reasonably similar to those seen 
in human depression ; these should be observable behavioural 
changes; the treatment techniques effective in human 
depression should reverse the "depressive state" seen in 
the animals; and the model should be reproducible by other 
investigators. 
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1.4.2 Separation-Loss Model: 
This model is a concrete version of the psychoanalytic 
object-loss concept. The separation of an infant from 
either its mother or peers has been shown to be a powerful 
inducer of depression in humans and non-human primates. 
In 1945, Spitz reported a deprivational reaction in human 
infants separated from their mothers in the second half of 
the first year. The syndrome, termed "anaclitic depression~ 
was characterized by: (i) apprehension and crying; (ii) 
wi thdrawal; (i ii) psychomotor retardation and rej ection; 
and (iv) insomnia, mass loss and anorexia (Spitz, 1945; 1946) . 
A similar reaction was demonstrated in older children 
(Robertson andBowlby, 1952; Bowlby, 1960). The syndrome 
had 3 phases; a "protest" stage in which the behaviour 
of the child was characterized by restlessness and tearful-
ness; a "despair" phase with apathetic withdrawal; and a 
"detachment" phase seen only in some children and character ized 
by rejection of the mother on reunion. 
The nature and variety of reactions to separation have also 
been studied in non-human primates by numerous investigators 
and are summarized in Table 17. In general, the monkey 
infants' reaction to separation whether from mother or 
peers, was similar to that described by Spitz (1945) and 
Robertson and Bowlby (1952). Initially they went through 
a "protest" phase with loud screaming, crying and random 
locomotion, followed by a "depressive" phase characterized 
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TABLE 11 : 
Investi.g o!l tor 
Marlo.< (1961) 
Jensen and 
To.l.man (1962) 
Uinde et 3l. 
(1966)- -
!<aufrr.an and 
Rcsetlblum (1967) 
Sucrni ~~. 
(1970) 
Bowden and 
McKinney (1972) 
McKinney et a1. 
(1972) - -
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SEPARATION EXPERIMENTS IN NON- BUMAN PRIMATES 
(Modified from McR lnney and Bunney. 1969) 
Animals Beh'lviou ral P recipitating Changes Incident 
Rhesus J!D1kej's (1) tcrying Exper imental 
(Macaca lll.Ilattal (2) ... play rrother- infant 
(3) .j.sccial int e raction sepa.rlltion 
(') +appetite 
(5) sleep disturbance 
Pigtail m:mkeys Infants const.ant ~imental 
(Macaca neoestrina ) 5Cre<ming nether-infant 
separation 
Rhesus monkeys (1) +activity EKper itnental 
(') Sitting huddled Il'Other-infant 
in corner separation 
Pigtail lrOliteys (1) Agitation RelrDVal of 
(2) Sitting hunched lTOther f rem 
over with head group living 
down between legs situation 
(3) iActivity 
(') .j.Scx:ial interactio 
(5) .Play behaviour 
Rhesus monkeys (1) tVccali zation Experimental 
(2) t5elf-clasping and peer-peer 
huddling separatia"l 
(3) i Activity 
Rhesus monkeys (1 ) tiLx:xnDtion EXper imental 
(2) tSeli- dl [ected peer-peer 
behaviour separat ion 
Mesus rronkeys (1) tI..or::aootion Elcper imental 
(2) tEnvirOl'1llental peer- peer 
exploration separation 
(3 ) fPassivity 
Course Duration 
of Change 
IlmIedlate (~ until 
attact'ment i n reunion 
:rost inst ances 
following 
reunion 
Increased Less than 
i ntensity of I ,,"" 
oother-infant 
relationship 
following 
reunion 
Presepar .tion separation 
activit
4 
l evel period af 
regained within 6 days 
1 wee'~ a f ter 
reunion 
(1) Reintroduo- 6-8 &:·s 
tion of mother 
led to greatly 
increased close-
ness of i nfants 
and rrol:hers 
(2) sane sp::.n-
taneous recovery 
in staqes 
I ncr eased vent ral I'lUltiple 
Clinging and separation~ 
social contact of I da~'s 
followi ng each 
reunion 
Ole day of I Unt il 
intense social r eunion 
activit. followed 2 W! ~ks 
by a retUrn to later 
preseparation 
activity l£"Jels 
Return to base- until 
line level s reunion 
upon reunion 2 weeks 
later 
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by withdrawal behaviour, an increase in huddling and self-
clasping and a marked decrease in locomotor activity. 
In addition, the age at which separation takes place 
(McKinney et al., 1972), prior experience with separation 
(Young et al., 1973) and the preseparation mother-infant 
relationship (Hinde and Spencer-Booth, 1970) have been shown 
to influence the nature of the separation response. 
the monkey model of object loss may provide important 
information with regards to the aetiology and treatment 
of depression. 
Thus 
The attachment of one human being to another, be that infant-
mother or peer-peer, is a powerful reinforcer. These 
experiments have demonstrated that a disruption of the 
attachment bond by separation represents a loss in 
reinforcement which, in turn, leads to a breakdown of 
motivated behaviour and depression. 
1.4.3 Learned Helplessness: 
Seligman and his associates have proposed the phenomenon 
of "learned helplessness" in animals as a model of depression 
in man (Overmier and Seligman , 1967; Seligman and Maier, 1967; 
Seligman et al., 1968; Seligman and Groves, 1970). 
Dogs while strapped in a Pavlovian harness were subjected 
to repeated, inescapable electric shock. When these dogs 
subsequently received electric shock in a shuttle-box they 
failed to cross the barrier and instead seemed to "give up" 
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and passively accept the shock. This behavioural state was termed 
"learned helplessness". In contrast, experimentally naive 
dogs who had not been previously exposed to inescapable 
shock, during escape avoidance training soon learnt that 
they could terminate the shock by jumping over the barrier . 
Learned helplessness is not restricted to dogs. Deficits 
in escaping and avoiding shock after experience with 
uncontrollable shock, have been seen in rats (Dinsmoor, 1958; 
Mullin and ~logenson, 1963; Weiss et al., 1968), cats (Seward 
and Humphrey, 1967), fish (Behrend and Bitterman, 1963; 
Padilla et al., 1970) and humans (Thornton and Jacobs, 1971; 
Hiroto , 1974). 
According to Seligman (1974; 1975) this behavioural condition 
has many similarities with human depressive symptomatology. 
It may also offer important clues to the unresolved questions 
of aetiology, treatme nt and prevention of depression. 
Seligman (1974; 1975) reported 6 characteristics 
associated with learned helplessness which are relevant to 
human depressions: (i) animals become passive in the face 
of trauma; (ii) animals are retarded at learning that their 
responses produce relief; (iii) learned helplessness 
dissipates with time; (iv) lowered aggression with a 
possible loss of dominant status; (v) anorexi a and mass 
loss; (vi) phys iologica l changes - helpless rats show 
noradrenaline depletio n (Weiss et al., 1970) and helpless 
cats may be cholinergically over-a.ctive 
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(Thomas and Balter, .1974). This similarity of 
symptoms indicates that learned helplessness may serve as 
a useful animal model of depression. According to 
Seligman, the cause of learned helplessness is not the 
trauma as such, but rather not having control over the 
trauma. He proposes that the depression-prone individual 
has had a life-long history characterized by failure in 
exercising control over his reinforcers in his environment. 
When the person perceives himself losing all control over 
such reinforcers, he is paralyzed by helplessness and 
passivity and depression results. 
Learned helplessness was reversed by forcibly dragging the 
animal to the non-electrified section of the shuttle-box i.e . 
teaching the dog that its own responses could bring relief 
and reinforcement. Hence therapy, according to this model, 
involves having the patient find out and come to believe that 
his responses can produce the gratifications he desires. 
Beck's cognitive therapy of depression (1970) as well as 
the "Tuscaloosa Plan" (Taulbee and Wright, 1971), assertive 
training (Wolpe and Lazarus, 1969) and Morita therapy (Kora, 
1965; Burgess, 1968) have similar goals, namely, to show 
the patient that he can control important reinforcers by 
his own actions (Section 1.1.6.1). 
In addition, it was demonstrated that animals that had 
previously experienced controllable trauma, were immunized 
against the helplessness caused by inescapable trauma 
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(Richter, 1957; Seligman and Maier, 1967). The extra-
polation of this information to human depression suggests 
that people who have had extensive experience in controlling 
and manipulating the sources of reinforcement in their lives, 
might be more resistant to depression, whereas those who have 
had little control over their reinforcements, may be 
particularly susceptible to depressive disorders. Seligman 
(1974) speculates that "a childhood of experiences in which 
ones own actions are instrumental in bringing about gratification 
and removing annoyances" may prevent depression in later life. 
1.4.4 Porsolt Model: 
This is described in detail in Chapter 5. 
1.4.5 Pharmacological "Depression": 
Biochemical abnormalities which have been reported in human 
depressive patients, have been simulated in animals to serve 
as models of depression. High doses of reserpine have been 
observed to induce depression in approximately 15 % 
of hypertensive patients (Bunney and Davis, 1965). Similar 
depressive states have been reported following a-
methyldopa (Fullerton and Morton-Jenkins, 1963; McKinney 
and Kane, 1967) and tetrabenazine administration 
(Lingjaerde, 1963). Research has shown that reserpine 
depletes the intraneuronal vesicles of noradrenaline 
(Holzbauer and Vogt, 1956) and serotonin (Pletscher et al., 
1955) by disrupting the capacity of the intracellular 
storage vesicles to accumulate and thereby protect the 
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biogenic amines from oxidative deamination by mitochondrial 
MAO (Kopin and Gordon, 1962; 1963; Stjarne, 1964). 
Tetrabenazine is thought to reduce brain noradrenaline and 
serotonin in a similar manner. Alpha-methyldopa depletes 
central catecholamines and serotonin by synthesis inhibition 
(Henning, 1969) and/in addition, the metabolites of a-
methyldopa, a -methyldopamine and a-methylnoradrenaline, 
act as false transmitters and displace the catecholamines 
from nerve endings (Henning, 1969; Cooper et al, 1974). 
Drug-induced depressions have been considered possible 
pharmacological models of the naturally occuring depressive 
disorders. Rhesus monkeys have been reported to exhibit 
depressive-like symptoms (decr ease in locomotion and visual 
exploration, increase in huddling behaviour) after ch ronic 
reserpine administration (McKinney et al. , 1971). Redmond 
et al. (1971) found that adult stump tail monkeys showed 
decreased social interaction , withdrawal behaviour and 
retarded motor activity following prolonged treatment with 
a-me thyl-p-tyrosine, a specific blocker o f the synthesis 
of dopamine and noradrenQline (Spector et al . , 1965). 
However, no appreciable behavioural effects were seen in 
monkeys treated with PCPA, the selective depletor of 
serotonin (Redmond et al., 1971) . 
Reserpine produces sedation in experimental animals and 
this has been proposed as a possible animal analogue of 
depression in man (Sulser et al., 1964; 1966; 1967; 
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Brodie, 1965). Other reserpine effects include ptosis, 
miosis, hypothermia, gastric ulcers, diarrhoea, salivation 
and bradycardia. At present, the reserpine model is the 
most prevalent experimental model of depression in use. 
studies by numerous investigators have suggested that 
reserpine-induced sedation is related to the depletion of 
central monoamines (Brodie and Shore, 1957; Carlsson, 1961; 
Haggendal and Lindqvist, 1964), but it is not known which 
monoamine plays the major role in its action. 
of the catecholamine precursor, L-DOPA, 
Administration 
to animals reverses the sedation induced by reserpine, 
whereas the serotonin precursor, 5-HTP, does 
not (Carlsson et al., 1957; McGeer et al., 1963; Wada et 
al., 1963). Degkwitz et al. (1960) demonstrated that L-DOPA 
administration counteracted the psychological effects of 
reserpine in human subjects. These findings suggest that 
the catecholamines are important in the reserpine syndrome. 
However, it has been proposed that dopamine rather than 
noradrenaline may produce the behav ioural effects of 
reserpine (Everett and Wiegand , 1962; Creveling _et al., 
1968) . Other workers have implicated serotonin in 
reserpine-induced sedation. Some have suggested that 
serotonin produces central excitation and the depletion of 
serotonin results in sedation (Woolley, 1962), while others 
have proposed that serotonin and noradrenaline antagonize 
each other in the brain and the free serotonin causes 
sedation (Brodie et al., 1966). Miller and Maickel (1969) 
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suggest that it is the relative ratios of free noradrenaline 
and serotonin that are important in producing the behavioural 
depression. 
Pretreatment with tricyclic drugs prevents or reverses 
reserpine-induced sedation in animals (Carlsson, 1961; 
Scheckel and Boff, 1964; Sulser et al., 1964). Sulser 
et al. (1964) have proposed that this phenomenon depends 
on the availability and release rate of the catecholamines. 
It has been suggested that the imipramine-like drugs may 
act either by limiting the access of noradrenaline to the 
mitochondrial MAO, thereby allowing free active nor-
adrenaline to leave the cell (Schildkraut et al., 1964), or 
by inhibiting the inactivation of noradrenaline by blocking 
the cellular reuptake (Glowinsk i and Axelrod, 1964). 
Another possible explanation, however, has been put forward. 
The neuronal uptake and subsequent action of guanethidine 
has been reported to be inhibited by the TADs, thus it has 
been proposed that the tricyclics may act similarly in blocking 
reserpine uptake which would, in turn, abolish reserpine's 
effect (Goodman and Gilman, 1975). 
The reserpine syndrome is also antagonized by prior 
treatment with MAO inhibitor·s (Chessin et al., 1957; 
Carlsson, 1961; Spector ~ al. , 1963). These drugs are 
believed to inhibit the intracellular degradation of the 
reserpine-re l eased noradrenaline which may then leak out 
of the cell onto the postsynaptic receptor sites (Kopin, 
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1964) . Thus, a l though differing in their mechanism of 
action, bo th the MAO inhibitors and the TADs may reverse 
the effects of reserpine by increasing noradrenaline at 
central adrenergic receptor sites (Scheckel and Boff, 1964; 
Schildkraut et al., 1964; Sulser et al., 1964). 
It has been suggested that this reversal of reserpine-
induced depression may be a useful test for evaluating new 
antidepressive drugs for use in man (Brodie et al., 1961; 
Garattini et al., 1962; Sulser et al., 1962). 
The reserpine model, however, has some limitations as a 
model of depression. Rese r pine releas es both catecholamines 
and serotonin and thus the phenomenon of reserpine-induced 
sedation cannot be related to an effect of one or anothe r 
specific amine. Hence the model does not provide evidence 
which could relate the aetiology of depression to a deficit 
of any single amine. The effecttiveness of this model in 
screening potential antidepressives has also been questioned. 
Zbinden (1962) has shown that the effects of reserpine can 
be antagonized by drugs which do not have any antidepressive 
effects. Conversely, some clinically effec ti ve anti-
depressives, such as iprindole (Gluckman and Baum, 1969) 
and mianserin (Van Riezen, 1972; Gouret et al., 1977), 
have only showed slight, transient anti reserpine activity. 
Neither of these 2 drugs is a po tent blocker of uptake 
and thus one is led further to believe t hat TADs reverse 
reserpine sedation by preventing its entry into nerves . 
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In addition, it seems unlikely that this empirical model 
will lead to the discovery of antidepressives with mechanisms 
of action different from those already in use. 
In conclusion, any model of depression should be based on 
behavioural as well as biochemical concepts. The reserpine 
model may be merely drug-induced sedation rather than anything 
resembling human depression . 
1.4.6 Other Behavioural Models Used in Drug Evaluation: 
1 .4.6 .1 ~£9£~£!£E_~9!~~~!Y: 
1.4.6.1.1 Serotonin and Locomotor Activity: 
Brodie and Reid (1968) postulated that serotonin mediates 
the effects of a trophotrophic system, a system which when 
activated causes drowsiness, sleep, increased central 
parasympathetic output and decreased motor activity. 
Noradrenaline, on the other hand, is postulated to mediate 
the activity of neuronal pathways underlying an ergotrophic 
system producing arousal, excitation, increased central 
sympathetic output and hyperactivity. The work of several 
investigators, however, strongly suggests that in some 
circumstances serotonin produces excitation (Dewhurst, 1968a; 
Grahame-Smith, 1971a; Modigh, 1972). 
1.4.6.1.1.1 5-Hydroxytryptophan Administration: 
When given alone, 5-HTP has been shown to induce sedation 
in mice and rats, whereas after inhibition of MAO it produces 
excitation with increased motor activity (Garattini and 
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Valzelli, 1965, re v iew). 
In studies quantitatively evaluat ing the effects of 5-HTP 
on motor activity in mice, Brown (1960) reported reduced 
spontaneous activity following the administration of 5-HTP 
(0,1 to 100 mg/kg), whilst Smith and Dews (1962) found no 
changes in activity following 5-HTP administration (10 to 
1000 mg/kg) . The findings of Modigh (1972), however , 
indicated tha t the decreased motor activity following the 
administration of large doses of 5-HTP is a peripheral 
effect since this decrease could be abolished after the 
inhibition of per ipheral decarboxylase. Moreover, he 
showed that the central effects of 5-HTP are excitatory 
producing increased motor activity in mice. The central 
stimulatory effects resulting from 5-HTP administration could 
be a result of both stimulation of the serotonin receptors 
and displacement of catecholamines from the catecholaminergic 
neurons. However, since the depletion of brain catechol-
amine stores did not counter this incr eased motor activity, 
it was concluded that excessive stimulation of the serotonin 
receptors is of major importance for the observed central 
excitation. Horita and Hamilton (1970) found corroborative 
evidence in a similar experiment using rabbits. 
1.4.6.1.1.2 L-Tryptophan Administration Following the 
Inhibition of MAO: 
Hyperactivity has been reported following the administration 
of I-tryptophan to rats pretreated with a MAO inhibitor 
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(Hess and Doepfner, 1961; Grahame-Smith, 1971a). In a 
series of experiments, Grahame-Smith and Green (Grahame-Smith 
1971a; 1971b; Grahame-Smith and Green, 1974a; 1974b; 
Green and Grahame-Smith, 1974; 1976) have tried to 
evaluate the rol e of brain neurotransmitters, particularly 
serotonin, in the production of this hyperactivity syndrome. 
Although no hyperactivity was observed following l-tryptophan 
administration (in doses up to 19/kg) to rats, after pre-
treatment with a MAO inhibitor (tranylcypromine 20 mg/kg) 
marked hyperactivity and hyperpyrexia were observed 
(Grahame-Smith, 1971a). This hyperactivity syndrome was 
shown to be dependent not only on inhibition of MAO but also 
on intact tryptophan hydroxylase and intact aromatic l-amino 
acid decarboxylase activity. Tranylcypromine (TCP) either 
alone or in combination with l-tryptophan however, was found 
to have no effect on the brain concentrations of DA 
and noradrenaline. Although these results sugges ted that 
serotonin is the monoamine responsible for the observed 
hyperactivity, the development and severity of the syndrome 
was found to be related not to the absolute concentration of 
brain serotonin but to the rate of accumulation of serotonin 
in the brain. In addition, both tetrabenazi ne and reserpine 
pretreatment increased the speed of onset and development of 
hyperactivity. 
As a result of these findings, Grahame-Smith (1971a) proposed 
the following hypothesis. Under normal conditions the 
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amount of serotonin synthesized is in excess of that required 
to fulfil the functional needs of the brain and this excess 
is metabolized by intraneuronal MAO to become functionally 
inactive. Following MAO inhibition, the increased rate of 
brain serotonin synthesis produced by tryptophan loading 
exceeds the capacity of intraneuronal serotonin stores to 
cope with and inactivate serotonin so that serotonin "spills 
over" into functional activity resulting in hyperactivity. 
On the other hand, when MAO activity is intact, tryptophan 
administration still increases the rate of serotonin synthesis 
but no hyperactivity results because the increased serotonin 
is metabolized by intraneuronal MAO and thereby prevented 
from becoming functionally active. The demonstrated 
excitatory effect of serotonin is inconsistent with the 
findings of Brodie and Reid (1968) who reported a correlation 
between the lowering of brain serotonin and the development 
of reserpine sedation. Although these authors deduced that 
the observed sedation was caused by the release of serotonin 
onto its receptor sites, another interpretation based on 
Grahame-Smith's model is possible. If reserpine releases 
serotonin from its intraneuronal granular binding sites not 
onto its receptor sites but onto MAO by which it is metabolized 
without becoming functionally active, then the amount of 
serotonin available within the neurons for functional 
"excitatory" activity would be lowered and sedation would 
ensue. 
This same syndrome of hyperactivity is also produced in rats 
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by 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) (Ahlborg et al., 
1968) and pretreatment with TCP (20 mg/kg) potentiated the 
hyperacti ve response (Grahame-Smith, 1971b). Pretreatment 
with PCPA, however, did not diminish this hyperactivity, 
thereby indirect ly suggesting that this action of 5-MeODMT 
is not mediated by the release of endogenous brain serotonin. 
Chlorpromazine pretreatment, on the other hand, inhi b ited the 
hyperactivity caused by either tryptophan or 5-MeODMT after 
MAO i nhibition (Grahame-Smith, 197Ib) . On the basis of 
these results, Grahame-Smith postulated that chlorpromazine 
acts either by competition with serotonin or 5-MeODMT at the 
receptor sites or by physiological antagonism. 
In a subsequent paper, Grahame-Smith and Green (1974a) 
reported that administration of a tyrosine hydroxylase 
inhibitor (AMPT) abolished th e hy peractivity syndrome while 
L-DOPA administration restored the response . These findings 
suggested a role for brain DA in the hyperactiv i ty s yndrome 
produced in rats after the administration of TCP and 
I-tryptophan . These authors therefore proposed that there 
may be a group of dopaminergic neurons situated between the 
serotoninergic neurons initiating the response and those 
mechanisms responsible for th e expression of the syndrome. 
A more recent report by Foldes and Costa (1975) supported 
this proposal that a catecholamine, perhaps DA, could be 
involved in the hyperactivity response since these authors 
found that destruction of the central sympathetic nerves 
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with 6-hydroxydopamine prior to the administration of TCP 
and I-tryptophan abolished th e hyperactivity due to J.-
tryptophan. The doses of 6-hydroxydopamine used in this 
study had been shown previously to result in a 70 to 80% 
decrease in brain catecholamine levels (Uretsk y and Iversen, 
1970), however, this treatment produced no significant change 
in the rate of accumulation of brain serotonin (Foldes and 
Costa, 1975) . On the basis of this finding and the fact 
that the hyperactivity had been shown not to correlate with 
serotonin synthesis or rate of accumulation; Foldes and 
Costa suggested that serotonin was not involved in the 
hyperactivity response . In addition, they found that 
exogenous tryptamine in doses as low as 0,5 mg/kg 1.P. also 
exhibited hyperactivity and this was antagonized by PCPA, 
reserpine and AMPT pretreatments . In order to explain 
their findings, they suggested that I-tryptophan loading 
of MAO-inhibited rats may result in the accumulation of 
other indole metabolites, perhaps tryptamine, which affects 
some catecholaminergic, probably dopaminergic,pathways 
leading to the observed hyperactivity. 
1.4.6.1.1.3 Melatonin and Locomotor Activity: 
The effect of melatonin on animal locomoto r activity is 
reviewed in Section 1.3.7.4. 
1.4 .6 .2 Avoidance Behaviour: 
-------------------
Spontaneous motor activity and avoidance behaviour are 
commonly used for the routine evaluation of new drugs . 
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The advantage of studying animal behaviour using conditioning 
techniques, however, is that I specific type of behaviour 
can be brought under the experimenter's control, this 
behaviour can be defined with precision and the effects 
which drugs have on it can be measured objectively. 
Locomotor activity determinations do not discriminate 
between the different types of depressant drugs, whereas 
avoidance behaviour responds d i fferentially to depressant 
drugs. 
There are 2 types of shock avoidance schedules in use: 
(1) discrete avoidance where the shock is preceded by a 
warning signal, such as a light or buzzer; and (2) continuous 
avoidance where no warning signal is provided and each 
response (lever pressing) postpones the occurrence of shock 
for a specified period of time. Discrete avoidance 
conditioning is the most useful for studying chlorpromazine-
like drugs but it has the disadvantage of not providing a 
good measure of stimulant drug activity. On the other 
hand, continuous avoidance conditioning is sensitive to 
both stimulant and depressant drug effects. 
Neuroleptics and hypnot.ic drugs exert different effects on 
continuous avoidance behaviour. The phenothiazines (such 
as chlorpromazine) block conditioned avoidance responses 
(CAR) in doses which do not interfere with escape responses 
(ER) (Cook and Weidley, 1957). In other words, the animals 
are sufficiently sedated so as not to avoid the shock, but 
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their ability to respond to and escape the shock is unimpai r ed. 
Hypnotic drugs (such as barbiturates) however, only block 
avoidance behaviour at the same doses that suppress escape 
behaviour and cause ataxia (Cook and Weidley, 1957). Thus 
chlorpromazine has a selective effect in that only 1 type 
of behaviour is blocked, whereas the barbiturates produce 
a non-specific depression of all behaviour. In contrast, 
antianxiety drugs (such as chlordiazepoxide ) have no 
characteristic effect on avoidance behaviour. High doses 
suppress CAR but this is most like l y due to muscle relaxation 
and ataxia and not to a behavioura l effect ~ se . However, 
these drugs attenuate conflict behaviour and increase food 
reinforced behaviour, while antipsychotics have non-specific 
depressant effects on these variables (Scheckel , 1970) . 
If only schedules that involve shock behaviour a r e considered, 
it is seen that antipsychotics and antianxiety drugs affect 
different types of avoidance behaviour ; antipsychotics 
select i vely reduce active avoidance (lever pressing to avoid 
shock is blocked) whereas antianxiety drugs reduce passive 
avoidance (lever withholding to avoid shock is blocked). 
1 . 4.6 . 2.1 Avoidance Conditioning : 
(1) Hi gh intensities of electric shock interfere with the 
acquisition of the avoidance response. Moyer and Korn 
(1964) found that the percentage of avoidance responses of 
a rat in a shuttle-box decreased as shock intensity increased 
and r eported the optimum shock i ntens i ty to be 0 , 5 rnA and 
1 , 0 rnA. Apparent l y high-intensity shock el i cits motor 
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responses (for example freezing) that are incompatible 
with instrumental avoidance conditioning. However, if an 
extremely low shock intensity is used, the mean response 
latency is long (Kimble, 1955) and few animals learn the 
avoidance response (Brush, 1957). 
(2) Pseudoconditioning has been found to occur more readily 
if a buzzer instead of a light is used as the conditioned 
stimulus (CS). Pseudoconditioning is a situation in which 
the CS becomes a noxious stimulus (which elicits a fear 
response) and many examples of this have been reported (for 
example, Smith et al., 1961). 
(3) An animal will learn an avoidance response more rapidly 
if (a) it has had prior conditioning experience (Church and 
Solomon, 1956), (b) the same response is used for avoidance 
as for escape (Mowrer and Lamoreaux, 1946), (c) the noxious 
stimulus terminates at the time of the escape response, and 
(d) the warning signal terminates at the time of the escape 
response (Kamin, 1959; Kamin et al., 1959). 
In the present study, the conditions specified above were 
therefore complied with in order to optimize the avoidance 
conditioning. 
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C RAP T E R 2 
THE EFFECT OF MELATONIN ON CONDITIONED AVOIDANCE BEHAVIOUR 
2.1 INTRODUCTION: 
Melatonin has been shown by many investigators to induce 
sedation in both humans and experimental animals 
(Section 1.3.7.1). Serotonin has been implicated in sleep 
(Jouvet, 1969, review) and since melatonin has been reported 
to increase serotonin levels in selected brain areas (Anton-
Tay et al., 1968), it is suggested that this could explain 
melatonin's sedative effect. In addition both serotonin 
(Cook and Weidley, 1957) and high doses of melatonin (Section 
3.3.2) have been shown to produce a general depression of 
spontaneous motor activity in rats. Consequently it has 
been postulated that melatonin exerts a sedating effect on 
CNS activity and thus may be important in the homeostatic 
system of the organism (Sampson, 1975). 
If this is the case, then perhaps this sedating or calming 
action of melatonin could be demonstrated on behavioural 
measures, particularly those that impose some kind of stress 
upon the animals. This effect has been demonstrated in a 
study by Martini and Fioretti (1971) . Subcutaneous injections 
of 250 ~g of melatonin were administered daily to male rats 
and, although this treatmen t was reported not to influence 
the rate of acquisition of an avoidance r esponse, significant 
differences in the rate of extinction we re demonstrated in 
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the melatonin-treated animals. These rats showed a more 
rapid extinction of the CAR than the control animals. 
Apart from this perhaps being due to a central effect of 
melatonin, another interpretation is possible. Melatonin 
has been shown to suppress the secretion of ACTH (Motta et 
al., 1971) and ACTH has been reported to be able to retard 
the extinction of avoidance responses (De Wied, 1969), 
consequently melatonin's effect may be mediated indirectly 
by the suppression of the secretion of ACTH. This finding 
was confirmed by Kovacs et al. (1974) who demonstrated that 
melatonin in a daily dose of 50 ~g/rat facilitated the 
extinction of an active avoidance response as well as : 
decreasing the intertrial activity during acquisition. 
In addition, melatonin (100 ~g/rat) given on two consecutive 
days facilitated the passive avoidance behaviour in water 
deprived animals in two different experimental situations. 
These results obtained in passive avoidance learning 
indicated that melatonin might affect the memory fixation 
processes under certain circumstances . 
The aim of this study was to investigate qualitatively the 
behavioural suppression induced by melatonin. For this 
purpose conditioned avoidance behaviour, which is affected 
differently by neuroleptic and hypnotic drugs, was used. 
This is discussed in more detail in Section 1.4.6.2 . 
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2.2 MATERIALS AND METHODS: 
2.2.1 Animals: 
Female rats (BD IX Agonti - S.A.B.S.) with a mass between 
190 and 220 g were used. They were housed individually in 
a controlled temperature room with free access to food and 
water. 
2.2.2 Apparatus: 
A shuttle-box (60 x 30 x 35 cm) was divided into two 
compartments by a thin aluminium barrier (7,5 cm high). 
The floor was a grid composed of 32 stainless steel rods, 
5 mm in diameter and placed 15 rnrn apart. Intermittent shock 
(24 V and 1 rnA a.c. current as provided by a Ralph Gerbrande 
shock generator) was delivered to the rats' feet via a shock 
scrambler circuit connected to the grid floor. This shock 
served as the unconditioned stimulus (UCS). The conditioned 
stimulus (CS) was a light (275 V, 15 W) which illuminated the 
entire apparatus. The continual sound of the shock scrambler 
counteracted any disturbing noise which occurred during 
training. 
2.2.3 Training: 
The rats were trained every day between 09hOO and 13hOO for 
6 months (May - October, 1979), each rat being trained at 
the same time every day. The training session for each 
rat lasted 30 minutes and consisted of an acclimatiza tion 
period (5 minutes) followed by 50 30-second trials. In 
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each trial the CS (light) was presented for 10 seconds, 
followed by the CS plus UCS (shock) for another 10 seconds 
and the following variables were recorded. Conditioned 
avoidance response (CAR): the rat jumped the barrier 
within 10 seconds after the CS had been presented. 
Escape response (ER): a jump within 10 seconds after the 
shock had been delivered. No response (NR): the rat 
remained in the same compartment for the entire trial 
(>20 seconds ) . The rats were trained until at least 3 
consecutive sessions with 85% CAR had been achieved. 
2.2 . 4 Drugs and Drug Treatment: 
Melatonin was disso lved in polyethylene glycol 400. 
Chlorpromazine and pentobarbitone sodium were used as the 
prepared injection (Largacti l: May and Baker, Ltd.; Sagatal: 
May and Baker Ltd.). All the rats were dosed at 09hOO, the 
drugs being injected intraperitoneally on a mg/kg basis. 
The test session consisted of a 3- minute acclimatization 
period followed by 20 30-second trials. Each rat was tested 
before drug administration and thereafter at 30 minut e inter-
vals until the drug effect had subsided. A minimum period 
of 2 weeks was allowed between the different drug treatments 
in order to avoid any carry-over drug effects. 
2.3 RESULTS : 
2.3.1 Effect on Untreated Rats: 
On the first tria l the rats exhibited random escape move-
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ments and manifested considerable emotional upset (vocaliza-
tion, urination, defaecation). Eventually, by chance, the 
animal jumped across the barrier to the other compartment, 
a response that resulted in escape from the shock and 
termination of the CS. Within a few trials the rat 
became motionless at the onset of the light signal with 
signs of emotionality and when the shock was delivered, the 
animal moved rapidly into the other compartment (ER). A 
few training sessions later, when the light was switched on, 
the rat moved into the other compartment (CAR), terminating 
the light signal and the shock. During subsequent trials 
the proportion of avoidance responses increased and the 
latency of the avoidance responses decreased. A typical 
example of a rat's progress, as a function of trials, is 
presented in Fig. 11. 
2.3.2 Effect of Pentobarbitone Sodium: 
Rats (n = 3) were treated with various concentrations of 
pentobarbitone sodium (10 mg/kg, 25 mg/kg and 50 mg/kg). 
Pentobarbitone (10 mg/kg) exerted no significant effect 
on avoidance conditioning, apart from a transient block of 
the CAR (maximum 20%) during the first hour after drug 
administration. Initially the rats showed slight signs 
of ataxia (loss of balance and difficulty in climbing over 
the barrier), however, 1,5 hours after the injection their 
appearance had returned to normal. 
Pentobarbitone in doses of 25 mg/kg and 50 mg/kg, however, 
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caused a complete block of the CAR and ER (Fi g. 12). Marked ataxia 
was observed, the rats being unable to move when the shock 
was delivered. The avoidance performanc e of the rats 
treated with pentobarbitone, 25 mg/kg, returned to predrug 
levels 5 hours after drug administration, whereas the 
animals injected with pentobarbitone, 50 mg/kg, recovered 
8 hours after drug treatment (Table 18) . This return to 
normal was characterized by a rapid changeover from high 
NR levels to high CAR levels with a relatively short ER 
phase. 
This non-specific depression of both the CAR and ER is 
characteristic of the barbiturate-like drugs. 
2 . 3.3 Effect of Chlorpromazine: 
Chlorpromazine (10 mg/kg) caused a marked suppression of 
the CAR up to 10 hours after drug administration with a 
corresponding increase in both the ER and NR. This effect 
is illustrated in Figure 13. Some residual effects were 
seen 24 hours after drug treatment, however, all the rats 
were responsive to the CS 2 days later. 
Initially the ER was high (maximum level occurring 30 minutes 
after treatment)but this later decreased with maximal 
suppression occurring 2 to 3 hours after drug administration . 
Suppression of the ER was caused by ataxia, the rat being 
unable to move and cross the barrier, which in turn led to 
an increase in the NR . Approximately 6 to 7 hours after 
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Fig. 12. Block of Cond itioned (CAR) and Escape Responses 
(ER) by Variou s Doses of Pentobarbitone Sodium. 
~ Block of CAR 
~ Block of ER 
Each poin t on the curve represents the maximum effect produced 
by that dose, regardless of the time it occurred . Each drug 
group consisted of 3 rats. 
. .. .. - 2 14 - / 
- 214 -
TABLE 18: 
THE EFFECT OF VARIOUS DOSES OF PENTOBARBITONE SODIUM ON THE 
DURATION OF BEHAVIOURAL SUPPRESSION. 
Pentobarbitone Sodium Hours After CAR ER NR Dose (mg/kg) Drug Administration 
25 3 0 0 20 
4 5 13 2 
5 18 2 0 
50 6 0 2 18 
7 2 8 10 
8 18 2 0 
The values represent the mean responses of 3 rats during 20 
trials. 
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Fig. 13. The Effect of Chlorpromazine (10 mg/kg) on Conditioned Avoidance Responses (CAR), 
Escape Responses (ER) and No Responses (NR). 
The control represents the test session immediately before the administration of 
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treatment, the rats appeared to walk normally and the NR 
levels decreased to zero. However, the CAR remained suppressed 
and high ER levels were observed. This was in contrast to 
the action of phenobarbitone which caused a rapid changeover 
from high NR to high CAR levels (Table 18) . 
These results confirm previous findings that chlorpromazine 
has a speci f ic acti on on the CAR, being able to suppress the 
CAR without effecting the ER at low doses. However, at 
relatively high doses of chlorpromazine (10 mg/kg) moderate 
ataxia was observed which caused suppression of the ER with 
a resultant increase in the NR. 
2.3.4 Effect of Melatonin: 
Melatonin was shown to have a dose-dependent effect on CAR. 
At d os e s of 50 mg / kg and 100 mg / kg, the drug had no 
significant effect on CAR, however, at 200 mg/kg a significant 
reduction of CAR was observed (p < 0,01; Wilcoxon matched-
pairs signed-ranks test). These results are shown in 
Figure 14. The effect on th e CAR was evident 30 minutes 
after melatonin administrat i on and continued for 5 hours. 
At the 6-hour interval the avoidance performance of the rats 
had r e turned to the pre-drug l evels. 
The effect of melatonin (200 mg/ kg) on CAR, ER and NR as 
a function of time is illustrated in Figure 15. Initially 
melatonin caused an increase in ER but 1,5 hours after drug 
administration this was also blocked and NR predominated . 
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Fig. 14 . The Effect of Different Concentrations of Melatonin on Avoidance Conditioning. 
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Fig. 15. The Effect of Melatonin (200 mg/kg) on Conditioned Avoidance Responses (CAR), 
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This effect was short-lived however, since an hour later 
the NR returned to zero and an increase in ER was again 
observed. This ER then gradually decreased in favour of 
CAR. 
As assessed by gross observation the rats were sedated, 
relaxed and exhibited no movement except when shocked. 
During the first hour, some rats, showing slight signs of 
ataxia, appeared uncoordinated and had difficulty in 
balancing. However, after 3 hours, all the rats were able 
to walk properly (no NR was observed) and appeared normal. 
The animals' eyes remained open throughout the test period. 
In order to qualitatively evaluate the effect of melatonin 
on avoidance conditioning, the drug was compared with 
chlorpromazine (10 mg/kg) and pentobarbitone (25 mg/kg). 
The comparison between the effect of these drugs on the 
CAR, ER and NR is illustrated in Figs. 16, 17 and 18 
respectively. The results indicate that high doses of 
melatonin (200 mg/kg) have a similar effect to chlorpromazine 
(10 mg/kg) on conditioned avoidance behaviour. Both drugs 
suppressed the CAR, although chlorpromazine had a longer 
duration of action. Thirty minutes after treatment, both 
drugs caused an increase in the ER but this was later 
decreased in favour of NR. The NR levels eventually 
returned to zero (3 hours after melatonin administration; 
7 hours after chlorpromazine administration) which resulted 
in a corresponding increase in the ER . This high ER 
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Fig. 16. The Effect of Melatonin , Chlorpromazine and Pentobarbitone on the Conditioned Avoidance 
Response of Trained Female Rats. 
~ Melatonin . 200 . mg/kg (8) 
*--~ Chlorpromazine 10 mg/kg (4) 
~ Pentobarbitone 25 mg/kg ( 3 ) 
Percent responses are represented by th e mean v alue obtained during 20 test trials. 
The figures in brackets refer to the number of rats used. 
AP, acclimatization per iod; DA, drug administration. 
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Fig. 17. The Effect of Melatonin , Chlorpromazine and Pentobarbitone on the Escape Response 
of Trained Female Rats. 
~ Melatonin 200 mg/kg (8) 
*---~ Chlorpromazine 10 mg/kg (4) 
i • Pentobarbitone 25 mg/kg (3) 
Pe r cent responses are represented by the mean value obtained during 20 test trials. 
The figures in brack e ts refer to the number of rats used. 
AP, acclimatization period; DA, drug administration. 
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gradually returned to pre-drug levels, the transition being 
complete 48 hours after drug treatment . 
Pentobarbitone differed from melatonin and chlorpromazine 
in that it caused a complete block of the CAR and ER and, 
upon recovery, a rapid transition from high NR to high CAR 
levels was observed. 
2.4 DISCUSSION: 
The above findings suggest that high doses of melatonin may 
have a chlorpromazine-like effect on the CAR in rats. 
A similarity between the effect of chlorpromazine and 
melatonin on avoidance behaviour is not inconsistent with 
previous findings. Chlorpromazine and melatonin have both 
been shown to alter EEG patterns, to interfere with the 
ovulatory or oestrous cycle of rats, to block some of the 
effects of serotonin on smooth muscle and to alter mammalian 
pigmentation (Wurtman and Axelrod, 1966, review). On the 
basis of these findings, the authors suggested that 
chlorpromazine might produce some of its effects by elevating 
the levels of melatonin in the tissues. This hypothesis was 
supported by a subsequent study in which chlorpromazine was 
shown to inhibit the in vivo metabolism of melatonin (Wurtman 
et al., 1968a). In contrast, however, melatonin and 
chlorpromazine have opposing effects on MSR release from the 
pituitary (Domino, 1971). 
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However, melatonin's effect on CAR could be explained by 
another mechanism . Cook and Weidley (1957) have demonstrated 
that serotonin (10 mg/kg, 20 mg/kg and 40 mg/kg) produces a 
specific block of the CAR. 
Serotonin has also been shown to facilitate the inhibitory 
processes invol ved in the habituation of activity and 
spontaneous alternation in a Y-maze (Swonger and Rech , 1972), 
suppress self-stimulation (Wise et al., 1973), strengthen 
behavioura l reactions based on punishment mechanisms (Stein 
et al., 1973; Wise et al., 1973) and inhibit the stress-
induced activation of the hypothalamic-pituitary-adrenal 
system (Vermes and Telegdy, 1972; Telegdy and Vermes, 1973) . 
Therefore it may be possible that melatonin's effect on CAR 
is mediated via serotonin. In addition , high doses of the 
precursor, tryptophan (600 mg/kg and 800 mg/kg), have been 
shown to produce a specific block of the CAR, although this 
effect was said to be unrelated to its effect on serotonin 
brain levels (Engel and Modigh, 1974). The maximum effect 
produced by serotonin (40 mg/kg) was a 50% block of the CAR 
(Cook and Weidley, 1957) and tryptophan (800 mg/kg) produced 
a maximum block of 60% (Engel and Modigh ) . In the present 
study, however, melatonin (200 mg/kg) caused a 100% block 
of the CAR. Anton-Tay et al. (1968) showed that low doses 
of melatoni n (1 mg/kg) increase brain serotonin levels, 
whereas in this study, only high doses of melatonin blocked 
the CAR. These findings suggest that mechanisms other than 
the increased concentration of brain serotonin are involved 
in the behavioural effect of melatonin . 
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C HAP T E R 3 
LOCOMOTOR ACTIVITY STUDIES 
3.1 INTRODUCTION: 
Grahame-Smith (1971a) postulated that the hyperactivity 
observed in rats following combined treatment with a MAO 
inhibitor and I -tryptophan is a result of excess serotonin 
which "spills over" into the synaptic cleft producing 
stimulation of the postsynaptic receptors (Section 1.4.6.1.1.2). 
This hyperactivity syndrome produced in rats may be a useful 
model of depression since the combination of I-tryptophan 
plus a MAO inhibitor has antidepressive properties (Section 
1.2.2l In addition, the administration of lithium, which 
has been reported to exert antidepressive effects in some 
depressed patients (Section 1.1.6.4.3), followed by the 
administration of a MAO inhibitor (TCP 20 mg/kg or pargyline 
75 mg/kg) has been shown to produce a hyperactivity response 
identical to that produced by TCP and I-tryptophan (Grahame-
Smith and Green, 1974b). The administration of PCPA 
abolished this hyperactivity suggesting a role for serotonin. 
Moreover,TRH which may have some antidepressive properties 
in man (Prange et al., 1972), potentiated the hyperactivity 
produced by the MAO inhibitor and I-tryptophan combination 
(Green and Grahame-Smith, 1974). On the other hand, the 
administration of chlorpromazine (Grahame-Smith, 1971b) and 
propranolol (Green and Grahame-Smith, 1976), which are both 
effective in the treatment of schizophren ia, inhibited the 
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characteristic syndrome produced by the administration of 
a MAO inhibitor and I-tryptophan . 
Thus, it can be inferred from the studies of Grahame-Smith 
and Green that a drug which produces a hyperactivity syndrome 
in rats following MAO inhibition, is acting in some way to 
increase the stimulation of serotonin receptors in the brain 
although this has been disputed by Foldes and Costa (1975). 
These authors have postulated that the observed hyperactivity 
is catecholamine- and not indoleamine-mediated (Section 
1.4.6.1.1.2) . 
In view of the biogenic amine hypothesis of depression 
(Sections 1.2.1 and 1.2.2),any drug which produces hyper-
activity in MAO-inhibited rats, may have potential anti-
depressive effects. As a preliminary screening test in 
the evaluation of melatonin as a possible antidepressive, 
melatonin was investigated in this behavioural model . 
3.2 MATERIALS AND METHODS: 
3.2.1 Animals: 
Naive male albino Wi star rats with a mass between 120 and 
180 g were used. Female rats were not used because of 
their known tendency for increased activity during oestrous 
and, in addition, the possibility of an interaction between 
hormonal changes and melatonin could be avoided. Between 
weaning and testing the rats were housed 3 to a cage in a 
room with a regular day/night lighting cycle (l2L:12D) with 
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free access to food and water. 
3.2.2 Apparatus: 
Locomotor activity was recorded by an improved version of the 
photocell activity cage (Physics Department, Rhodes University). 
The main part of the system is a black box measuring 50 cm by 
50 cm by 20 cm high which is incorporated onto a base 80 cm 
high. The light source consists of 8 infra-red (i7r) light 
emitting diodes s ituated equidistantly (10 cm apart) in 2 of 
the cage walls, opposite to which are placed 8 corresponding 
phototransis t ors . The i-r source eliminates the use of a bright 
visible light source usually employed in photocell activity cages and 
which is said to provide "a mildly -stressful s ituation (Sampson, 1975). 
When a rat inte rrupts an i-r beam, the circuit is broken 
and a switching pulse is fed into an operational amplifier 
where it is amplified to logic levels and fed into a micro-
processor. The microprocessor scans the circuit every rio 
of a second and any change from the one frame to the next 
is registered as a count. By means of a timer, sum counts 
for either 1,5 or 10 minute intervals can be obtained. 
At the end of the required time interval these counts are 
stored in a memory and the microprocessor is reset . This 
resetting process is in the order of micro-seconds, thu s , 
no noticeable time lag in counting occurs. The data is 
then read out of the memory into a digital printer. 
Another advantage is that the cage is designed to measure 
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not only horizontal locomotor activity but also e xploratory 
behaviour (a component of a rat's overall activity) . This 
is made possible by the existence of 9 holes (6 em diameter ) 
each placed 11 cm apart in the floor of the cage with 6 i-r 
transmitter-receiver pairs placed beneath the floor. A rat 
peering through the hole will, therefore, break the circuit 
and this is counted and p r in t ed out separately as a measure 
of exploratory behaviour. 
In addition, the transmitter- receiver pairs and holes are 
placed in such a way that if a rat blocks a beam, a 
second rat moving past will break another circuit and thus 
be counted. Moreover, since the microprocessor measures 
changes in the circuits, a rat sitting in front of a beam 
will only be counted once when it enters and once when it 
leaves the beam. These modifications , therefore, make the 
registrations very accurate measurements of the rats' 
activity. 
3 .2 .3 Drugs and Drug Treatment: 
Pargyline HCl and TCP were dissolved in saline (0,9% w/v 
NaCl) , while dl-tryptophan was dissolved in a small amount 
of dilute HCl (8 % v/v) before being made up to volume with 
saline. Me l atonin , depending on the amount, was dissolved 
in various concentrations of ethanol. All the drugs were 
administered by intraperitoneal injection o n a mg/kg basis . 
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3.2.4 Procedure: 
Since environmental lighting could affect the phototransistors, 
the cages were fitted with black tops Rnd the experiments were 
carried out in subdued lighting. All the experiments were 
performed at the same time each day starting at 16hOO, each 
animal being allowed a 30-minute period of adaptation before 
drug administration. 
After a preliminary study it was decided to use groups of 
3 rats per cage and combine at least 6 groups i.e. the mean 
activity of 18 rats per drug treatment . 
In order to eliminate the biological variables which may 
affect locomotor activity such as mass, age, reaction to 
drug etc . , each group of rats was us e d as its own control. 
On Day 1 the control drug p lus test drug solvent was 
administered and on Day 2, the control plus test drug and, 
therefore, any reduction or potentiation of motor activity 
could be observed. Furthermore, occasionally the drug 
treatments were reversed in order to check that the observed 
effect on locomotor activity was, in fact, a true drug effect 
and not due to the rats' acclimatizing to the experimental 
situation. Moreover, p reliminary experiments showed that neithe r 
ethanol nor dilute Hel in the concentrations used had any 
effect on rat locomotor activity. 
The rats' activity was recorded every 5 minutes on a digital 
printout. However, for graphic representation and statistical 
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treatment of the results, the average activity over each 
30-minute period was used. Computer programmes were 
written to facilitate these calculations, as well as to 
test for statistical significance (Wilcoxon matched-pairs 
signed-r~nks test; Student's t-test) and to draw graphs. 
3.3 RESULTS : 
3.3 .1 Effect of MAO Inhibition and DL-~ryptophan on Rat 
Locomotor Activity: 
On Day 1 rats were dosed with TCP (20 mg/kg) and 24 hours 
later were pretreated with TCP (20 mg/kg) 30 minutes before 
the administration of various concentrations of dl-tryptophan. 
Following TCP pretreatment, the effect of 1 mg/kg, 10 mg/kg 
and 100 mg/kg dl-tryptophan on rat locomotor activity is 
presen t ed in Figs . 19, 20 and 21 respectively. Although a 
significant increase in activity was recorded in all cases, 
the time and number of deaths was dependent on the amount 
of dl-tryptophan administered (Table 19). An hour after 
dl-tryptophan (100 mg/kg) and TCP (20 mg/kg) administration, 
death of some rats occurred which accounts for the decrease 
in locomotor activity observed in Fig . 21. 
The administration of TCP (20 mg/kg) alone on Day 2 also 
caused a significant increase in activity as compared to 
TCP administration o n Day 1 (Fig.22) , however , no deaths 
were recorded. Furthermore, in all the treatment groups 
the symptoms of drug treatment (defaecation, increased 
squeaking during handling, forepaw padding, piloerection, 
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The Effect of 1 mg /kg DL-Tryptophan on Ra t Locomotor Activity over a Period of 
3 Hours Following Tranylcypromine Administration. 
1---1 Control (TCP, 2D mg/kg) 
~--~ TCP, 2D mg/kg, followed by TRY, 1 mg/kg, 3D minutes later. 
Six groups of rats (3 per group) were used. 
AP, acclimatization period ; TCP, tranylcypromine; TRY, dl-tryptophan . 
P <: 0,05 as compared to control (Wilcoxon matched-pairs signed rank test). 
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Fig. 20 . The Effect of 10 mg/kg DL-Tryptophan on Rat Locomotor Activity over a Period of 
3 Hours Following Tranylcypromine Administration . 
1----1 Control (TCP, 20 mg/kg) 
r--~ TCP, 20 mg/kg,followed by TRY, 10 mg/kg, 30 minutes later. 
Six groups of rats (3 per group) were used. 
AP, acclimatization period; TCP, tranylcypromine; TRY , dl-tryptophan. 
P < 0,05 as compared to control (Wilcoxo n matched-pa i rs signed-rank test) . 
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Fig. 21. The Effect of 100. mg/kg DL- Tryptophan on Rat Locomotor Activity over a Period of 
3 Hours Following Tranylcypromine Administration. 
1---1 Control (TCP, 20 mg/kg) 
~---I TCP, 20 mg / kg l followed by TRY, 100 mg/kg , 30 minutes later. 
Six groups of rats (3 per group) were used. 
AP, acclimatizati on period; TCP, tranylcypromine; TRY, dl-tryptophan. 
P < 0,0 5 as compared t o contro l (Wilcoxon matched-pairs signed-rank te st) . 
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TABLE 19: 
EFFECT OF VARIOUS DOSES OF DL-TRYPTOPHAN 
AND MELATONIN ON THE RAT DEATH RATE FOLLOWING 
THE ADMINIS~RATION OF TRANYLCYPROMINE 
Concentration Number Death Ra te 
of drug (mg/kg I. P. ) of rats % 
used 
dl-tryptophan 1 18 0 
10 18 44 
100 9 100 
melatonin 1 18 0 
10 2 4 17 
100 18 67 
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Fig. 22 . The Effect of Tranylcypromine Administration on Rat Locomotor Activity over a Per iod 
of 6 Hours. 
t----j Control (TCP, 20 mg/kg, on Day 1) 
r--~ TCP, 20 mg/kg, on Day 2 
Six groups of rats (3 per group) were used. 
AP, acclimatization period; TCP, tranylcypromine. 
P < 0,05 as compared to control (Wilcoxon matched-pairs signed-rank test). 
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penile erections, salivation) were more marked on Day 2. 
The results show that TCP alone or in combination with dl-
tryptophan increased tat locomotor activity. However, 
following TCP pretreatment, dl-tryptophan administration was 
found to further increase the absolute counts (Fig.23), this 
potentiation be ing statistically significant. 
In order to confirm that it was d l-tr yptophan that was 
potentiating the locomotor activity and not just the effect 
of TCP administration , another MAO inhibitor, pargyline, was 
used. Pargyline (75 mg/kg) alone does not cause any 
significant increase in locomotor activity when administered 
alone either on Day 1 or on Day 2 (Fig.24). The administration 
of dl-tryptophan (100 mg/kg) 30 minu t es after pargyline pre-
treatment, however, resulted in a significant increase in 
motor activity (Fig.25). Thus the observed hyperact i vity 
is a result of dl-tryptophan following MAO inhibition. 
3.3.2 Effect of MAO Inhibition and Melatonin on Rat 
Locomotor Activity: 
Thirty minutes after TCP (20 mg/kg) pretreatment , rats were 
dosed with various concentrations of melatonin and the 
locomotor activity was recorded . They had been injected 
on the previous day with TCP, 20 mg/kg. The effect of 
1 mg / kg, 10 mg/kg and 100 mg/kg melatonin in this 
experimental situation is illustrated in Figs. 26, 27 
and 28 respectively. Hyperactivity was observed following 
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The Effect of Pargyline Administration on Rat. Locomotor Activity over a Period of 
6 Hours. 
~ Control (Pargyline, 75 mg/kg, on Day 1) 
~--, Pargyline, 75 mg/kg, on Day 2 
Six groups of rats (3 per group) were used. 
AP, acclimatization period; PAR, pargyline. 
P < 0,05 as compared to control (Wilcoxon matched-pairs signed-rank test). 
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Fig. 25. The Effect of 100 mg/kg DL-Tryptophan on Rat Locomotor Activity over a Period of 
5 Hours Following Pargyline Administration. 
I----l Control (pargyline, 75 mg/kg) 
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The Effect of 1 mg/kg Melatonin on Rat Locomotor Activity over a Period of 
6 Hours Following Tranylcypromine Administration 
~ Control (TCP, 20 mg/kg) 
~- -~ TCP, 20 mg/kg, followed by melatonin, 1 mg/kg, 30 minutes later. 
Six groups of rats (3 per group) were used. 
AP, acclimatization period; MEL, melatonin; TCP, tranylcypromine. 
P < 0,05 as compared to control (Wilcoxon matched-pairs signed-rank test). 
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Fig. 27. The Effect of 10 mg/kg Melatonin on Rat Locomotor Activity over a Period of 
3 Hours Following Tranylcypromine Administration. 
~ Control (TCP, 20 mg/kg) 
~--~ TCP, 20 mg/kg, followed by melatonin, 10 mg/kg, 30 minutes later . 
Eight groups of rats (3 per g roup) were used. 
AP, acclimatization per iod; MEL, melatonin; TCP, trany lcypromi ne. 
P < 0,01 as compared to control (Wilcoxon matched-pairs s i gned- rank test). 
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Fig. 28. The Effect of 100 mg/kg Melatonin on Rat Locomotor Activity over a Period of 
3 Hours Following Tranylcypromine Administration. 
~ Control (TCP, 20 mg/kg ) 
~- - ~ TCP, 20 mg/kg, followed by melatonin, 100 mg/kg, 30 minutes later. 
Six groups of rats (3 per group) were used. 
AP, acclimatization period; MEL, melatonin; TCP, tranylcyp romine. 
P < 0,05 as compared to control (Wilcoxon matched-pairs signed-rank test) . 
- 243 -
the administration of melatonin and TCP, while melatonin, 
30 mg/kg and 100 mg/kg, administered alone on Day 1 and Day 
2 showed no potentiation of rat locomotor activity (Figs. 29 
and 30, respectively) . Furthermore the absolute activity 
values observed show that the administration of melatonin 
alone decreases locomotor activity just as serotonin (Brodie 
and Reid, 196B; Goodman and Gilman, 1975) and tryptophan 
does (Modigh, 1973). 
Following TCP administration, melatonin in the concentrations 
used behaved in a manner similar to dl-tryptophan (Section 
3.3.1). At a dose of 1 mg/kg both melatonin and dl-
tryptophan had no significant effect on rat locomotor 
activity as compared to those rats which received TCP 
alone. However, at 10 mg/kg both drugs produced a 
significant increase in motor activity. Melatonin and dl-
tryptophan at a dose of 100 mg/kg also resulted in elevated 
motor activity but this effect was lost due to the death of 
some of the rats. A comparison between the various doses 
of dl-tryptophan or melatonin and TCP alone is presented 
in Figs. 23 and 31 respectively. 
Melatonin administration (100 mg/kg) following pargyline 
(75 mg/kg) pretreatment also resulted in a significant 
increase in locomotor activity (Fig.32). 
3.4 DISCUSSION: 
Melatonin and tryptophan appear to affect the locomotor 
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Fig. 29. The Effect of 30 mg/kg Melatonin on Rat Locomotor Activity over a Period of 
6 Hours. 
~ Control (melatonin, 30 mg/kg, on Day 1) 
I- --~ Melatonin, 30 mg/kg, on Day 2 
Ten groups of rats (3 per group) were used. 
AP, acclimatization period; MEL, melatonin . 
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The Effect of 100 mg/kg Melatonin on Rat Locomotor Activity over a Period of 
6 Hours. 
f-1 Control (melatonin, 100 mg/kg, on Day 1) 
b--~ Melatonin, 100 mg/kg, on Day 2 
Thirteen groups of rats (3 per group) were used. 
AP, acclimatization period; MEL, melatonin. 
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Fig. 31. Comparison Between the Effects of Various Doses of Melatonin and Tranylcypromine 
on Rat Locomotor Activity over a Period of 3 hours. 
~ Melatonin 1 mg/kg (18) 
~ Melatonin 10 mg/kg (24)* 
)f---'i( Melatonin 100 mg/kg (18) 
f----I TCP 20 mg/kg (18) 
All the rats were pretreated 24 hours previously with TCP (20 mg/kg ). 
Th e numbers in b rackets refe r to the number of rats u sed . 
AP, acclimatization period ; MEL, melatonin; TCP, tranylcypromine. 
*P < 0,05 as compared t o the TCP-tr eated rat s (Student's t -test ). 
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Fig. 32. The Effect of 100 mg/kg Melatonin on Rat Locomotor Activity over a Period of 
6 Hours Following Pargyline Administration. 
f---i Control (Pargyline, 75 mg/kg) 
~--~ Pargyline, 75 mg/kg, followed by melatonin, 100 mg/kg, 30 minutes late r, 
Six groups of rats (3 per group) were used. 
AP, acclimatization; MEL, melatonin; PAR, pargyline 
P < 0 , 05 as compared to control (Wilcoxon matched-pairs signed-rank test). 
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activity of rats pretreated with a MAO inhibitor in a 
similar dose-dependent manner . 
Brain serotonin is presumed to be implicated in the observed 
hyperactivity although there is evidence to suggest that 
other central neurotransmitters may be involved (Section 
1.4.6.1.1.2). Based on the proposal put forward by 
Grahame-Smith (1971a), these findings suggest that melatonin 
acts by increasing brain serotonin which results in the 
production of hyperactivity. This may either be by a 
direct (excess serotonin "spills over" and stimulates 
its receptors) or indirect (increased serotonin influences 
the dopaminergic neurons) mechanism. 
Since tryptophan has been shown to have some antidepressive 
properties particularly in combination with a MAO inhibitor 
(Section 1.2.2) and in view of the fact that tryptophan 
(Grahame-Smith, 1971a) and melatonin (Anton-Tay et al., 
1968) both increase serotonin brain levels and produce 
hyperactivity in rats following MAO inhibition, it is 
suggested that melatonin may have antidepressive properties . 
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C HAP T E R 4 
MELATONIN AND A FROG MODEL OF DEPRESSION 
4.1 INTRODUCTION: 
Reserpine-induced sedation has been proposed as an animal 
analogue of depression in man. This sedation has been 
associated with decreased levels of noradrenaline, dopamine 
and serotonin in the brain (Brodie and Shore, 1957; Carlsson, 
1961) but there is no equivocal opinion about which of these 
amines plays the most important role in the action of 
reserpine (Section 1.4.5) . Since the mammalian brain 
contains more or less equal amounts of serotonin and 
noradr e naline (Bogdanski et al., 1963) and since reserpine 
and the tricyclic antidepressives affect both the catechol~ 
amine and serotonin brain levels, it is difficult to evaluate 
the effect of the drug on one specific amine. The amphibian 
brain, however, has been found to differ from other vertebrate 
brains in that it contains adrenaline instead of noradrenaline 
(Bogdanski et al., 1963; 1964; Brodie and Bogdanski, 1964) 
(Table 20). The reason for this is not understood. 
Although there is no data for the Xenopus species, it was 
assumed that they would not differ significantly from the 
Rana species, as it seems this pecularity occurs throughout 
the amphibian class. In addition, these authors found that 
the concentration of serotonin in the amphibian brain is high 
relative to that in mammals. This makes the frog an ideal 
species for the evaluation of the influence of antidepressives 
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TABLE 20: 
DISTRIBUTION OF SEROTONIN AND CATECHOLAMINES IN VARIOUS 
SPECIES OF VERTEBRATES 
(Adapted from Bogdanski et al., 1963 and Brodie and 
Bogdanski-,-1964) 
Species Level of amine in brain (l1g/g of tissue) 
Serotonin Adrenaline Noradrenaline 
MAMMAL 
Rabbit 0,67 (6) 0,60 (6) 
Rat 0,48 (6 ) 0,49 (6) 
BIRD 
Pigeon 0,70 (7) 0,38 (7) 
Chicken 1,0 (3) 0,60 (3) 
REPTILE 
Lizard - S. cyanogenys 3, 1 (2 ) 1,6 (2) 
AMPHIBIAN 
Frogs - R. EiEiens 3,8 (18) 2,3 (21) 
- R. cinerea 2,1 (2) 0,94 (2) 
- R. temporaria* - 0,84(11) <0,01 (9) 
-
Toads - B. americanus 9,1 (4 ) 0,83 (2) 
B. marinus 1,5 (2) 2,4 (2 ) 
-
Salamander - Desrnognathus 2,8 (1) 1,24 (1) 
A. tiS!rinurn 2,9 (2 ) 0,75 (3) 
N. rnaculosus 1,1 (1) 0,39 (1) 
FISH 
c. auratus 0,15 (3) 0,49 (2) 
A. calva 0,48 (1) 0,33 (1) 
* Lapin et al., 1968. 
Figures in brackets refer to the number of determinations. 
- Comparative figures not available. 
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on the serotoninergic system alone and the effects of this 
influence on the action of reserpine. 
Brodie and Bogdanski (1964) have demonstrated that reserpine 
has a selective action on the serotonin stores of the frog 
brain (Rana pipiens). At 23° C, reserpine (100 mg/kg) 
depleted serotonin levels by 30%, whereas the content of 
brain adrenaline decreased by 15% . This was more pronounced 
at 37° C; serotonin stores were depleted by 70% while 
adrenaline brain levels diminished by 40%. In addition, 
pargyline was shown to cause a 38% rise in the level of 
brain serotonin with little or no rise in the adrenaline 
level. 
Reserpine, even in high doses (5 0 mg/kg) was shown t o have 
no visible effect in the frog (Brodie and Bogdanski, 1964; 
Brodie et al., 1964). However, after pretreatment with 
the MAO inhibitor, pargyline, a loss of the righting reflex 
was observed which demonstrated an enhancement of the sedative 
effect of reserpine. This sedative effect was thought to be 
due to the accumulation of free serotonin in the brain and any 
enhancement of this would indicate serotonin potentiation. 
It has been proposed that the thymoleptic effect is mediated 
through the activation of the central serotoninergic processes 
(Carlsson et al., 1969; Lapin and Oxenkrug, 1969; Section 
1.2 .2) . Consequently a drug which potentiates the sedative 
effect of reserpine after MAO inhibition may have a 
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thymoleptic effect. The tricyclic antidepressives were 
shown to enhance the sedative action of reserpine in the 
frog model (Lapin et al . , 196B; Lapin and Oxenkrug, 1970) 
which further supports this hypothesis. 
Melatonin was, therefore, investigated in the frog model 
to evaluate its effect on the serotoninergic system and to 
determine any possibl e thymoleptic effect. 
4.2 MATERIALS AND METHODS: 
Male and female frogs (Xenopus laevis) weighing 20 to 45 g 
were used. These were housed in a glass tank (90 x 40 x 
35 cm) containing water maintained at 23 - 25° c. Room 
temperature was 20 - 22° C. During the experiment the 
frogs were placed individually in plastic tanks (30 x 12 x 
12 cm) containing 1 00 ml of water . 
The water-soluble salts 0f imipramine, amitriptyline and 
pargyline were freshly dissolved in distilled water . 
Melatonin was dissolved in a solution containing 25% w/v 
polyethylene glycol 400 . Reserpine was first dissolved 
in a small amount of glacial acetic acid (B% w/v) and then 
made up to volume with distilled water. All the drugs 
were injected into the supra femoral lymph sac. All the 
experiments were carried out at the same time of day 
starting at 09hOO. Pargyline was administered two hours 
before, and imipramine, amitriptyline or melatonin thirty 
minutes before, reserpine administration. The righting 
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reflex was tested 10 times in every frog. This was 
recorded before and for up to 6 hours after reserpine 
administration. Vocalizations and any twitches of the 
extremities were also registered. 
4.3. RESULTS: 
4 .3.1 Effect of MAO Inhibition Followed by Reserpi ne 
Administration upon the Frog Righting Reflex: 
In preliminary studies, low doses of pargyline had no apparent 
effect on the righting reflex of the frog. However, a 
transient sedative effect, which returned to normal after 
approximately 3 hours, was produced by higher doses (200 mg/kg 
and 300 mg/kg) of the drug. This effect was shown to be 
significantly altered by temperature (p < 0,005; Student's 
t-test) . At 100 C, th e frogs showed profound sedation, 
loss of th e righting reflex and subsequent death, whereas 
at 23 0 C, the depression was less pronounced and of shorter 
duration (Table 2lA). 
Reserpine, in doses up to 50 mg/kg, did not elicit any 
sedative effect in the frog. Reserpine, 100 mg/kg, caused 
a slight loss of the righting reflex but this was not 
significant (Table 21B). 
Sedation and a loss of the righting reflex were observed, 
however, when the frogs were dosed with reserpine 2 hours 
after pargyline pretreatment (Fig. 33). This 
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TABLE 21A: 
EFFECT OF PARGYLINE ADMINISTRATION ON THE FROG RIGHTING 
REFLEX AT 23°C AND 10 °C 
Temp. Pargyline Number Number of rightings from 10 trialsMean±S.E.M. 
(0 C) (mg/ kg) of Frogs 1 hour 2 hours 3 hours 
23° C 200 22 8,0±0,6 9,8±0,1 10±0 
300 12 1,1±0,6* 2±1,1* 9, 75±0, 25 
10° C 200 15 O±O* O±O* O±O* 
300 5 O±O O±O O±O* 
*p < 0,005 when compared with pargyline, 200 mg/kg, at 23° C 
(Student's t-test). 
TABLE 21B: 
4 hours 
10±0 
10±0 
DEAD 
DEAD 
EFFECT OF VARIOUS DOSES OF RESERPINE ON THE FROG RIGHTING 
REFLEX 
Reserpine Number Number of. rightings f rom 10 trials .Mean ± S.E.M. 
(mg/kg) of Frogs 2 hours 4 hours 6 hours 24 hours 
12 , 5 5 10 ± 0 10 ± 0 10 ± 0 10 ± 0 
25 5 10 ± 0 10 ± 0 10 ± 0 10 ± 0 
50 5 9,8±0,2 9,2±0,6 10 ± 0 9,6±0,4 
100 9 9 ± 0,5 8,8±1,2 8,8±1,2 9,2±0,8 
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~ Reserpine 100 mg/kg (9) 
o Reserpine 100 mg/kg 2 hours following pargyline administration, 200 mg/kg (11) 
Reserpine 100 mg/kg 2 hours following 
pargyline administration, 300 mg/kg (8) 
* 
• 
2 
Hours 
· . 
" . .. 
. . 
· . 
· . 
. . 
The Effect of Reserpine on the Frog Righting 
Reflex Following Pargyline Pretreatment. 
The figures in parentheses represent the number of frogs 
used in the trial . 
* P < 0,005 when compared with reserpine-treated frogs 
(Student's t - test). 
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potentiation was dose-dependent and most evident within the 
first hour after reserpine administration (p < 0,005; 
Student's t-test). The dose s of reserpine and pargyline 
were then manipulated so as to give a very slight sedative 
effect and thus allow any synergism between the test drug 
and the pargyline-reserpine combination to be evaluated. 
Table 22 shows that concentrations of reserpine lower than 
100 mg / kg had no appreciable effect upon the righting reflex 
after pargyline pretreatment . On the other hand, pargyline 
(300 mg/kg) and reserpine (100 mg/kg) e xhibited a marked 
sedative effect within the first hour after drug administration 
(p < 0,05; Student's t - test) and therefore, pargyline (200 
mg / kg) administered 2 hours before reserpine (100 mg/kg) 
appeared to be the most suitable dose regimen. 
4.3.2 Enhancement of the Sedative Action of Reserpine by 
Imipramine, Amitriptyline and Melatonin: 
Following pargyline pretreatment (200 mg/kg), imi p ramine 
(10 mg / kg) and amitripty line (10 mg/kg) significantly 
enhanced the action of reserpine (100 mg/kg) (Fig . 34). The 
potentiation of the effect of reserpine was accompanied 
by the appearance of twitches of the extremities. 
As presented in Table 23, various doses of melatonin 
(5 mg/kg, 10 mg/kg, 25 mg/kg and 50 mg/kg) alone, or in 
combination with reserpine (100 mg/kg), had no visible 
effect on the frog righting reflex, except in high doses 
(100 mg/kg) . When melatonin was administered with rese rpine 
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TABLE 22: 
THE EFFECT OF VARIOUS DOSES OF RESERPINE AND PARGYLINE ON THE FROG RIGHTING REFLEX 
Number of rightings from 10 trials Mean ± S . E.M . 
Pargyline Reserpine Number of 
(mg/kg) (mg/kg) Frogs 1 hour 2 hours 3 hours 4 hours 5 hours 
200 10 4 10 ± 0 9,7 5 ± 0,3 0,5±0,5 9,5 ± 0,5 9,75±0,3 
200 25 5 9 ± 0,8 10 ± 0 10 ± 0 9,2 ± 0,6 9,8 ± 0,2 
200 50 5 10 ± 0 10 ± 0 10 ± 0 10 ± 0 10 ± 0 
20(1 100 11 7,5 ± 0,8 8,6±0,6 8,6±0,6 8,5±0,6 8,9 ± 0,6 
300 50 4 10 ± 0 10 ± 0 10 ± 0 10 ± 0 10 ± 0 
300 lOO 8 4,25±2* 7,5±1,6 8,5 ± 1,5 8 ,75 ± 1 9 ± '1 
Reserpi ne was injected 2 hours after pargyline administration. 
*p < 0,05 when compared with pargyline (200 mg/kg) followed by reserpine (100 mg/kg) 
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14 
* 
CONTROL 10 mg/kg 
~ PARGYLINE (200 mg/kg) + DISTILLED WATER . + RESERPINE (100 mg/ kg) 
D PARGYLINE (200 mg/kg) + AMITRIPTYLINE (10 mg/kg) + RESERPINE (100 mg/kg) 
~2[~ PARGYLINE (200 mg/kg) + IMIPRAMINE (10 mg/kg) + RESERPINE (100 mg/kg) 
** 
POTENTIATION OF THE SEDATIVE EFFECT OF RESERPINE 
BY I MIPRAMINE AND AMITRIPTYLINE. 
The frogs wer e pretreated with pargyline 1,5 hours before the 
administration of the tricyclic drug . Reserpine was injected 
30 minutes following tricyclic administration and the righting 
reflex was recorded two hours later. 
The figures in brackets refer to the number of frogs used. 
* P < 0,05 when comp~red with control (Student's t - test). 
** P < 0,001 when compared with control (Student's t-test) . 
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TABLE 23: 
ENHANCEMENT OF THE SEDATIVE ACTION OF RESERPINE BY VARIOUS DOSES OF MELATONIN 
1 hour 5 hours 
Number of Number of 
Drugs Number of rightings fran frogs ·lost rightings fran frogs lost 
(mg/kg) frogs 10 trials righting 10 trials righting 
M.ean ± S.E.M. reflex with Mean ± ti. E.M. reflex with 
twitches twitches 
Control 
PAR200 + lli + Res 100 11 7,5 ± 0,8 0 8,9 ± 0,6 0 
DW + mel 5 + Res 100 5 10 ± 0 0 10 ± 0 0 
PAR 200 + mel 5 + Res 100 5 10 ± 0 0 10 ± 0 0 
DW + mell0 + lli 8 10 ± 0 0 10 ± 0 0 
lli + mell0 + Res 100 5 10 ± 0 0 10 ± 0 0 
PAR 200 + mell0 + Res 100 13 4,3 ± 1,2* 5 4,8 ± 1,4* 6 
lli + mel 25 + Res 100 5 10 ± 0 0 10 ± 0 0 
PAR 200 + mel 25 + Res 100 9 3,9 ± 1,5* 4 2,2 ± 1,5** 7 
lli + me150 + Res 100 4 10 ± 0 0 10 ± 0 0 
PAR 200 + me150 + Res 100 9 2,6 ± 1,0** 4 2,8 ± 1, 2** 4 
OW + mell.00 + lli 4 7,25 ± 1,4 0 9,3 ± 0,5 0 
lli + mell00 + Res 100 4 5,0 ± 1,1 0 7,0 ± 1,5 0 
PAR 200 + mel 100 + Res 100 4 
° 
± 0** 4 4,0 ± 1,8** 1 
Differences fran the control were determined statistically using the Student!s t-test. 
fJlr, distilled water.; mel, melatonin; PAR, pargyline; Res , reserpine. 
* p < 0,05 as compared to control. 
** p < 0,001 as canpared to control. 
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(100 mg/kg), following pargyline pretreatment (200 mg/kg) 
however, marked sedation and loss of the righting reflex 
were observed. This effect was significantly different 
from the control group (Table 23) and was shown to be dose-
dependent (Fig . 35). A loss of the righting reflex 
was always accompanied by twitching of the extremities, 
similar to that observed with tricyclic antidepressive 
treatment. 
4.4 DISCUSSION: 
The effect of pargyline administration on the frog righting 
reflex was shown to be temperature dependent. This could 
be explained by the fact that MAO activity changes markedly 
at different temperatures . Brodie and Bogdanski (1964) 
demonstrated that at 2° C, the activity of MAO in the frog 
brain was 110±lB ug/g/hr, whereas at 37° C, the activity 
was 121B ±150 ug/g/hr. Temperature is also an important 
variable in the action of reserpine, brain amines being 
released more readily at 37° C than at 23° C (Brodie et al., 
1964) . 
The low turnover of serotonin in the frog brain (Brodie et al., 
1964) could account for the failure of reserpine to elicit 
sedation by itself. However, when pretreated with pargyline, 
sedation and loss of the righting reflex occurred . This 
effect is associated with the selective release of brain 
serotonin and its protection from destruction by MAO 
inhibition. 
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Fig.35. 
PARGYLINE (200 mg/ 
+ DISTILLED WATER 
+ RESERPINE (lOO/m 
0 PARGYLINE (200 mg/ + MELATONIN + RESERPINE (100 m 
-r 
(13 ) * 
-'-
-r 
( 9) * 
-'-
(9)T* 
-.l (4) * 
5 10 25 50 100 
DOSE (mg/kg ) 
kg) 
g/kg) 
kg) 
g/kg) 
POTENTIATION OF THE SEDATIVE EFFECT OF RESERPINE 
BY VARIOUS DOSES OF MELATON I N. 
The frogs were pretreated with . pargyline 1,5 hours before the 
administration of melatonin. Reserpine was injected 30 minutes 
following melatonin administration and the righting reflex was 
recorded two hours later. 
The figures in brackets refer to the number of frogs used. 
* P < 0,001 when compared with control (Student's t-test) • 
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Imipramine and amitriptyline enhanced the sedative action 
of reserpine after pargyline pretreatment. Both drugs 
are potent serotonin reuptake blockers (Table 7). 
Desipramine, however, being a relatively ineffective 
blocker of serotonin uptake, has previously been shown 
to be less effective in this model (Lapin et al . , 1968). 
The potentiation of reserpine's action therefore is probably 
related to the inhibition of serotonin reuptake, which in 
turn, increases the level of free serotonin and causes 
sedation. The fact that melatonin administration also 
caused profound sedation and loss of the righting reflex 
in the test system could be explained by its reported effect 
on serotonin brain levels (Section 1.3.6.1). 
Enhancement of the action of reserpine by melatonin and 
imipramine and amitriptyline was accompanied by twitches 
of the extremities. Head twitches have also been observed 
in mice after serotonin treatment (Corne et al., 1963). 
This suggests that both these syndromes may be due to the 
activation of the serotoninergic processes in the CNS. 
In addition, twitching has been shown to be blocked by the 
administration of the serotonin antagonist, BOL-148 (Lapin 
et al., 1968) which further supports this assumption. 
Twitching has thus been used to differentiate between drugs 
which have a non-specific effect on the frog righting r e flex, 
such as chlorpromazine and benactyzine (Lapin and Oxenkrug, 
1970) and drugs which potentiate serotoninergic effects . 
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In conclusion, therefore , the results indicate that 
melatonin has a central serotoninergic potentiating 
effect in the frog which) in turn, could suggest a possible 
thymoleptic effect. 
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C HAP T E R 5 
THE PORSOLT MODEL 
5 . 1 INTRODUCTION, 
There is a need for an animal model of depression which 
is (1) similar to depression in man; (2) sensitive to the 
clinically effective antidepressives; and (3) based on 
behavioural as well as biochemical concepts (Section 1.4.1). 
The helplessness and despair seen in animals that have been 
subjected to uncontrollable trauma ("learned. helplessness" 
model), as well as the depressive-like behaviour induced in 
non-human primates by separation from either mo thers or peers 
("se paration-loss" model) serve as convincing behavioural 
models of depression. These models are discussed in more 
detai l i n Sections 1.4.2 and 1.4.3. However, because of 
cost and practicabili t y they cannot be used to screen for 
potential antidepressive drugs. 
The Porsolt model (Porsolt et al. , 1977) has attempted to 
overcome these limitations. In this test, rats are forced 
to swim in a situation from which they cannot escape and it 
has been proposed that the characteristic immobility which 
develops, may represent a state of depression and despair. 
In addition, drugs which are effective in the treatment of 
depression, have been reported to reduce the duration of 
this immobility (Porsolt et al., 1977; 1978). Consequent l y 
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the authors have suggested that the model could serve as 
a simple and inexpensive animal model of depression which 
would be useful in the evaluation of possible antidepressive 
drugs. 
The tricyclic drugs, which are known to be effective in the 
treatment of depressive illness, were tested in the model 
in order to confirm the findings of Porsolt and his co-workers. 
Melatonin, a potential antidepressive, was also evaluated in 
this system. 
5.2 MATERIALS AND METHODS: 
5.2.1 Animals: 
Male albino Wistar rats weighing between 200 and 300 g were 
used. They were housed in a constant temperature room, in 
single cages with free access to food and water. 
5.2.2 Modifications of the Porsolt Model: 
Two modifications to the Porsolt model were made. 
(1) The depth of the water level was increased form 15 to 25 
cm. In this study large rats (200 - 300 g), which were able 
to stand in 15 cm of water, were used and thus less 
expenditure of energy would have been required and a less 
stressful situation produced. Consequently the development 
and duration of the despair or immobility phase might have 
been affected. 
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(2) When the rats were dosed with amphetamine, it was 
observed that some rats were active for the entire test 
period. Thus the test period was increased in order to 
obtain a quantitative measure of the duration of immobility. 
In addition, there is a brief burst of hyperactivity which 
frequently occurs after 7 to 8 minutes and this would have 
been undetected using a 5-minute test period. The 5-
minute test period on Day 2 was extended to 10 minutes. 
5.'2.3 Induction and Measurement of Immobility: 
All experiments were performed between 14hOO and 17hOO. 
Naive rats were plunged individually into a glass tank 
(30 x 17 x 35 cm) containing water (depth: 25 cm) and 
maintained at a constant temperature of 25 - 27° C. After 
swimming for 15 minutes, they were removed, dried in an oven 
(30 - 32° C) for another 15 minutes and then returned to 
their original cages. 
later (Day 2). 
This procedure was repeated 24 hours 
A rat was judged to be immobile in the water when all escape 
movements had ceased and it was floating passively, only 
making slight movements to keep its nose above the water. 
The duration of this immobility was measured during the 
first 10 minutes on both Day 1 and Day 2, e ach rat, there-
fore acting as his own control. 
5.2.4 Drugs and Drug Treatment: 
The water soluble salts of imipramine, desipramine, 
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amitriptyline and amphetamine were freshly dissolved in 
normal saline (0,9% w/v NaCl solution). Melatonin, 
depending on its concentration, was dissolved in various 
amounts of polyethylene glycol 400. The doses, expressed 
in terms of the salt, were given on a mg/kg basis. 
rats were given the vechile only. 
Control 
The first dose of a given drug was administered intra-
peritoneally after the rat had been removed from the oven on 
Day 1, and then the dose was repeated 5 hours and 1 hour 
before the test period on Day 2. 
5.3 RESULTS: 
5.3 . 1 Swimming Behaviour without Drugs: 
Many rats (n = 206) were tested in this experimental 
situation and a characteristic behavioural pattern emerged. 
Rats which were placed in the water for the first time, 
showed an initial period of hyperactivity consisting of 
vigorous swimming, splashing at the sides, diving and 
frequent defaecation. This activity subsided after 2 to 
3 minutes and a phase of headshaking and face wiping ensued. 
During this phase the rats' movements slowed down and 
periods of immoblity of increasing duration followed. 
This immobility was characterized by the animal floating 
in a vertical but hunched position, resting its tail on 
-the bottom of the tank and making occasional movements to 
keep its nose above the water (Fig. 36). Frequently, 
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Fig. 36 . Rat Showing the Characteristic Posture of Immobility. 
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after 7 to 8 minutes, another brief period of hyperactivity 
was noted, perhaps as part of a final bid to escape. Upon 
removal from the water, the rats were hypothermic (-2 0 C) 
and hypoactive. 
On Day 2, when the rats were retested in the water, a similar 
behavioural pattern was observed. The duration of immobili t y , 
howeves was shown to increase significantly (p < 0,001; 
Wilcoxon matched-pairs signed-rank test). This is shown 
in Fig. 37 . . In addition, the amount of diving, apparently 
in search of an exit, was significantly reduced (p < 0,001; 
X2 test). A decrease in the amount of headshaking and 
defaecating was also noted, a lthough this was not significant. 
This suggests that the rat, having been rescued on Day 1, may 
have adapted to the situation and be less fearful on Day 2. 
In addition, different rats showed large variations in the 
duration of immobility and consequently, each rat was used 
as his own control to eliminate the high standard deviation 
wh ich would have resulted. 
5 . 3.2 Effects of Different Drugs on the Duration of 
Immobility: 
5.3.2.1 ~p~~!~~~E~: 
Fig . 38 shows that amphetamine administration caused a 
dose-dependent reduction in the duration of immobility 
(p < 0,001; Dunnett test). The rats were generally 
hyperactive, splashing and diving for the major part of 
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400 
300 
Duration of 
Immobili ty 
(sees) 
Mean ± S.E.M. 200 
100 
Day 1 Day 2 
Fig. 37. Mean Duration of Rat Immobi lity on Day 1 and Day 2 . 
On Day 1, rats (n=26) were placed in the water 
for the first time and the duration of immobility 
was measured during a 10-minute test period. 
This was repeated 24 hours later (Day 2). 
* P < 0,001 (Wilcoxon matched-pairs signed-rank test) . 
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THE EFFECT OF AMPHETAMINE ADMINISTRATION ON THE 
DURATION OF U1MOBILITY DURING A 5-MINUTE TEST PERI OD. 
The figures in brackets refer to the number of rats used. 
** P < 0,001 difference from control (Dunnett test) . 
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the test and stereotype head movements were observed at 
higher doses (1,5 mg/kg and 3,0 mg/kg) . However, the 
stereotype behaviour is thought to be due to the drug's 
motor stimulating effect rather than to any possible anti-
depressive effect. 
Rats dosed with a tricyclic antidepressive showed a marked 
reduction in diving, headshaking and defaecation (p < 0,001 
x2 test). 
As presented in Fig. 39, desipramine (10 mg/kg and 20 mg/kg) 
and imipramine (15 mg/kg and 30 mg/kg) caused a significant 
reduction in the duration of immobility measured on Day 2. 
Amitr iptyline was found to be less effective i n this test, only reducing the 
immobility period at relatively high doses (30 mg/kg). In 
contrast to the effect of amphetamine administration, slow 
but continual movements of t h e limbs were observed with 
tricyclic antidepressive treatment. 
5.3.2 . 3 Melatonin: 
Although a wide range of concentrations were used (5 mg/kg, 
50 mg/kg, 100 mg/kg and 200 mg/kg), melatonin was only found 
to significantly decrease the duration of immobility at a 
very high dose (200 mg/kg). This is shown in Fig. 40. 
The amount of di v ing, headshaking and defaecating, however, 
did not differ markedly from the control group . 
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Fig. 39. THE EFFECT OF VARIOUS TRICYCLIC ANTIDEPRESSIVES ON THE 
DURATION OF IMMOBILITY DURING A 10-MINUTE TEST PERIOD. 
The figures in brackets refer to the number of rats used. 
* P < 0,01 difference from control (Student's t-test) . 
** P < 0,001 difference from control (Student's t-test) • 
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~ POLYETHYLENE GLYCOL 400 
D MELATONIN 
+5 
(8 ) 
(15 
o 
(8 * 
CONTROL 5 50 100 200 
DOSE (mg/kg) 
Fig. 40. THE EFFECT OF MELATONIN ON THE DURATION OF 
IMMOBILITY DURING A 10-MINUTE TEST PERIOD. 
The figures in brackets refer to the number of rats used. 
* P < 0,05 difference from control (Student's t-test) . 
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5.4 DISCUSSION: 
The immobility induced in this experiment is thought to 
reflect a "state of lowered mood" in the rat (Porsolt et al., 
1977; 1978) and thus it has been suggested that this model 
may be used to discover new antidepressive drugs. 
The tricyclic antidepressives (desipramine, imipramine and 
amitriptyline) were shown to differ in their effects on the 
duration of immobility. Desipramine, a relatively selective 
noradrenaline reuptake blocker, was the most effec ti ve in 
r educing the duration of immobility. Imipramine which has 
approximately equal effects on noradrenaline and serotonin 
reuptake, was a lso active in the test at slightly higher 
concentrations. Amitriptyline, a relatively selective 
blocke r of serotonin reuptake, only incr eased the swimming 
time at a r elatively high concentration (30 mg/kg). Thus 
the stimulant tricyclic drugs appear to be more effective 
than the sedative tricyclics in this model . Likewise, 
melatonin which has been shown to exert a sedative effect 
in animals and humans, only had a significant effect on the 
duration of immobility at very high doses. 
The above results suggest that a reduction in the duration 
of immobility may be due to the motor stimulating properties 
of a drug and not necessarily reflect an antidepressive effect. 
The fact that amphetamine, which has little antidepressive 
action, was active in this test further supports this 
assumption. 
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Thus the Porsolt model may be useful in discovering 
"stimulant" antidepressives acting primarily on the 
catecholaminergic system but its effectiveness in 
detecting "sedative" antidepressives is debatable . 
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C HAP T E R 6 
SUMMARY 
Chapter 1: 
Numerous theories involving the aetiology of depressive dis-
orders have been proposed. A deficiency in the concentration 
of serotonin at functionally important receptor sites has been 
implicated, although whether this is a primary defect or 
secondary to developmental and interpersonal events is not 
known. Melatonin, a possible antidepressive, was 
investigated in a number of behavioural models, since the 
indoleamine had previously been reported to increase serotonin 
levels in selective brain areas. 
Chapter 2: 
In a preliminary screening test using avoidance conditioning, 
high doses of melatonin were found to exert a similar effect 
to chlorpromazine administration on rat avoidance behaviour, 
causing suppression of the conditioned avoidance response. 
Chapter 3: 
Spontaneous rat locomotor activity was suppressed following 
melatonin administration. However, in rats pretreated with 
a MAO inhibitor, locomotor activity was significantly 
increased following the administration of melatonin 30 minutes 
later. This e ffect indicated a potentiation of the serotonine rgic 
processes and was similar to that observed following the 
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administration of an equivalent amount of dl-tryptophan. 
Chapter 4: 
In the frog model, following MAO inhibition, melatonin 
administration produced a loss of the righting reflex which 
was dose-dependent. Amitriptyline and imipramine, in similar 
doses , produced the same effect. The action of melatonin in 
this experimental situation again indicated a serotonin- like 
potentiat ing effect which was confirmed by the appearance of 
characteristic twitching of the extremities. 
Chapter 5: 
Melatonin, although only in high doses, also reduced the 
duration of immobility in the Porsolt model of depress ion, 
indicating a possible antidepressive effect. 
The TADs were shown to differ in their effects when 
investigated in the 2 newer animal models of depression. 
The relatively selective serotonin reuptake blockers were 
more effective in the frog model whereas the noradrenali ne 
reuptake inhibitors were more effective in the Porsolt model . 
These findings suggest that the Porsolt model may be useful 
in discovering stimulant antidepressives acting primarily on 
the catecholaminergic system, whereas the frog model may be 
used in detecting pot entia l sedative antidepressives which 
act on the serotoninergic system. 
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CONCLUSION: 
The results show that melatonin has a serotonin-like 
potentiating effect in the behavioural models used and 
consequently may be a useful antidepressive. In view of 
its known sedative effect in humans, it is suggested that 
melatonin be investigated in a well-controlled clinical 
trial of patients suffering from "agitated" depressions in 
order to confirm these pred i ctions from animal pharmacology . 
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